Announcement of Listed Companies in Shanghai Stock Exchange (August 17th)

  The new lake treasure: 820 million corporate bonds will be paid at the interest rate of 7.9% on August 25th.

  On August 15th, () Co., Ltd. announced the interest payment of "20 Xinhu 01" in 2022.

  According to the announcement, the 2020 public offering corporate bonds of the new lake treasure Co., Ltd. (Phase I) issued by the new lake treasure on August 25th, 2020 will pay the interest from August 25th, 2021 to August 24th, 2022.

  The bond is abbreviated as 20 Xinhu 01, with a total issue amount of 820 million yuan, a bond term of 4 years and a bond interest rate of 7.90%. the new lake treasure has the right to decide whether to adjust the coupon rate of this bond at the end of the second year of its existence.

  It is reported that China Securities Depository and Clearing Co., Ltd. Shanghai Branch is the institution for registration, settlement, bond dividend distribution and redemption.

  (Editor: Pu Shasha)

  The real controller of Dongfang Huanyu intends to reduce its shareholding by no more than 0.26%.

  () Announcement was made. On August 16th, the company received the Letter of Notice on Share Reduction Plan issued by Mr. Li Weiwei, the actual controller, director and deputy general manager. Mr. Li Weiwei intends to reduce his holdings of the company’s shares by centralized bidding within six months after 15 trading days from the date of announcement, accounting for no more than 500,000 shares, accounting for no more than 0.26% of the company’s total share capital.

  Sino-international alliance plans to set up a Japanese subsidiary to expand overseas business with US$ 5 million.

  () Announcement, the company intends to set up a wholly-owned secondary subsidiary (3S Japan Co., Ltd.) in Japan with its own funds through its wholly-owned subsidiary, China International Hong Kong, with a total investment of 5 million US dollars, and provide the company with early working capital; Through the establishment of Japanese companies, technology development, product sales and after-sales service can be realized locally, which is conducive to overseas business development, expanding the company’s business scale and enhancing the company’s profitability.

  Dongfang Huanyu: The actual controller intends to reduce the company’s shares by no more than 0.26%.

  Dongfang Huanyu announced on the evening of August 16th that Li Weiwei, the company’s actual controller, director and deputy general manager, intends to reduce the company’s shares by no more than 500,000 shares, accounting for no more than 0.26% of the company’s total share capital.

  Guo Mao shares: the actual controller and its concerted actions intend to reduce their holdings by no more than 2%.

  () On the evening of August 16th, it was announced that Shen Huiping, one of the company’s actual controllers, and Xu Ling, a concerted action person, planned to reduce the company’s shares by no more than 2%.

  Shen Huiping, the actual controller of Guo Mao shares, and his concerted actions intend to reduce their holdings by no more than 2%.

  Guo Mao Co., Ltd. announced that Ms. Shen Huiping, one of the actual controllers of the company, and Ms. Xu Ling, who acted in concert, reduced their holdings by no more than 13,250,500 shares, and the reduction ratio did not exceed 2.00% of the company’s total share capital. Among them, Ms. Shen Huiping plans to reduce the company’s shares by no more than 3,312,600 shares, with the reduction ratio not exceeding 0.50% of the company’s total share capital, and Ms. Xu Ling plans to reduce the company’s shares by no more than 9,937,900 shares, with the reduction ratio not exceeding 1.50% of the company’s total share capital.

  Fudan Fuhua subsidiary participated in bidding for plot 02-04, Fengcheng Town, Fengxian District, Shanghai.

  () Announcement: Shanghai Fuhua Zhixian Economic Development Co., Ltd., a holding subsidiary of the company, intends to participate in the listing and transfer of the right to use state-owned construction land in Shanghai, and participate in the bidding for plot 02-04 in Fengcheng Town, Fengxian District on August 17, 2022. The above plot is located in 02-08 plot in the east, Planning Road in the south, Fenggan Highway in the west, and 02-03 plot in the north, with a transfer area of 68,079.4 square meters and a plot ratio of 2.0. The land use is industrial land, the transfer period is 50 years, and the initial listing price is 35.75 million yuan.

  Zejing Pharmaceutical Co., Ltd.: The clinical trial of "ZGGS18 for injection" for the treatment of advanced solid tumor was approved.

  Zejing Pharmaceutical announced that the company recently received the Notice of Approval for Clinical Trials of Drugs issued by National Medical Products Administration (hereinafter referred to as "National Medical Products Administration"), and the clinical trial of ZGGS18 for injection for the treatment of advanced solid tumors was approved.

  It is reported that ZGGS18 is a bifunctional antibody fusion protein drug developed by Gensun Biopharma Inc and its subsidiary through its bispecific antibody research and development platform, and it is also the second bispecific antibody drug submitted by the company for clinical trial application. ZGGS18 is registered and classified as a kind of therapeutic biological product, which is expected to become an innovative biological product for the treatment of solid tumors.

  Zejing Pharmaceutical Co., Ltd.: ZGGS18 for injection was approved by the clinical trial.

  Zejing Pharmaceutical announced on the evening of August 16th that the company recently received the Notice of Approval for Clinical Trials of Drugs issued by National Medical Products Administration, and the clinical trial of ZGGS18 for injection for the treatment of advanced solid tumors was approved.

  Yi Delong plans to set up new companies in Singapore and Vietnam to establish a manufacturing base in Southeast Asia.

  () Announcement: In order to further expand overseas markets, optimize procurement and logistics modes, and improve the satisfaction of customers in North America and Europe in terms of comprehensive cost and flexible delivery, Elbow International Co., Ltd., a wholly-owned subsidiary of the company in Hong Kong, plans to use its own funds to establish a new Singapore company (registered capital of 3.05 million US dollars) as a route company, and then invest in a new Vietnam company (registered capital of 3 million US dollars). This foreign investment will establish its own manufacturing base in Southeast Asia.

  Yi Delong plans to increase the capital of its Hong Kong subsidiary by US$ 20 million to meet the capacity demand of new orders.

  Yi Delong announced that in order to further expand overseas markets, optimize procurement and logistics modes, and improve the satisfaction of customers in North America and Europe in terms of comprehensive cost and flexible delivery, the company plans to use its own funds to increase the capital of its wholly-owned subsidiary, Elubao International Co., Ltd. ("Elubao Company") by 20 million US dollars. After this capital increase, the registered capital of Elubao Company will increase from 4.5 million US dollars to 24.5 million US dollars. The main reason for this capital increase is to meet the capacity demand of new orders and increase capital investment.

  Bank of Nanjing: The acquisition of controlling stake in Suning Consumer Finance Co., Ltd. was approved by the regulatory authorities.

  On the evening of August 16th, Bank of Nanjing announced that China Banking and Insurance Regulatory Commission agreed that the company would accept 36% equity of Suning Xiaojin held by Suning.cn Group Co., Ltd. and 5% equity of Suning Xiaojin held by Jiangsu Yanghe Winery Co., Ltd. After the completion of the equity change, the company’s shareholding in Suning Xiaojin will increase from 15% to 56%.

  Donghu High-tech: Hubei Road and Bridge Consortium won the bid for PPP development and construction project in Dangyang Economic Development Zone Industrial Park.

  () Announcement. Recently, Hubei Road and Bridge Group Co., Ltd. (hereinafter referred to as "Hubei Road and Bridge"), a wholly-owned subsidiary of the company, as the leader of the consortium, received the Notice of Winning the Bid for PPP Development and Construction Project of Dangyang Economic Development Zone Industrial Park jointly issued by Hubei Dangyang Economic Development Zone Management Committee (tenderee), Hubei Dejun Construction Project Management Co., Ltd. (tendering agency) and dangyang city Public Resource Trading Center, and won the bid for the PPP development and construction project of Dangyang Economic Development Zone Industrial Park.

  Wansheng Co., Ltd.: Trial production of Wansheng Dawei technical transformation project, a wholly-owned subsidiary.

  () On the evening of August 16th, it was announced that the technical transformation project of Wansheng Dawei, a wholly-owned subsidiary (with an annual output of 15,000 fatty tertiary amines, 10,000 tons of quaternary ammonium salts and 2,000 tons of electronic-grade trioctylamine) had officially entered the trial production stage.

  Wansheng Co., Ltd.: Trial production of "Technical transformation project with an annual output of 27,000 tons of fatty amines and their derivatives"

  Wansheng shares announced that Jiangsu Wansheng Dawei Chemical Co., Ltd. ("Wansheng Dawei"), a wholly-owned subsidiary of the company, has completed the main construction of the project and the installation and commissioning of equipment for the technical transformation project with an annual output of 27,000 tons of fatty amine and its derivatives (including electronic-grade trioctylamine, tertiary alkyl amine and quaternary ammonium salt) ("technical transformation project" with an annual output of 15,000 tons of fatty tertiary amine, 10,000 tons of quaternary ammonium salt and 2,000 tons of electronic-grade trioctylamine).

  It is reported that Wansheng Dawei fatty amine products can be produced as fabric softeners, shampoos, cosmetics, printing and dyeing auxiliaries, synthetic fiber oil agents, demulsifiers, fungicides, buffers, etc., which are widely used in daily chemical industry, textile industry, petroleum industry, mining industry, transportation industry and other fields. Tertiary fatty amines are derived downstream into quaternary ammonium salts. Quaternary ammonium salts have excellent properties such as stable chemical properties, good dispersion and corrosion inhibition, and at the same time avoid the risk factors of chlorine-containing and oxygen-containing compounds. It is one of the leading directions in the development of disinfectant products in the world and has been widely used in food, cosmetics, textiles, oil fields and industrial water treatment. After the technical transformation project of Wansheng Dawei is put into production, it is beneficial to broaden the downstream product matrix and optimize and expand the company’s amine and daily chemical raw materials sector.

  Bank of Nanjing: The acquisition of controlling stake in Suning Consumer Finance Company was approved by the regulatory authorities.

  On the evening of August 16th, Bank of Nanjing announced that China Banking and Insurance Regulatory Commission agreed that the company would accept 36% equity of Suning Xiaojin held by Suning.cn Group Co., Ltd. and 5% equity of Suning Xiaojin held by Jiangsu Yanghe Winery Co., Ltd. After the completion of the equity change, the company’s shareholding in Suning Xiaojin will increase from 15% to 56%.

  Hongda Co., Ltd.: The production base and holding subsidiary of the headquarters temporarily cut off power and stopped production.

  () On the evening of August 16th, it was announced that the non-ferrous production base and phosphorus chemical production base (located in shifang city, Deyang City, Sichuan Province) of the company headquarters and Sichuan Mianzhu Chuanrun Chemical Co., Ltd., the holding subsidiary, were temporarily suspended from August 15th, and the expected suspension time was 24:00 on August 20th. The temporary suspension of production is expected to reduce the output of zinc alloy by about 1,000 tons, phosphorus chemical products by about 4,000 tons and synthetic ammonia by 2,000 tons. At present, the company’s inventory of related products is relatively sufficient, and this temporary suspension of production will not have a significant adverse impact on the company’s operating performance.

  The production base and subsidiaries of Hongda Co., Ltd. were temporarily suspended due to the power restriction policy.

  Hongda shares announced that in order to implement the emergency notice of Sichuan Provincial Department of Economy and Information Technology and State Grid Sichuan Electric Power Company, it was about "expanding the implementation scope of industrial enterprises transferring electricity to the people in 19 cities (states) in the whole province (except Panzhihua and Liangshan), and implementing a full production stop (except security load) for all industrial power users (including white-listed key security enterprises) in the orderly power utilization scheme of Sichuan Power Grid". The company’s headquarters non-ferrous production base and phosphorus chemical production base (located in shifang city, Deyang City, Sichuan Province) and its holding subsidiary, Sichuan Mianzhu Chuanrun Chemical Co., Ltd. (located in Mianzhu City, Deyang City, Sichuan Province) have temporarily stopped production since August 15, 2022, and the expected production suspension time is 24:00 on August 20, 2022 (subject to the notice of relevant departments).

  It is reported that the temporary suspension of production is expected to reduce the output of zinc alloy by about 1,000 tons, phosphorus chemical products by about 4,000 tons and synthetic ammonia by 2,000 tons.

  Donghu High-tech: Winning the bid for PPP development and construction project in Dangyang Economic Development Zone Industrial Park.

  Donghu High-tech announced on the evening of August 16 that Hubei Luqiao, a wholly-owned subsidiary, as the leader of the consortium, won the bid for the PPP development and construction project in the industrial park of Dangyang Economic Development Zone. According to the approved feasibility study report, the total investment of the project is 1.867 billion yuan. The project adopts BOT operation mode, and the cooperation period of the project is 20 years, including 3 years of construction and 17 years of operation.

  Bank of Nanjing: The shareholding ratio of Suning Xiaojin’s controlling stake was increased from 15% to 56%.

  On August 16th, Bank of Nanjing announced that recently, Suning Xiaojin received the Reply from the Insurance Regulatory Commission of Bank of China on the Change of Equity of Suning Consumer Finance Co., Ltd. (Yin Bao Jian Fu [2022] No.592), and agreed that the company would accept 36% equity of Suning Xiaojin held by Suning.cn Group Co., Ltd. and 5% equity of Suning Xiaojin held by Jiangsu Yanghe Winery Co., Ltd. After the completion of this equity change, the proportion of shares held by Nanjing Bank in Suning Xiaojin will increase from 15% to 56%.

  (Editor: Qian Xiaorui)

  120 million restricted shares of Xingfa Group were listed and circulated on August 22nd.

  () Announced that the number of restricted shares listed and circulated by the company this time is 120 million shares, and the date of listing and circulation of restricted shares is August 22, 2022.

  *ST Hengyu signed a major daily operation contract of 56.56 million yuan.

  *ST Hengyu announced that the company recently signed a product sales contract with a European customer. The subject matter of the contract is a 30,000-ton/year industrial continuous waste tire cracking production line, with a total contract amount of 8,366,700 US dollars, about 56.56 million yuan (including tax).

  This agreement is a contract for daily business activities. According to the performance schedule agreed in the contract, it will not have a significant impact on the company’s performance in 2022. If this contract is successfully performed, it is expected to have a positive impact on the company’s operating performance in 2023, and at the same time, it will help to enhance the company’s ability to continue to operate and brand influence, and have a positive impact on the company’s exploration of overseas markets.

  *ST Hengyu: signed a product sales contract of 56.56 million yuan with a European customer.

  *ST Hengyu announced on the evening of August 16th that the company recently signed a product sales contract with a European customer, with a total contract value of USD 8,366,700, or about RMB 56.56 million.

  Ai Ai Seiko 2021: It is planned to distribute 0.164 yuan per share, with ex-dividend on August 25th.

  () Announce the company’s annual profit distribution plan for 2021: a cash dividend of 0.164 yuan per share (including tax).

  The date of record for this equity distribution is August 24, 2022, and the ex-dividend date is August 25, 2022.

  Chifeng Gold: Wanxiang Mining has made progress in the general survey of rare earth minerals in the southern mining area of Sepon mine in Laos.

  () Announcement: Vientiane Mining Co., Ltd. ("Vientiane Mining"), a holding subsidiary of the company, has the exclusive right to explore and exploit mineral resources within a total area of 1247km, including Sepon Mining Area. At the beginning of 2021, when Wanxiang Mining Company was exploring gold and copper mines in the southern mining area, ionic rare earth ore anomalies were found in the granite distribution area. By studying the geological data and field geological investigation, it was found that the granite weathering crust in this area was rich in ion-adsorbed rare earth, and the prospecting prospect was considerable. From December 2021 to July 2022, Vientiane Mining carried out the general survey of rare earth minerals in this region, and has made progress in stages and compiled the General Survey Report of Rare Earth Minerals in the Southern Mining Area of Sepon Mine in Shawan Naji Province, Laos. The general survey progress of rare earth minerals in the southern mining area of Sepon Mine in Vientiane Mining is announced as follows:

  The general survey is carried out within 10km of the southern west area within the exploration right. In the southern western area, two ore bodies were identified by general survey. The ore bodies occurred in granite weathering crust, and the genetic type of the deposit belongs to ion adsorption rare earth deposit of weathering crust. The estimated total economic resources of the two ore bodies are (332+333) 32,047.52 tons, with an estimated area of 9.1km, the average vertical thickness of the ore bodies is 4.83m, and the average grade is 0.045%, of which 332 kinds of total rare earth oxides (TREO) are 8,075.02 tons, accounting for 25.2% of the total resources. Total phase rare earth oxide (TREO) is 23,972.5 tons in 333 categories, accounting for 74.8% of the total resources. The partition of ionic rare earth oxides shows that its partition type belongs to rare medium and heavy rare earth. Analogical evaluation of the technical performance of ore processing and extraction shows that the hydrogeological conditions in the mining area are simple, the engineering geological conditions are simple and the geological environment quality is good.

  The internal and external conditions for the development of this mining area are good. In-situ leaching process is used to extract rare earths, which has the advantages of simple production process, low cost, high output and high utilization rate of mineral resources. At present, the control range of drilling engineering in the southern western part of the mining area is about 10km, and the actual exposed area of granite exceeds 50km, so there is great potential for prospecting and increasing reserves in the mining area; In addition, about 330km of granite is exposed in the blank area around the mining area. Therefore, the prospect of weathering crust rare earth prospecting in this area is broad.

  Zejing Pharmaceutical’s application for marketing of Donafenib Toluene Sulfonate Tablets was approved.

  On the evening of August 15th, Zejing Pharmaceutical announced that its first-class new drug, Donafenib Toluene Sulfonate Tablets (trade name: Zepusheng, hereinafter referred to as "Donafenib"), which was independently developed by Zejing Pharmaceutical, was approved for the marketing of new drugs for the treatment of advanced, locally advanced or metastatic differentiated thyroid cancer. This is the second indication that Donafenib has been approved for marketing after it has been approved for patients with unresectable hepatocellular carcinoma who have not received systemic treatment before.

  Donafenib is an oral multi-target and multi-kinase inhibitor small molecule anti-tumor drug independently developed by the company. The marketing approval for the indication of treating advanced, locally advanced or metastatic radioactive iodine refractory differentiated thyroid cancer is mainly based on the results of a multi-center, randomized, double-blind, placebo-controlled phase III clinical trial of Donafenib in the treatment of locally advanced/metastatic radioactive iodine refractory differentiated thyroid cancer (research code ZGDD3). The main effectiveness results show that Donafenib group can significantly reduce the risk of disease progression, significantly prolong the survival time without disease progression and obtain better objective relief compared with placebo group. Detailed data of this clinical trial will be published in international academic journals in due course.

  In June 2021, the indications of Donafenib for patients with unresectable hepatocellular carcinoma who have not received systemic treatment before have been approved for marketing. Donafenib has been listed in the National Drug List of Basic Medical Insurance, Work Injury Insurance and Maternity Insurance (2021). At the same time, it has been included in the Health and Health Commission’s Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2022 Edition), Guidelines for Diagnosis and Treatment of Primary Liver Cancer by Chinese Society of Clinical Oncology (CSCO) (2022), Guidelines for Integrated Diagnosis and Treatment of Cancer in China (CACA Guide), Guiding Principles for Clinical Application of New Antitumor Drugs (2021 Edition), and China Expert Consensus on Perioperative Management of Hepatocellular Carcinoma (2021) Expert Consensus on Multidisciplinary Comprehensive Treatment of Liver Cancer in China, Clinical Practice Guidelines for TACE of Liver Cancer in China (2021 Edition) and Radiotherapy Guidelines for Primary Hepatocellular Carcinoma in China (2020 Edition).

  Proofread Liu Baoqing

  Sichuan Jinding subsidiary temporarily stopped production due to the restriction of electricity policy.

  () Announcement is issued, in order to implement the Emergency Notice of Sichuan Provincial Department of Economy and Information Technology and State Grid Sichuan Electric Power Company on Expanding the Implementation Scope of Power Transfer for Industrial Enterprises to the People, the company "expands the implementation scope of power transfer for industrial enterprises to the people in 19 cities (states) in the whole province (except Panzhihua and Liangshan), and implements a full production stop (except security load) for all industrial power users (including white-listed key security enterprises) in the orderly power consumption plan of Sichuan Power Grid. Sichuan Jindingshun Mining Co., Ltd., Sichuan Shuncai Building Materials Co., Ltd. and Sichuan Shuncai Xingshu Calcium Industry Co., Ltd., all wholly-owned subsidiaries of the company, stopped production on August 14, 2022.

  Since August 9, 2022, the production and operation of Sichuan Jindingshun Mining Co., Ltd., Sichuan Shuncai Building Materials Co., Ltd. and Sichuan Shuncai Xingshu Calcium Industry Co., Ltd., all wholly-owned subsidiaries of the company, have been affected by the power restriction policy. The company expects that by August 20, 2022, the power cut and shutdown will reduce the company’s limestone production by about 280,000 tons and calcium oxide production by about 20,000 tons, and the estimated net profit attributable to listed companies will be reduced by about 4.49 million yuan.

  (): Vanadium products are not the main products of the company, and the revenue generated in 2021 accounts for only 1.28%.

  Zhenhua shares announced that the deviation of the closing price of the company’s shares in three consecutive trading days on August 12, August 15 and August 16, 2022 exceeded 20%, which was an abnormal fluctuation of stock trading.

  It is reported that the company’s share price has increased greatly recently, and the company is concerned that some media have included the company in the vanadium battery concept stocks. Now the relevant information is as follows: The company is mainly engaged in the research and development, manufacturing and sales of chromium chemicals, vitamin K3 and other chromium salt co-production products, ultrafine aluminum hydroxide and other chromium salt by-products. The company’s vanadium product is a by-product of chromium salt of the company, which does not belong to the company’s main product. In 2021, the operating income of this product was 38.2 million yuan, accounting for 1.28% of the company’s operating income in the same period. This product accounted for a small proportion of the company’s operating income and did not have a significant impact on the company’s operation.

  Guanshi Technology: Xianghe Yongyuan and others intend to reduce their holdings by no more than 6%.

  () On the evening of August 16th, it was announced that the shareholders of the company, Xianghe Yongyuan, Yongjie Investment, Yongji Huachuang and Haoxin Investment, acted in concert, holding a total of 6.6% of the shares, and planned to reduce their holdings by no more than 6%.

  Four shareholders of Guanshi Technology intend to reduce their holdings by no more than 6%.

  Guanshi Technology announced that due to its own capital needs, the company’s shareholders Xianghe Yongyuan, Yongjie Investment, Yongji Huachuang and Haoxin Investment intend to reduce their holdings of the company’s shares through centralized bidding and block trading, with a total reduction of no more than 4.386 million shares, accounting for 6.00% of the company’s total share capital.

  Dongfang Fashion signed the first examination room operation and maintenance service project with a contract value of 13.8 million yuan.

  () Announcement was issued. On July 18th, 2022, the company received the Notice of Winning Bid from shenzhen public Traffic Police Bureau, which confirmed that the company was the successful bidder for the operation and maintenance service project of Yuanshan Examination Room of shenzhen public Traffic Police Bureau. Recently, the company and shenzhen public Traffic Police Bureau formally signed the "2022 Yuanshan Examination Room Operation and Maintenance Service Project Contract" with a total contract amount of 13.8 million yuan.

  This contract is the company’s first examination room operation and maintenance service project. If the project can be successfully implemented, it indicates that the company’s operation mode and management experience have been standardized and reproducible, which is of positive significance for the company’s future development.

  Kangxinuo sent 8 yuan date of record for every 10 shares on August 22nd.

  Kangxinuo announced that the company will distribute the rights and interests of A shares in 2021, and distribute the cash dividend (including tax) to all shareholders for every 10 shares in 8 yuan and date of record on August 22nd.

  Xingfa Group subsidiary Xingfu Electronics listed counseling for the record.

  Xingfa Group announced that the company received a notice from Hubei Xingfu Electronic Materials Co., Ltd. ("Xingfu Electronics"), a holding subsidiary, on August 16, 2022. On August 15, 2022, Xingfu Electronics handled the initial public offering counseling registration in Hubei Supervision Bureau of China Securities Regulatory Commission ("Hubei Securities Regulatory Bureau"). On the same day, Hubei Securities Regulatory Bureau officially issued a confirmation letter for counseling registration, and the counseling institution was () Co., Ltd.

  Xingfa Group subsidiary Xingfu Electronics listed counseling for the record.

  Xingfa Group announced that the company received a notice from Hubei Xingfu Electronic Materials Co., Ltd. ("Xingfu Electronics"), a holding subsidiary, on August 16, 2022. On August 15, 2022, Xingfu Electronics handled the initial public offering counseling registration in Hubei Supervision Bureau of China Securities Regulatory Commission ("Hubei Securities Regulatory Bureau"). On the same day, Hubei Securities Regulatory Bureau officially issued a confirmation letter for counseling registration, and the counseling institution was TF Securities Co., Ltd.

  From April to June, Vogel Optronics made provision for credit impairment and asset impairment totaling 6.072 million yuan.

  () Announce that, according to the Accounting Standards for Business Enterprises and the company’s accounting policies, in order to accurately and objectively reflect the company’s financial status as of June 30, 2022 and its operating results from April to June 2022, the company and its subsidiaries conducted a comprehensive inventory and impairment test on various accounts receivable, other accounts receivable and inventories, and the total provision for credit impairment and asset impairment was RMB 6.072 million from April to June 2022.

  Guo Mao shares: Shareholders Shen Huiping and Xu Ling intend to reduce their holdings by no more than 2% in total.

  Release on August 16th-Guo Mao announced that shareholders Shen Huiping and Xu Ling intend to reduce their holdings of the company’s shares by no more than 13,250,507 shares in total, with the reduction ratio not exceeding 2.00% of the company’s total share capital.

  China Telecom announced the half-year rights distribution plan for 2022, and plans to send 10 1.2 yuan.

  () The announcement was made on August 17th, and the contents of the company’s half-year equity distribution plan for 2022 are as follows: based on the total share capital of 77,629,728,700 shares, a cash dividend of RMB 1.20 will be distributed to all shareholders for every 10 shares, and a total cash dividend of RMB 9.316 billion will be distributed, accounting for 50.93% of the net profit attributable to the mother in the same period. No bonus shares will be distributed, and no capital reserve will be converted into share capital.

  According to the semi-annual performance report released by China Telecom in 2022, the company’s operating income was 240.219 billion yuan, a year-on-year increase of 10.42%; The net profit attributable to shareholders of listed companies was 18.291 billion yuan, a year-on-year increase of 3.09%; The basic earnings per share was 0.20 yuan, compared with 0.22 yuan in the same period last year.

  China Telecom Co., Ltd. is a leading large-scale comprehensive intelligent information service operator, whose main business is to provide mobile communication services, fixed-line and smart home services, and industrial digital services. The company’s main products and services include personal communication and information service (mobile communication service), home communication and information service (fixed network and smart home service), government-enterprise communication and information service (industrial digitalization). The company’s own brand "Tianyi Cloud" ranks first in the global public cloud IaaS.

  (Source: () iFinD)

  Wansheng Co., Ltd.: Trial production of subsidiary Wansheng Dawei technical transformation project

  On the evening of August 16th, Wansheng Co., Ltd. announced that Jiangsu Wansheng Dawei Chemical Co., Ltd., a wholly-owned subsidiary, had completed the main construction of the project, equipment installation and debugging, and the trial production plan was approved by experts and filed by relevant authorities, which met the trial production conditions and officially entered the trial production stage.

  The company said that at present, the project has only entered the trial production stage, and it will take some time from trial operation and production to full production and economic benefits. At the same time, it may also be affected by factors such as changes in market demand environment and intensified competition.

  Donghu High-tech: Winning the bid for 1.867 billion yuan PPP development and construction project.

  On the evening of August 16, Donghu High-tech announced that Hubei Luqiao, a wholly-owned subsidiary, as the leader of the consortium, won the bid for the PPP development and construction project in the industrial park of Dangyang Economic Development Zone. According to the approved feasibility study report, the total investment of the project is 1.867 billion yuan. The project adopts BOT operation mode, and the cooperation period of the project is 20 years, including 3 years of construction and 17 years of operation.

  Chen Lihong, the shareholder of Tianyong Intelligent, has reduced its holdings by 800,800 shares, and the time for reduction has expired.

  () Announcement was issued. On August 16, 2022, the company received the Letter of Notice on the Implementation Results of the Reduction Plan of Shanghai Tianyong Intelligent Equipment Co., Ltd. from the shareholder Chen Lihong. By August 16th, 2022, Chen Lihong reduced its holdings of 800,800 shares through call auction, accounting for 0.74% of the total share capital. As of the disclosure date of this announcement, the time interval of this reduction plan expires.

  6.66% of Shenzhen Qianhai Rongyao Capital Jiezhi Company, the major shareholder of Anfu Technology.

  () Announcement: Shenzhen Qianhai Glory Capital Management Co., Ltd. ("Shenzhen Qianhai Glory"), a shareholder holding 6.66% of the company’s shares, released the pledge of 7,457,200 shares on August 15, 2022, accounting for 6.66% of the company’s total share capital. Shenzhen Qianhai Glory plans to pledge the shares separately after this pledge to support the company’s follow-up financing.

  The actual controller of Guo Mao intends to reduce its shareholding by no more than 2%.

  Guo Mao shares announced that Shen Huiping, one of the company’s actual controllers, and Xu Ling, a concerted action person, intend to reduce their holdings by no more than 2%.

  Yijiahe completed the repurchase of 960,400 shares at a cost of 50,444,800 yuan.

  () Announcement was issued. As of August 16th, 2022, the implementation period of the company’s share repurchase has expired. The total number of shares repurchased by the company through centralized bidding transaction is 960,400 shares, accounting for 0.4619% of the company’s total share capital. The highest transaction price is 57.990 yuan/share, and the lowest transaction price is 47.463 yuan/share. The total amount of funds paid is 50,444,800 yuan (. The company’s share repurchase plan has been implemented.

  Shenzhen Maoye, the major shareholder of Heavy Drugs Holdings, and its concerted actions reduced their holdings by 1.08%.

  () Announcement was issued. On August 15, 2022, the company received the Notice on Reducing the Holding Shares of Heavy Drugs from Shenzhen Maoye (Group) Co., Ltd. ("Shenzhen Maoye"), a shareholder holding more than 5% of the company’s shares. Shenzhen Maoye and its concerted action () Co., Ltd. reduced their holdings by a total of 18,804,900 shares, with a reduction ratio of 1.078%.

  Huajian Group made LP and invested 480 million yuan.

  On August 16th, the investment community reported that East China Construction Group Co., Ltd. () announced that the company intends to use its own funds to subscribe for 480 million yuan to participate in the investment of high-quality private equity partnership enterprises in Shanghai Park as a limited partner.

  It is reported that the target scale of the fund is planned to be RMB 3.481 billion, with Shanghai Linfang Equity Investment Management Co., Ltd. as the fund manager, focusing on investing in the infrastructure of the park, with industrial workshops, R&D, innovative design and pilot platforms, warehousing and logistics, business incubators and industrial accelerators, and affordable rental housing.

  Huajian Group is a high-tech listed enterprise relying on Pioneer Technology. The group is positioned as an integrated service provider with engineering design consulting as the core and providing high-quality comprehensive solutions for urban construction. It owns more than 20 molecular companies and professional institutions, including East China Architectural Design and Research Institute, Shanghai Architectural Design and Research Institute, East China Urban Architectural Design and Research Institute and Shanghai Hydraulic Engineering Design and Research Institute.

  Fangda Special Steel plans to set up a wholly-owned subsidiary with a registered capital of 30 million yuan.

  () Announce that in order to effectively improve the company’s management level and realize the effective allocation of resources, according to the needs of the company’s business development, the company established a wholly-owned subsidiary Ningbo Changli International Trade Co., Ltd. with its own funds (subject to the approval of the industrial and commercial department) with a registered capital of RMB 30 million. The establishment of Ningbo Changli is conducive to meeting the needs of the company’s business development, optimizing the company’s resource allocation and improving the company’s management level.

  Hua ding shares’s 47,816,600 restricted shares will be listed and circulated on August 22nd.

  () Announced that the number of restricted shares listed and circulated this time was 47,816,600 shares, accounting for 4.19% of the company’s total share capital, and the listing and circulation date was August 22, 2022.

  Southern Media sent 3.3 yuan date of record for every 10 shares on August 22nd.

  () It is announced that the company will distribute the annual rights and interests in 2021, and distribute a cash dividend of 3.30 yuan (including tax) to all shareholders for every 10 shares, with date of record on August 22nd.

  Tianchen shares plan to pay 0.055 yuan per share in cash dividend on August 23rd.

  () Announcement, the company plans to distribute a cash dividend of 0.055 yuan (including tax) per share in the annual equity distribution in 2021, and the cash dividend distribution date is August 23, 2022.

  Tianchen co., ltd. completed the investment in Shanghai Chenhao architectural decoration engineering company.

  Tianchen shares announced that the company set up a wholly-owned subsidiary "Shanghai Chenhao Building Decoration Engineering Co., Ltd." with its own funds of RMB 5 million. Shanghai Chenhao Building Decoration Engineering Co., Ltd. has completed the relevant industrial and commercial registration procedures and obtained the Business License issued by Shanghai Baoshan District Market Supervision Administration.

  Anhui Zhidao, the shareholder of Shengxiang Bio, intends to reduce its shareholding by no more than 2%.

  Shengxiang Bio announced that due to its own capital needs, Anhui Zhidao intends to reduce its holdings of Shengxiang () by no more than 11,769,200 shares through centralized bidding, accounting for 2.00% of the company’s total share capital, which will be implemented within 6 months after 15 trading days from the date of the reduction plan, and the total number of shares reduced within 90 consecutive days will not exceed 1% of the company’s total shares.

  Anhui Zhidao, the shareholder of Shengxiang Bio, intends to reduce its shareholding by no more than 2%.

  Shengxiang Bio announced that due to its own capital demand, Anhui Zhidao intends to reduce its holdings of Shengxiang Bio by no more than 11,769,200 shares through centralized bidding transactions, accounting for 2.00% of the company’s total share capital, which will be implemented within 6 months after 15 trading days from the date of release of the reduction plan, and the total number of shares reduced within 90 consecutive days will not exceed 1% of the company’s total shares.

  The application for clinical trial of another antiviral drug in Kexing Pharmaceutical was accepted.

  On August 15th, Kexing Pharmaceutical announced that its application for clinical trial of "human interferon α2b spray" had been accepted by National Medical Products Administration.

  This is the third clinical trial application for antiviral drugs disclosed by Kexing Pharmaceutical for three months in a row. The first two are Shen 26, a small molecule oral drug against COVID-19 (disclosed on July 17, and approved), and α2b effervescent capsules, which are also human interferon (disclosed on June 20, and accepted).

  Kexing Pharmaceutical Co., Ltd. is an innovative international biopharmaceutical enterprise mainly engaged in the integration of R&D, production and sales of recombinant protein drugs and microecological agents. The company has been deeply involved in the field of antivirus for more than 20 years and achieved fruitful results. Its wholly-owned subsidiary, Shenzhen Kexing, is the first batch of the first industrialization base of China’s 863 Program achievements, and successfully developed the first domestic biological agent interferon α 1b-siroqin. With the entry of two products, SHEN26, a small molecule oral drug against COVID-19, and human interferon α2b, the pipeline layout of antiviral products of Kexing Pharmaceutical has become more complete and rich.

  It is understood that interferon can be described as a "sword" in the field of antivirus. It is a cytokine released by cells stimulated by virus infection. It is a soluble protein with multiple functions produced by monocytes and lymphocytes. It is a key effector molecule of innate and adaptive immunity, with broad-spectrum antiviral activity and immunomodulation, and is an important part of the body’s defense system. Interferon induces cells to produce a variety of antiviral proteins by binding to cell surface receptors, and inhibits virus replication in cells. At the same time, the specific cytotoxicity of macrophages and lymphocytes on target cells is enhanced by regulating immune function, which can effectively curb the occurrence of virus invasion and infection, enhance the activity of natural killer cells, inhibit the growth of tumor cells and eliminate early malignant cells.

  The human interferon α2b spray declared this time is two kinds of improved new drugs independently developed by Kexing Pharmaceutical. It optimizes the dosage form and administration route of the listed drugs, and increases the drug concentration in the focus by targeted local administration. It is convenient to use and carry, and has good patient compliance, which has obvious clinical advantages. The indication of the company’s human interferon α2b spray is to treat primary or recurrent skin herpes simplex (oral herpes and genital herpes) caused by virus.

  Kexing Pharmaceutical said that the research and development of the company’s human interferon α2b spray will help optimize the company’s product structure, enrich the product pipeline, enhance the company’s overall research and development capabilities and enhance the company’s long-term profitability. (Tan Pengpeng)

  Xiamen Tungsten Industry and Northern Rare Earth signed a strategic cooperation framework agreement.

  () announced that the Company and () signed this Agreement in Baotou City, Inner Mongolia Autonomous Region on August 16th, 2022. The two sides established a strategic partnership with each other. The two sides agreed that mutual benefit and win-win will be achieved through the coordinated development plan in the field of cooperation, so as to jointly form development advantages and promote all parties and their affiliated companies to become bigger and stronger. The two sides intend to carry out extensive cooperation in rare earth products, technical cooperation, equity, industrial operation, management, personnel training and exchanges.

  Xiamen Tungsten Industry and Northern Rare Earth signed a strategic cooperation framework agreement.

  Xiamen Tungsten Industry announced that the company and Northern Rare Earth signed this Agreement in Baotou City, Inner Mongolia Autonomous Region on August 16, 2022. The two sides established a strategic partnership with each other. The two sides agreed that mutual benefit and win-win will be achieved through the coordinated development plan in the field of cooperation, so as to jointly form development advantages and promote all parties and their affiliated companies to become bigger and stronger. The two sides intend to carry out extensive cooperation in rare earth products, technical cooperation, equity, industrial operation, management, personnel training and exchanges.

  70 million shares of the company held by the controlling shareholder of Blu-ray Development will be auctioned by the judiciary.

  () Announcement, the company received a notice from the controlling shareholder Blu-ray Group that some of its shares will be auctioned in September 2022. As of August 15, 2022, Blu-ray Investment Holding Group Co., Ltd. (hereinafter referred to as "Blu-ray Group"), the controlling shareholder of the company, held 1.048 billion shares of the company, accounting for 34.53% of the company’s total share capital. The shares auctioned by the judiciary this time are 70 million shares held by Blu-ray Group, accounting for 2.31% of the company’s total share capital.

  Blu-ray development: The relevant resources and technical personnel of the invested photovoltaic company have not been equipped.

  Blu-ray Development announced the change on the evening of August 16th. Recently, some media reported that Blu-ray Development cooperated with Guangdong Ouhao Group Co., Ltd. to establish Chengdu Oulan Photovoltaic Co., Ltd. to carry out photovoltaic projects. Chengdu Oulan Photovoltaic Co., Ltd. is a recently registered company with a registered capital of 100 million yuan, and its shareholding ratio is 30% (non-holding), which has not been paid in. At present, relevant resources and technical personnel have not been equipped, and there are no cooperation projects, so there are uncertainties in the follow-up. Up to now, the company’s debt restructuring plan is still being drafted, and there is no substantial progress.

  Two-panel blue light development: at present, photovoltaic related resources and technical personnel have not been equipped, and there are no cooperation projects.

  Blu-ray Development announced a change announcement. Recently, some media reported that Blu-ray Development cooperated with Guangdong Ouhao Group Co., Ltd. to establish Chengdu Oulan Photovoltaic Co., Ltd. to carry out photovoltaic projects. Chengdu Oulan Photovoltaic Co., Ltd. is a recently registered company with a registered capital of 100 million yuan, and its shareholding ratio is 30% (non-holding), which has not been paid in. At present, relevant resources and technical personnel have not been equipped, and there are no cooperation projects, so there are uncertainties in the follow-up.

  The cumulative reduction ratio of Lan Jian intelligent shareholder Jinan Venture Capital reached 1.03%, and the reduction amount was more than half.

  Lan Jian Intelligent announced that on August 16, 2022, the company received a letter of notification from the shareholder Jinan Technology Venture Capital Group Co., Ltd. (hereinafter referred to as "Jinan Venture Capital"). From July 29, 2022 to August 16, 2022, Jinan Venture Capital reduced its holdings of the company’s shares by centralized bidding, accounting for 749,500 shares, accounting for 1.03% of the company’s total shares. The number of this reduction plan has exceeded half, and the reduction plan has not yet been implemented.

  Parker New Materials: The application for non-public offering of shares was approved by CSRC.

  () Announcement: The company received a reply from the China Securities Regulatory Commission, approving the company to issue no more than 21.6 million new shares in a non-public manner.

  Shengxiang Bio: Zhidao Investment intends to reduce its shareholding by no more than 2%.

  Shengxiang Bio announced on the evening of August 16 that Anhui Zhidao Investment Co., Ltd., a shareholder holding 5.1% of the company’s shares, intends to reduce its shareholding by no more than 2%.

  Donghu High-tech: The subsidiaries jointly won the bid for the PPP development and construction project in the industrial park.

  Donghu High-tech announced that the consortium led by Hubei Luqiao, a wholly-owned subsidiary, won the bid for the PPP development and construction project of Dangyang Economic Development Zone Industrial Park, with a total investment of 1.867 billion yuan.

  Dongfang Huanyu: Li Weiwei, the actual controller, intends to reduce his shareholding by no more than 0.26%.

  Released on August 16th-Dongfang Huanyu announced that the company received the Letter of Notice on Share Reduction Plan issued by Li Weiwei, the actual controller, director and deputy general manager, on August 16th, 2022, and that Li Weiwei intends to reduce the shares of the company he holds by centralized competitive bidding within six months after fifteen trading days from the date of disclosure of this announcement, with a total of no more than 500,000 shares, accounting for no more than 0.26% of the total share capital of the company.

  Trial production of Wansheng Dawei technical transformation project of Wansheng Co., Ltd.

  Wansheng Co., Ltd. announced that Wansheng Dawei, a wholly-owned subsidiary, has completed the construction of the main body of the project and the installation and commissioning of equipment for the technical transformation project of fatty amine and its derivative products (including electronic trioctylamine, tertiary alkyl amine and quaternary ammonium salt) with an annual output of 27,000 tons. After the trial production plan has been reviewed and approved by experts and filed by relevant competent authorities, it meets the trial production conditions and has officially entered the trial production stage.

  Shareholders of Guanshi Technology intend to reduce their holdings by no more than 6% in total.

  Guanshi Technology announced that the shareholders of the company, Xianghe Yongyuan, Yongjie Investment, Yongji Huachuang and Haoxin Investment, intend to reduce their shares in the company through centralized bidding and block trading, with a total reduction of no more than 4,385,973 shares, accounting for 6% of the total share capital of the company. The main body of the above reduction is a concerted action.

  Bank of Nanjing: The acquisition of Suning Xiaojin’s equity was approved by the regulatory authorities, and the shareholding ratio increased from 15% to 56%.

  On August 16th, Bank of Nanjing announced that Xiaojin had recently received the Reply of China Bank on the Change of Equity of Suning Co., Ltd. from the Insurance Regulatory Commission, and agreed that the company would accept 36% equity of Suning Xiaojin held by Suning.cn Group Co., Ltd. and 5% equity of Suning Xiaojin held by Jiangsu Yanghe Winery Co., Ltd. After the completion of this equity change, the company’s shareholding in Suning Xiaojin will increase from 15% to 56%.

  It is understood that on January 13, 2022, the Ninth Meeting of the Ninth Board of Directors of Bank of Nanjing reviewed and approved the Proposal on Acquisition of Controlling Shares of Participating Financial Institutions, and started the acquisition of equity of Suning Xiaojin. On March 4, 2022, the signing of the 41% equity acquisition agreement of Suning Xiaojin was completed.

  Zhongheng Group obtained the drug registration certificate and the notice of approval for the listing application of chemical raw materials.

  () It was announced that Chongqing () Co., Ltd. (hereinafter referred to as "Laimei Pharmaceutical"), the holding subsidiary of the company, received the Drug Registration Certificate of esmomeprazole magnesium enteric-coated capsules of 20mg and 40mg approved and issued by National Medical Products Administration, and Chongqing Laimei Longyu Pharmaceutical Co., Ltd. (hereinafter referred to as "Laimei Longyu"), the holding grandson of the company, received the Notice of Approval for the Listing of Esomeprazole magnesium API approved and issued by National Medical Products Administration.

  This time, Laimei Pharmaceutical and Laimei Longyu obtained the Drug Registration Certificate of Esomeprazole Magnesium Enteric-coated Capsules (specifications: 20mg and 40mg) and the Notice of Approval for the Marketing Application of Esomeprazole Magnesium Bulk Drug, which is conducive to further enriching the company’s product line and increasing the company’s market share of digestive tract drugs.

  From January to July, China Chemical signed a total of 182.939 billion yuan of new contracts, a year-on-year increase of 29.56%.

  () Announced that from January to July, 2022, the company realized an accumulated operating income of 88.69 billion yuan, a year-on-year increase of 35.52%; The cumulative amount of newly signed contracts was 182.939 billion yuan, a year-on-year increase of 29.56%.

  China Chemistry: In the first seven months, the revenue reached 88.69 billion yuan, a year-on-year increase of 35.52%.

  China Chemical announced on the evening of August 16 that from January to July, the company realized an accumulated operating income of 88.69 billion yuan, a year-on-year increase of 35.52%; The cumulative amount of newly signed contracts was 182.939 billion yuan, a year-on-year increase of 29.56%.

  Shenzhen Venture Capital, a shareholder of Pumen Technology, and its related parties reduced their holdings by 4 million shares to 5.55%.

  Pumen Technology announced that the company’s shareholder Shenzhen Innovation Investment Group Co., Ltd. ("Shenzhen Venture Capital") and its related parties Shenzhen Hongtu Peacock Venture Capital Co., Ltd., Shenzhen Talent Innovation Venture No.1 Equity Investment Fund (Limited Partnership), Jiangsu Hongtu Software Venture Capital Co., Ltd., Guangdong Hongtu Venture Capital Co., Ltd. and Dongguan Hongtu Venture Capital Co., Ltd. reduced their holdings by 4,002,200 shares from February 17 to August 16, 2022, accounting for 0.95% of the company’s total share capital.

  The final success rate of online issuance of Xuantai Medicine after callback was 0.0337%.

  Xuantai Pharmaceutical announced that after the callback mechanism was started, the final number of shares issued offline was 30,151,000 shares, accounting for 70.00% of the number issued after deducting the number of strategic placements, and the final number of shares issued online was 12,922,000 shares, accounting for 30.00% of the number issued after deducting the number of strategic placements. After the callback mechanism is started, the final winning rate of online issuance is 0.03366050%.

  Grasping the opportunity of "new infrastructure", Sichuan Road and Bridge strives to create a new field of "intelligent manufacturing"

  Recently, () announced that the main purpose of strategic cooperation with Sichuan Energy Investment Group Co., Ltd. (hereinafter referred to as "Nengtou Group") and () Co., Ltd. (hereinafter referred to as "BYD") is to better empower the company to be digital and green and low-carbon. "Listed companies are committed to digital transformation, and Nengtou Group and BYD have important strategic resources for the transformation and upgrading of the transportation infrastructure construction business undertaken by Sichuan Luqiao through technology empowerment".

  It is reported that at present, Sichuan Road and Bridge has cooperated with Chinese Academy of Sciences to carry out intelligent driving research in the field of construction machinery, and its core technology has been successfully applied to the self-developed automatic intelligent loader, and the construction equipment has been tested and put into trial operation in the construction scene of Sichuan Road and Bridge. In the future, Sichuan Luqiao will deepen cooperation with strategic partners such as BYD and Nengtou Group in the research field to further promote the digitalization and green low-carbon transformation of enterprises.

  Respond to the call of national intelligent construction and comprehensively lay out green and low-carbon construction equipment.

  According to Lu Wei, chief engineer of Sichuan Road and Bridge, as early as July 2020, 13 departments including the Ministry of Housing and Urban-Rural Development jointly issued the Guiding Opinions on Promoting the Coordinated Development of Intelligent Construction and Building Industrialization. In September, 2021, the State Council, the Central Committee of the Communist Party of China issued the Opinions on Completely, Accurately and Comprehensively Implementing the New Development Concept and Doing a Good Job of Carbon Neutralization in peak carbon dioxide emissions. The introduction of these policies are all important instructions made by the state for energy conservation, emission reduction and high-quality development of traditional construction machinery and construction industry.

  This also means that the construction machinery and construction industry, as traditional high-energy enterprises, must actively upgrade their industrial intelligence and use cleaner and more environmentally friendly energy in order to stay ahead of the times. At the same time, relevant information also shows that at present, the bidding standards of road and bridge construction owners in many developed areas abroad have gradually upgraded from economically applicable requirements to the requirements of carbon neutrality, carbon emission and sustainable development, and the external ability of traditional construction technology to obtain orders is gradually weakening.

  From this point of view, whether it is the business layout planning of Sichuan Road and Bridge as an advanced domestic construction unit "going out" or the strategic guidance of domestic macro-planning, actively deploying intelligent manufacturing has become the only way for Sichuan Road and Bridge to transform and upgrade and move towards high-quality development.

  In terms of actual progress, the data show that at present, Sichuan Road and Bridge has established a low-carbon intelligent innovation laboratory of Shudao Group with BYD and many large domestic machinery and equipment manufacturers, which is committed to solving technical problems such as standardization of charging and replacing battery interfaces, battery modularization and charging and replacing facilities for intelligent road openers, road rollers, construction heavy commercial vehicles and construction machinery vehicles. In addition, in the field of "Three Electricity" (battery, motor and circuit system) of construction machinery, BYD has also cooperated with Sichuan Road and Bridge to complement each other’s advantages and worked together to provide a more economical, durable and suitable package of construction services for the construction site, further enhancing the core competitiveness of China Construction and jointly promoting the innovation and commercial application of related technologies in the field of transportation infrastructure construction.

  Embrace the core technology and promote the improvement of construction energy efficiency

  At the same time, Wang Yue, general manager of Sichuan Intelligent Construction Technology Co., Ltd. further introduced that through years of joint research with the Chinese Academy of Sciences, Sichuan Road and Bridge now has the leading artificial intelligence driving system for construction machinery in China.

  "Sichuan Road and Bridge has invested two things through the artificial intelligence driving system and a large number of equipment in engineering construction scenes, forming supporting intellectual property rights for information intelligent construction. At present, the fully-automatic loader applying the company’s independent intellectual property rights has been put into trial use. In the future, road and bridge planning will cooperate with strategic parties in the production and leasing of fully-automatic loaders, which may become another new profit growth engine of Sichuan Road and Bridge. "

  It is worth mentioning that in addition to in-depth research and development of artificial intelligence digital production equipment, Sichuan Road and Bridge has completed research and development and put into trial use, as well as intelligent construction beam factory. According to reports, Sichuan Luqiao 2.0 Beam Factory, which has an intelligent factory line, has nearly doubled its production efficiency compared with the traditional one, and its production quality and production safety guarantee have also been improved and strengthened. The demand for workers in the production line has also dropped from 100 to 80.

  At the same time, Sichuan Road and Bridge is also upgrading its intelligent manufacturing in the fields of unmanned pavement construction and intelligent tunnel construction. Taking the intelligent tunnel construction as an example, in related operations, the company not only seamlessly transformed and connected the construction equipment on the AI platform through each process, but also changed the traditional construction norms and made technological innovations in the blasting mode of blasting explosives, which solved the problem of difficult control of initiation in fully automatic scenes.

  "The company’s research on industrial upgrading is to find an industrial scene that is more suitable for intelligent manufacturing in the whole industrial chain of new infrastructure. And this kind of technological innovation is not simply digital and intelligent machinery. The core connotation of the company’s industrial upgrading is to study the technical scheme and reconstruct the construction production from the bottom logic, in order to improve the production energy efficiency and meet the requirements of energy conservation and emission reduction. "

  Complementary advantages, the frontier of production, investment and research work together to overcome technical difficulties

  It is foreseeable that with the advantages of multiple construction scenes of Sichuan Road and Bridge, the existing technical reserves and the heavy support of BYD’s core technologies and production capacity, such as batteries, motors, electronic control systems, and car-level chips, the two partners will surely overcome all links involving intelligent manufacturing in the future, and gradually carry out pilot and promotion. "From enterprise standards to local standards, and then complete the old and new transformation and technological change of the new infrastructure industry".

  However, in the process of upgrading the whole industry, the company also said that there are still some technical difficulties that have not been overcome, such as the replacement of new energy lithium batteries, the energy storage of mechanical engineering power, and the application of artificial intelligence in pavement construction.

  In view of the technical difficulties that have been overcome in the current research and development, the company actively carries out technical reserves and strategic layout, with a view to the transformation of core technologies in the future: in terms of battery energy storage, the company established a mining investment and development company to reserve mineral resources and make resource reserves for the battery processing of the company’s construction equipment.

  From the layout of intelligent manufacturing to the introduction of strategic partners, the successful incubation of intelligent beam factory and the successful trial of fully automatic road loader, Sichuan Luqiao has gradually transformed and upgraded from a traditional large-scale infrastructure company with multiple construction qualifications to a new intelligent manufacturing infrastructure company with core intellectual property rights. In the future, after further deepening cooperation with BYD and Nengtou Group, we look forward to the next breakthrough in the technical difficulties of intelligent construction.

  Vast depth will be listed on the Shanghai Stock Exchange in science and technology innovation board on August 18th.

  Vast depth announcement, the company’s stock will be listed in science and technology innovation board on August 18th, 2022.

  Shengxiang Bio-shareholders intend to reduce their holdings by no more than 2%.

  Shengxiang Bio announced that Anhui Zhidao, a shareholder holding 5.10% shares, intends to reduce the company’s shares by no more than 2% of the company’s total share capital through centralized bidding transactions.

  () 4.6136 yuan will be distributed for every 10 shares in 2021, and date of record will be August 22nd.

  Haier Zhijia announced that the implementation plan of the company’s annual equity distribution in 2021 is as follows: based on the total share capital of 6,224,810,900 shares, a cash dividend of 4.61 yuan will be distributed to all shareholders for every 10 shares, and a total cash dividend of 2.872 billion yuan will be distributed, accounting for 21.98% of the net profit attributable to the mother in the same period. No bonus shares will be distributed, and no capital reserve will be converted into share capital.

  The distribution of rights and interests in date of record is August 22nd, and the ex-dividend date is August 23rd.

  According to the 2021 annual performance report released by Haier Zhijia, the company’s operating income was 227.556 billion yuan, an increase of 8.5% year-on-year; The net profit attributable to shareholders of listed companies was 13.067 billion yuan, a year-on-year increase of 47.1%; The basic earnings per share was 1.41 yuan, compared with 1.34 yuan in the same period last year.

  Haier Zhijia Co., Ltd. is an electrical appliance company. The company is mainly engaged in the production and operation of refrigerators, air conditioners, electric freezers, washing machines, water heaters, dishwashers, gas stoves and other household appliances and related products, as well as the commercial circulation business in gooday.

  Up to now, the company has accumulated more than 53,000 patent applications around the world, including more than 33,000 invention patents, accounting for more than 60%, ranking first in China’s home appliance industry, reflecting the leading patent quality; There are more than 11,000 overseas invention patents, covering 28 countries, and it is the China household appliance enterprise with the most overseas patents; Accumulated 9 national patent gold medals, ranking first in the domestic industry; "National Science and Technology Progress Award" is the highest honor in China’s scientific and technological circles, and Haier has won 15 awards, which is the home appliance enterprise that has won the most awards, accounting for more than half of the industry. It has won 3 "China Excellent Industrial Design Gold Awards" by the Ministry of Industry and Information Technology, and is the only enterprise that has won the "National Industrial Design Gold Award" for three consecutive years; Accumulated 3 international design gold medals and 194 design awards (including the above 3 gold medals).

  (Source: Straight Flush iFinD)

  In 2021, Kangxinuo sent 8 yuan date of record for every 10 shares on August 22nd.

  Kangxinuo announced that the implementation plan of the company’s annual equity distribution in 2021 is as follows: based on the total share capital of 114,279,000 shares, a cash dividend of 8.00 yuan will be distributed to all shareholders for every 10 shares, and a total cash dividend of 91,423,200 yuan will be distributed, accounting for 4.78% of the net profit attributable to the mother in the same period. No bonus shares will be distributed, and no capital reserve will be converted into share capital.

  The distribution of rights and interests in date of record is August 22nd, and the ex-dividend date is August 23rd.

  According to the 2021 annual performance report released by Kangxinuo, the company’s operating income was 4.300 billion yuan, a year-on-year increase of 17,174.82%; The net profit attributable to shareholders of listed companies was 1.914 billion yuan, turning losses into profits year-on-year, compared with-397 million yuan in the same period last year; The basic earnings per share was 7.74 yuan, compared with -1.72 yuan in the same period last year.

  The main business of Kangxinuo Biological Co., Ltd. is research and development, production and commercialization of innovative vaccines that meet China and international standards. The company’s main products are Ebola virus disease vaccine, meningitis vaccine, DTP vaccine, pneumonia vaccine, tuberculosis vaccine, herpes zoster vaccine, COVID-19 vaccine, adenovirus vaccine and polio vaccine. The company has won many honors, such as "Tianjin Gazelle Enterprise Outstanding Innovation Award", "China’s Most Growing Scientific and Innovative Pharmaceutical Enterprise" and "Tianjin Key Laboratory of Respiratory Bacterial Recombination and Combined Vaccine Enterprise".

  (Source: Straight Flush iFinD)

  Ai Ai Seiko will pay 1.64 yuan for every 10 shares in 2021, and date of record will be August 24th.

  Aiai Seiko announced that the company’s annual equity distribution implementation plan for 2021 is as follows: based on the total share capital of 130,673,200 shares, a cash dividend of 1.64 yuan will be distributed to all shareholders for every 10 shares, and a total cash dividend of 21,430,400 yuan will be distributed, accounting for 62.9% of the net profit attributable to the mother in the same period. No bonus shares will be distributed, and no capital reserve will be converted into share capital.

  The distribution of rights and interests in date of record is August 24th, and the ex-dividend date is August 25th.

  According to the 2021 annual performance report released by Ai Ai Seiko, the company’s operating income was 252 million yuan, a year-on-year increase of 30.04%; The net profit attributable to shareholders of listed companies was 34.073 million yuan, an increase of 11.48% year-on-year; The basic earnings per share was 0.26 yuan, compared with 0.23 yuan in the same period last year.

  Aiai Precision Industrial Conveying System (Shanghai) Co., Ltd. is mainly engaged in the research and development, production and sales of light conveyor belts. The main products are light industrial belts made of ordinary polymer materials and precision industrial belts made of environment-friendly polymer materials.

  (Source: Straight Flush iFinD)

  Mubang Hi-Tech plans to invest 4.8 billion yuan to build a 10GW TOPCON photovoltaic cell production base project.

  () Announced that the company signed the Strategic Cooperation Framework Agreement with the People’s Government of Echeng District. Both parties are willing to make full use of their respective resource advantages, arrange about 500 mu of project land in the People’s Government Park of Echeng District, and build a 10GW TOPCON photovoltaic cell production base project. The investment scale of the project is estimated to be 4.8 billion yuan.

  At present, the company is not engaged in photovoltaic cell business, nor has TOPCON photovoltaic cell production technology reserve, nor has TOPCON cell talent team, and is actively contacting to introduce talents in related fields, which may lead to the risk that the introduction of talents is not up to expectations.

  Mubang Hi-Tech terminated the construction of 8GW TOPCON photovoltaic cell production project.

  Mubang Hi-Tech announced that on June 2, 2022, the company signed the Investment Strategic Cooperation Framework Agreement with the Anyi County People’s Government, and arranged about 300 mu of land for the project within the industrial park to build an 8GW TOPCON photovoltaic cell production project.

  After the signing of the Framework Agreement, the company and the Anyi County People’s Government fully communicated and exchanged views on the project promotion of this cooperation, and no specific cooperation agreement has been formed so far. Through friendly negotiation, the company decided to terminate the Framework Agreement signed with the Anyi County People’s Government.

  Pingxiang Jingyi, the shareholder of Platinum, intends to reduce its shareholding by no more than 2.8%.

  Platinum announced that Pingxiang Jingyi, a shareholder holding 11.23% of shares, intends to reduce its holdings by no more than 2.8% of the company’s total share capital through centralized bidding and block trading.

  Mubang Hi-Tech: It is planned to build a 10GW TOPCON photovoltaic cell production base project.

  Mubang Hi-Tech announced that the company has signed the Strategic Cooperation Framework Agreement with the government of Echeng District, and plans to arrange about 500 mu of project land in the government park of Echeng District to build a 10GW TOPCON photovoltaic cell production base project. The investment scale of the project is estimated to be 4.8 billion yuan.

  On the same day, the company announced that on June 2, 2022, the company signed the Framework Agreement on Investment Strategic Cooperation with Anyi County Government, and planned to arrange about 300 mu of land for the project within the industrial park to build an 8GWTOPCON photovoltaic cell production project. After the signing of the Framework Agreement, the company and Anyi county government have fully communicated and exchanged views on the promotion of this cooperation project, and no specific cooperation agreement has been formed so far. Through friendly negotiation, the company decided to terminate the Framework Agreement signed with Anyi County Government.

  CDH Investment, the major shareholder of Xinneng Technology, has reduced its shareholding by 1%.

  () Announcement: from July 18, 2022 to August 16, 2022, Dinghui Investment, a shareholder holding more than 5% of the company’s shares, has reduced its holdings of 5 million shares through centralized bidding, accounting for 1.0000% of the company’s total share capital. The planned reduction of shares through this centralized bidding has exceeded half.

  Mubang Hi-Tech: It is planned to invest 4.8 billion yuan to build a 10GW TOPCON photovoltaic cell production base project.

  Mubang Hi-Tech announced on the evening of August 16th that the company signed the Strategic Cooperation Framework Agreement with the government of Echeng District. Both parties are willing to arrange about 500 mu of land for the project in the government park of Echeng District to build a 10GW TOPCON photovoltaic cell production base project. The investment scale of the project is estimated to be 4.8 billion yuan. In addition, the company terminated the framework agreement signed with Anyi county government for the construction of 8GW TOPCON photovoltaic cell production project.

  Bolite: Pingxiang Jingyi intends to reduce its shareholding by no more than 2.8%.

  On the evening of August 16th, Platinum announced that Pingxiang Jingyi Business Information Consulting Partnership (Limited Partnership) (hereinafter referred to as "Pingxiang Jingyi"), a shareholder holding 11.23% of the company’s shares, intends to reduce its holdings by no more than 2.8%.

  Platinum shareholders intend to reduce their holdings by no more than 2.8%.

  Platinum announced that Pingxiang Jingyi, a shareholder holding 11.23%, plans to reduce the company’s shares by no more than 2.8% of the company’s total share capital.

  Lianglianban Guangan Aizhong: At present, the company’s production and operation activities are normal.

  The financial sector announced on August 16th that the company’s current production and operation activities are normal. Recently, the power supply in Sichuan is facing a severe situation, and the company has started the first-level power supply control measures. The company’s power supply pressure is obvious, but the internal production and operation order is normal, and the company’s operating performance has not been significantly affected.

  Tianchen shares will be paid 0.55 yuan for every 10 shares in 2021, and date of record will be August 22nd.

  Tianchen Co., Ltd. announced that the implementation plan of the company’s annual equity distribution in 2021 is as follows: based on the total share capital of 686,677,100 shares, a cash dividend of 0.55 yuan will be distributed to all shareholders for every 10 shares, and a total cash dividend of 37,767,200 yuan will be distributed, accounting for 30.69% of the net profit attributable to the mother in the same period. No bonus shares will be distributed, and no capital reserve will be converted into share capital.

  The distribution of rights and interests in date of record is August 22nd, and the ex-dividend date is August 23rd.

  According to the 2021 annual performance report released by Tianzhu Co., Ltd., the company’s operating income was 41.8176 million yuan, a year-on-year increase of 13.37%; The net profit attributable to shareholders of listed companies was 123 million yuan, a year-on-year increase of 16.84%; The basic earnings per share was 0.18 yuan, compared with 0.15 yuan in the same period last year.

  Shanghai Tianchen Co., Ltd. mainly engages in taxi operation, property leasing and property management. Mainly including taxi operation and property leasing.

  (Source: Straight Flush iFinD)

  Southern Media will send 3.3 yuan date of record for every 10 shares in 2021 as August 22nd.

  Southern Media announced that the company’s annual equity distribution implementation plan for 2021 is as follows: based on the total share capital of 881,970,100 shares, a cash dividend of 3.30 yuan will be distributed to all shareholders for every 10 shares, and a total cash dividend of 291 million yuan will be distributed, accounting for 36.01% of the net profit attributable to the mother in the same period. No bonus shares will be distributed, and no capital reserve will be converted into share capital.

  The distribution of rights and interests in date of record is August 22nd, and the ex-dividend date is August 23rd.

  According to the 2021 annual performance report released by Southern Media, the company’s operating income was 7.598 billion yuan, a year-on-year increase of 10.17%; The net profit attributable to shareholders of listed companies was 808 million yuan, a year-on-year increase of 6.3%; The basic earnings per share was 0.90 yuan, compared with 0.85 yuan in the same period last year.

  The main business of Southern Publishing Media Co., Ltd. is book publishing, printing and material supply, newspapers and new media. The company’s main products are teaching materials, teaching AIDS, general books, audio-visual products, stationery and newspaper media.

  Nine books, such as China’s Great Logic of Reform, China Bridge: The Dream of Hong Kong-Zhuhai-Macao Bridge, Far Sunflower Field, and two audio-visual products, such as Forty Years of Fengyun and Hong Kong-Zhuhai-Macao Bridge, were awarded the "Five One Projects" in the 11th Guangdong Province. By the end of June 2019, the number of commercial downloads of "Time Finance" APP reached 15 million/person, with 500,000 registered users. It won the "Best New Media Platform" award in the list of new economic innovation forces in China in 2019, and ranked fourth in the list of financial apps in Internet Weekly of Chinese Academy of Sciences in the first half of 2019.

  (Source: Straight Flush iFinD)

  Mubang Hi-Tech: It is planned to invest 4.8 billion yuan to build a 10GW TOPCON photovoltaic cell production base project.

  The financial sector announced on August 16th that Mubang Hi-Tech had signed the Strategic Cooperation Framework Agreement with the People’s Government of Echeng District. Both parties are willing to make full use of their respective resource advantages, arrange about 500 mu of project land in the people’s government park of Echeng District, and build a 10GW TOPCON photovoltaic cell production base project. The investment scale of the project is estimated to be 4.8 billion yuan. On the same day, it was announced that the company terminated the framework agreement signed with the Anyi County People’s Government for the construction of 8GW TOPCON photovoltaic cell production project.

  Guang ‘an Aizhong’s current production and operation activities are normal.

  Guang ‘an Aizhong announced that the deviation of the closing price of the company’s shares in three consecutive trading days on August 12, August 15 and August 16, 2022 was more than 20%, which was an abnormal fluctuation of stock trading according to the relevant provisions of the Trading Rules of Shanghai Stock Exchange.

  The company’s current production and operation activities are normal. Recently, the power supply in Sichuan is facing a severe situation, and the company has started the first-level power supply control measures. The company’s power supply pressure is obvious, but the internal production and operation order is normal, and the company’s operating performance has not been significantly affected.

  Further focus on the main business Xingfa Group intends to spin off its holding subsidiary Xingfu Electronics to list in science and technology innovation board.

  Xingfa Group announced on the evening of August 16 that the company received a notice from its holding subsidiary Xingfu Electronics on August 16, and Xingfu Electronics registered the initial public offering counseling in Hubei Securities Regulatory Bureau on August 15. On the same day, Hubei Securities Regulatory Bureau officially issued a confirmation letter for counseling registration, and the counseling institution was TF Securities.

  It is understood that Xingfa Group intends to spin off Xingfu Electronics to the Shanghai Stock Exchange for listing in science and technology innovation board. After the completion of this spin-off, the ownership structure of Xingfa Group will not change, and it will still maintain its control over Xingfu Electronics.

  Through this spin-off, Xingfa Group will further focus on the production and sales of fine phosphorus chemical products such as phosphate rock and phosphate, glyphosate, silicone products, chlor-alkali, dimethyl sulfoxide and fertilizer products, and the trade business of related chemical products; Xingfu Electronics will become an independent electronic chemicals business listing platform under Xingfa Group. The spin-off and listing is conducive to further enhancing the cohesion of the core personnel of Xingfu Electronics, enhancing the brand awareness and social influence of Xingfu Electronics, strengthening the competitive position and advantages of Xingfu Electronics in the field of electronic chemicals, enhancing the R&D investment of Xingfu Electronics in core and cutting-edge technologies and products, maintaining the vitality of business innovation, enhancing the market development ability and promoting its healthy and sustainable development.

  This spin-off can only be implemented after meeting a number of conditions, including but not limited to obtaining the formal approval of the company’s shareholders’ meeting and fulfilling the corresponding procedures of Shanghai Stock Exchange and China Securities Regulatory Commission. There are uncertainties about whether this spin-off can be approved or not, and when it will finally be approved or approved. (Cheng Wei)

  Further focus on the main business Xingfa Group intends to spin off its holding subsidiary Xingfu Electronics to list in science and technology innovation board.

  Xingfa Group announced on the evening of August 16 that the company received a notice from its holding subsidiary Xingfu Electronics on August 16, and Xingfu Electronics registered the initial public offering counseling in Hubei Securities Regulatory Bureau on August 15. On the same day, Hubei Securities Regulatory Bureau officially issued a confirmation letter for counseling registration, and the counseling institution was TF Securities.

  It is understood that Xingfa Group intends to spin off Xingfu Electronics to the Shanghai Stock Exchange for listing in science and technology innovation board. After the completion of this spin-off, the ownership structure of Xingfa Group will not change, and it will still maintain its control over Xingfu Electronics.

  Through this spin-off, Xingfa Group will further focus on the production and sales of fine phosphorus chemical products such as phosphate rock and phosphate, glyphosate, silicone products, chlor-alkali, dimethyl sulfoxide and fertilizer products, and the trade business of related chemical products; Xingfu Electronics will become an independent electronic chemicals business listing platform under Xingfa Group. The spin-off and listing is conducive to further enhancing the cohesion of the core personnel of Xingfu Electronics, enhancing the brand awareness and social influence of Xingfu Electronics, strengthening the competitive position and advantages of Xingfu Electronics in the field of electronic chemicals, enhancing the R&D investment of Xingfu Electronics in core and cutting-edge technologies and products, maintaining the vitality of business innovation, enhancing the market development ability and promoting its healthy and sustainable development.

  This spin-off can only be implemented after meeting a number of conditions, including but not limited to obtaining the formal approval of the company’s shareholders’ meeting and fulfilling the corresponding procedures of Shanghai Stock Exchange and China Securities Regulatory Commission. There are uncertainties about whether this spin-off can be approved or not, and when it will finally be approved or approved. (Cheng Wei)

  Mubang Hi-Tech plans to invest 4.8 billion yuan to build a photovoltaic cell production base project and terminate the project signed with Anyi County.

  Mubang Hi-Tech announced on the evening of August 16th that it had signed the Strategic Cooperation Framework Agreement with the people’s government of Echeng District. Both parties are willing to make full use of their respective resource advantages, arrange about 500 mu of project land in the people’s government park of Echeng District, and build a 10GW TOPCON photovoltaic cell production base project. The investment scale of the project is estimated to be 4.8 billion yuan.

  Mubang Hi-Tech’s 2021 annual report shows that the company mainly has three modules: educational toy business, educational business and medical device business. Mubang Hi-Tech acquired 100% equity of Haoan Energy jointly held by Zhang Zhongan and Yu Jumei in cash in the first half of this year, with a transaction consideration of 980 million yuan. After the transaction is completed, Haoan Energy will become a wholly-owned subsidiary of the listed company.

  Haoan Energy is a high-tech enterprise mainly engaged in R&D, production and sales of photovoltaic silicon wafers and silicon rods. Its main products are solar monocrystalline silicon wafers and silicon rods, among which solar monocrystalline silicon wafers are the main ones, and the main specifications of solar monocrystalline silicon wafers are 166mm, 182mm and 210 mm. After the transaction is completed, the company’s main business is to increase the research and development, production and sales of photovoltaic silicon wafers and silicon rods.

  After putting Haoan Energy into the bag, Mubang Hi-Tech has made frequent moves in the field of photovoltaic cell production projects.

  Mubang Hi-Tech announced on the evening of June 2 that the company signed the Framework Agreement on Investment Strategic Cooperation with the Anyi County People’s Government. Both parties are willing to make full use of their respective resource advantages, and arrange about 300 mu of project land within the industrial park to build 8GWTOPCON photovoltaic cell production project. At present, the company has not formulated a specific investment plan, and the investment amount is still unclear.

  At that time, Mubang Hi-Tech suggested in the announcement that the main business of the photovoltaic sector is the research, development, production and sales of monocrystalline silicon rods and silicon wafers, and the silicon wafer products are the upstream materials of photovoltaic cells. At present, the company is not engaged in photovoltaic cell business, nor has TOPCON photovoltaic cell R&D talents and production technology reserves.

  However, Mubang Hi-Tech announced at the same time on the evening of August 16th that the company and the Anyi County People’s Government had fully communicated and exchanged views on the promotion of cooperative projects, and no specific cooperation agreement has been formed so far. Through friendly negotiation, the company decided to terminate the Framework Agreement signed with the Anyi County People’s Government.

  In addition, Mubang Hi-Tech also announced on the evening of July 20th that it had signed the Investment Contract of 10GW TOPCON Photovoltaic Cell Production Base Project with Wuzhou Municipal People’s Government, with an estimated total investment of 5.2 billion yuan. Mubang Hi-Tech said in this announcement that the relevant talent team is under construction.

  Mubang Hi-Tech said in the latest announcement that the company had reached a cooperation with Wuzhou Municipal People’s Government in the early stage and planned to build a 10GW TOPCON photovoltaic cell production base. The company and Wuzhou Municipal People’s Government jointly build a 10GW TOPCON photovoltaic cell production base, which is currently in progress.

  Mubang Hi-Tech announced the risk of stock trading on the evening of August 15th, suggesting that the company and Wuzhou Municipal People’s Government jointly built a 10GW TOPCON photovoltaic cell production base, and now it plans to set up a project subsidiary. The investment of this project is large, and there are risks in capital, technology and talent. The project investment amount is much higher than the company’s book monetary fund level, and the fund gap is large, and some funds need government support. Wuzhou municipal government will give corresponding support to the company only after the investment amount, production capacity and output value of the company’s projects reach the agreed standards. The company intends to solve the capital problem by means of bank financing and equity finance. Due to the limited net assets of the company, the financing amount may not reach the expectation, thus there is a risk that the project progress will be less than expected or the project will be stagnant.

  *ST Hengyu wins European big orders overseas market, which is expected to promote performance growth.

  On the evening of August 16th, *ST Hengyu announced that it had recently signed a product sales contract with a European customer, with a total contract value of 8.3667 million US dollars, or about 56.56 million yuan (including tax). The company said that according to the performance schedule agreed in the contract, it will not have a significant impact on the company’s performance in 2022. If this contract is successfully performed, it is expected to have a positive impact on the company’s operating performance in 2023. At the same time, it is conducive to enhancing the company’s sustainable operation ability and brand influence, and has a positive impact on the company’s exploration of overseas markets.

  The announcement shows that the subject matter of this contract is 30,000 tons/year industrial continuous waste tire cracking production line.

  According to the data, the new signing amount of *ST Hengyu in the first quarter of 2022 was 128 million yuan, while the new signing amount of the company in 2021 was 190 million yuan. The signing of this overseas order has undoubtedly laid a solid foundation for the company’s future performance growth.

  *ST Hengyu is a service provider of industrial continuous cracking production line, and its products are applied to environmental protection fields such as waste tires, waste plastics and oily sludge. The international market is an important source of income for *ST Hengyu. In this year’s business plan, the company stated that it will adhere to and strengthen the "going out" sales strategy, pay attention to the attempts of strategic cooperation within the industry, regional market development cooperation and overseas regional agency cooperation, and enrich and strengthen the construction of the company’s marketing system.

  In 2022, *ST Hengyu overseas market progressed smoothly. According to the quarterly report of *ST Hengyu, the company and American customers have started the implementation of the waste plastic cracking production line with a contract amount of US$ 6 million. The customer’s project startup node order has been signed and approved, and the corresponding payment has been paid.

  It is worth mentioning that the breakthrough in overseas markets will help *ST Hengyu expand in the field of environmental protection segmentation. Last year’s annual report showed that the Danish waste plastic project of the company’s customer has been recognized by BASF, an international chemical giant. By the end of the first quarter, the company’s overseas customers in hand include Quantafuel AS, British customers and American customers, and their application fields are all industrial continuous waste plastic cracking production lines. (Tan Pengpeng)

  Shaanxi Black Cat: The subsidiary donated 300,000 yuan to support local epidemic prevention and control.

  () On the evening of August 16th, it was announced that the epidemic situation of COVID-19 in Shandan County of Zhangye City had relapsed recently, and the situation was grim. Under the premise of strictly preventing and controlling the epidemic situation of enterprises, Zhangye Hongneng Coal Industry Co., Ltd., a subsidiary of the company, adheres to the concept that enterprises will grow and repay the society, responds to the call of the local government, and helps the local epidemic prevention and control work with practical actions, and decides to donate 300,000 yuan to the Red Cross Society of Shandan County, Zhangye City to support the development of local epidemic prevention and control.

  The company said that this time, Hongneng Coal Industry implemented foreign donations to support the development of local epidemic prevention and control, and passed positive energy with practical actions; This foreign donation is funded by Hongneng Coal’s own funds, and this donation does not have a significant impact on the company’s current and future operating performance.

  Zhongheng Group: Obtained the drug registration certificate and the notice of approval for the listing application of chemical raw materials.

  On the evening of August 16th, Zhongheng Group announced that Chongqing Laimei Pharmaceutical Co., Ltd., a holding subsidiary, had received the Drug Registration Certificate of esmomeprazole magnesium enteric-coated capsules of 20mg and 40mg approved and issued by National Medical Products Administration, and Chongqing Laimei Longyu Pharmaceutical Co., Ltd., the holding grandson of the company, had received the Notice of Approval for the Listing of Esomeprazole magnesium API approved and issued by National Medical Products Administration.

  According to the company, Laimei Pharmaceutical and Laimei Longyu obtained the Drug Registration Certificate of Esomeprazole Magnesium Enteric-coated Capsules (specifications: 20mg, 40mg) and the Notice of Approval for the Listing Application of Esomeprazole Magnesium Bulk Drug, which is conducive to further enriching the company’s product line and increasing the company’s market share of digestive tract drugs.

  Mubang Hi-Tech received an inquiry letter from Shanghai Stock Exchange about photovoltaic cell project.

  Mubang Hi-Tech announced that on August 16, 2022, the company received the "Inquiry Letter on Investment Framework Agreement of Jiangxi Mubang Hi-Tech Co., Ltd." issued by Shanghai Stock Exchange.

  On August 16th, 2022, the company announced that it had signed a strategic cooperation framework agreement with the people’s government of Echeng District, and planned to build a 10GW TOPCON photovoltaic cell production base, with an estimated investment scale of 4.8 billion yuan. At the same time, it terminated the 8GW TOPCON photovoltaic cell production base investment strategic cooperation framework agreement signed with the people’s government of Anyi County.

  According to the requirements, the company needs to make supplementary disclosure: (1) The reasons for the termination of the above investment framework agreement, and combined with the previous project demonstration, feasibility study and internal decision-making process, explain whether the previous investment decision was prudent and whether Dong Jiangao performed his duties diligently; (2) Whether the progress of other large-scale investment framework agreements and sales contracts disclosed by the company in the early stage may lead to unexpected or termination risks; (3) According to the actual progress of the project, self-check whether there is an exaggeration of the project scale to mislead investors, and whether there is a situation of using non-binding large-scale investment framework agreements to cater to market hotspots and cooperate with stock price speculation. (4) Since the first disclosure of the relevant framework agreement, the company’s R&D investment in photovoltaic cell projects, investment amount and investment category; (5) In the current situation of lack of production technology reserves and the talent team is still in the preparatory stage, the reasons and commercial rationality of the proposed large investment are frequently disclosed.

  Mubang Hi-Tech plans to build a 10GW TOPCON photovoltaic cell production base project with 4.8 billion yuan.

  Mubang Hi-Tech announced that the company has signed the Strategic Cooperation Framework Agreement with the government of Echeng District, and plans to arrange about 500 mu of project land in the government park of Echeng District to build a 10GW TOPCON photovoltaic cell production base project. The investment scale of the project is estimated to be 4.8 billion yuan.

  On the same day, the company announced that on June 2, 2022, the company signed the Framework Agreement on Investment Strategic Cooperation with Anyi County Government, and planned to arrange about 300 mu of land for the project within the industrial park to build an 8GWTOPCON photovoltaic cell production project. After the signing of the Framework Agreement, the company and Anyi county government have fully communicated and exchanged views on the promotion of this cooperation project, and no specific cooperation agreement has been formed so far. Through friendly negotiation, the company decided to terminate the Framework Agreement signed with Anyi County Government.

  [Company Report]

  It is planned to spend 4.475 billion yuan to set foot in photovoltaic cells.

  Another company crosses the field of TOPCON photovoltaic cells. On August 4th, Mubang Hi-Tech announced that the board of directors of the company reviewed and approved the Proposal on the Company’s Foreign Investment in the Construction of a 10 GW TOPCON Photovoltaic Cell Production Base Project, etc., and made it clear that the company’s investment in this project is expected to be 4.475 billion yuan, and it is planned to set up a wholly-owned subsidiary in Wuzhou High-tech Zone, Guangxi Zhuang Autonomous Region to operate the project. This means that the company’s investment in the field of TOPCON photovoltaic cells has reached a new level. (Shanghai Securities Journal reporter Li Xingcai)

  Mubang Hi-Tech plans to invest 5.2 billion yuan to build a 10GW TOPCON photovoltaic cell production base project.

  Mubang Hi-Tech announced on July 20th that the company signed the Investment Contract of 10GW TOPCON Photovoltaic Cell Production Base Project with Wuzhou Municipal Government, and the project name was "10GW TOPCON Photovoltaic Cell Production Base". It is estimated that the total investment of the project is 5.2 billion yuan, of which the investment in production equipment is about 2.775 billion yuan. The project will build about 200,000 square meters of standard factory buildings and supporting buildings, and a 10GW TOPCON photovoltaic cell production line, mainly engaged in the production of TOPCON photovoltaic cells, with an annual production capacity of about 10GW.

  70 million shares held by the controlling shareholder of Blu-ray Development will be auctioned.

  On August 16th, Sichuan Blu-ray Development Co., Ltd. (referred to as "Blu-ray Development") announced that some shares of the company held by its controlling shareholder Blu-ray Investment Holding Group Co., Ltd. (referred to as "Blu-ray Group") will be publicly auctioned in September.

  According to the announcement, as of August 15, 2022, Blu-ray Group held about 1.048 billion shares of Blu-ray Development, accounting for 34.53% of the company’s total share capital. The shares auctioned this time are 70 million shares of Blu-ray Development held by Blu-ray Group, accounting for 2.31% of the company’s total share capital. The applicant for the auction is China Railway Trust Co., Ltd., and the reason for the auction is the default disposal of stock pledge.

  The announcement shows that the auction is still in the publicity stage, and the follow-up may involve bidding, payment, court execution of legal procedures, equity change and transfer, and there is some uncertainty. According to the final results, the company will fulfill the corresponding information disclosure obligations according to law. In addition, if this auction is successful, it will not lead to changes in the controlling shareholder and actual controller of Blu-ray Development for the time being.

  On the same day, Blu-ray Development announced another announcement that the deviation of the closing price increase of Blu-ray Development shares for three consecutive trading days on August 12, 15 and 16, 2022 reached 20%, which is an abnormal fluctuation of stock trading according to the relevant provisions of the Trading Rules of Shanghai Stock Exchange.

  Blu-ray Development said in the announcement that there has been no substantial progress in the corporate debt restructuring plan. As of June 30, 2022, the total amount of debt principal and interest that Blu-ray Development failed to repay due was 38.775 billion yuan, which had a great impact on the company’s operation and financing. Up to now, the relevant debt restructuring plan is still being worked out, and no substantial progress has been made. In terms of business performance, Blu-ray Development expects the net profit attributable to shareholders of listed companies to be around-4.6 billion yuan in the first half of 2022.

  In addition, recently, some media reported that Blu-ray Development cooperated with Guangdong Ouhao Group Co., Ltd. to establish Chengdu Oulan Photovoltaic Co., Ltd. to carry out photovoltaic projects. According to Blu-ray Development, Chengdu Oulan Photovoltaic Co., Ltd. is registered recently with a registered capital of 100 million yuan, and the shareholding ratio of Blu-ray Development is 30% (non-holding), which has not been paid. At present, relevant resources and technical personnel have not been equipped, and there are no cooperation projects. There are uncertainties in the follow-up. In addition to the above matters, the controlling shareholder and actual controller of Blu-ray Development have no other important matters or information that should be disclosed but not disclosed that affect the abnormal fluctuation of the company’s stock trading.

  Editor Yang Juanjuan

  Proofread Li Ming

  Jianmin Group: It is planned to acquire 100% equity of Huafang Medical and Care and wholly hold Huafang Hospital.

  () On the evening of August 16th, it was announced that the company intends to acquire 100% equity of Zhejiang Huafang Medical Care Co., Ltd. held by related party Huali Pharmaceutical Group Co., Ltd., with a total transaction price of 15,204,400 yuan. The main asset of Huafang Medical is its wholly-owned subsidiary Huafang Hospital, and the company will wholly control Huafang Hospital through the transfer of equity of Huafang Medical. This equity transfer is conducive to accelerating the regional layout of the company’s TCM diagnosis and treatment. In addition, the company intends to subscribe for the fund share of Hangzhou Chaosheng Phase II Venture Capital Partnership (Limited Partnership) as a limited partner of 20 million yuan.

  Shengxiang Bio: shareholders holding more than 5% of shares intend to reduce their holdings by no more than 11.77 million shares; shareholders holding more than 5% of shares intend to reduce their holdings by no more than 11.77 million shares.

  Last night, Shengxiang Bio announced the plan of centralized bidding for shareholders holding more than 5% shares to reduce their shares. Due to its own capital demand, the shareholder Anhui Zhidao Investment Co., Ltd. (hereinafter referred to as "Anhui Zhidao") intends to reduce its holdings of Shengxiang Bio-shares by centralized bidding, accounting for 2.00% of the company’s total share capital, and it will be implemented within 6 months after 15 trading days from the date of release of the reduction plan, and the total number of shares reduced within 90 consecutive days will not exceed 1% of the company’s total shares.

  As of the disclosure date of the announcement, Anhui Zhidao holds 29,987,768 shares of Shengxiang Bio, accounting for 5.10% of the total shares of the company. The shares held by Anhui Zhidao were listed and circulated on August 30, 2021.

  Shengxiang Bio: shareholders holding more than 5% of shares intend to reduce their holdings by no more than 11.77 million shares; shareholders holding more than 5% of shares intend to reduce their holdings by no more than 11.77 million shares.

  Last night, Shengxiang Bio announced the plan of centralized bidding for shareholders holding more than 5% shares to reduce their shares. Due to its own capital demand, the shareholder Anhui Zhidao Investment Co., Ltd. (hereinafter referred to as "Anhui Zhidao") intends to reduce its holdings of Shengxiang Bio-shares by centralized bidding, accounting for 2.00% of the company’s total share capital, and it will be implemented within 6 months after 15 trading days from the date of release of the reduction plan, and the total number of shares reduced within 90 consecutive days will not exceed 1% of the company’s total shares.

  As of the disclosure date of the announcement, Anhui Zhidao holds 29,987,768 shares of Shengxiang Bio, accounting for 5.10% of the total shares of the company. The shares held by Anhui Zhidao were listed and circulated on August 30, 2021.

  Shengxiang Bio: Shareholders holding more than 5% of shares intend to reduce their holdings by no more than 11.77 million shares.

  Last night, Shengxiang Bio announced the plan of centralized bidding for shareholders holding more than 5% shares to reduce their shares. Due to its own capital demand, the shareholder Anhui Zhidao Investment Co., Ltd. (hereinafter referred to as "Anhui Zhidao") intends to reduce its holdings of Shengxiang Bio-shares by centralized bidding, accounting for 2.00% of the company’s total share capital, and it will be implemented within 6 months after 15 trading days from the date of release of the reduction plan, and the total number of shares reduced within 90 consecutive days will not exceed 1% of the company’s total shares.

  As of the disclosure date of the announcement, Anhui Zhidao holds 29,987,768 shares of Shengxiang Bio, accounting for 5.10% of the total shares of the company. The shares held by Anhui Zhidao were listed and circulated on August 30, 2021.

  (Editor: Jiang Ninglu)

  Shengxiang Bio: Shareholders holding more than 5% of shares intend to reduce their holdings by no more than 11.77 million shares.

  Last night, Shengxiang Bio announced the plan of centralized bidding for shareholders holding more than 5% shares to reduce their shares. Due to its own capital demand, the shareholder Anhui Zhidao Investment Co., Ltd. (hereinafter referred to as "Anhui Zhidao") intends to reduce its holdings of Shengxiang Bio-shares by centralized bidding, accounting for 2.00% of the company’s total share capital, and it will be implemented within 6 months after 15 trading days from the date of release of the reduction plan, and the total number of shares reduced within 90 consecutive days will not exceed 1% of the company’s total shares.

  As of the disclosure date of the announcement, Anhui Zhidao holds 29,987,768 shares of Shengxiang Bio, accounting for 5.10% of the total shares of the company. The shares held by Anhui Zhidao were listed and circulated on August 30, 2021.

  (Editor: Jiang Ninglu)

  Jianmin Group intends to acquire 100% equity of Huafang Medical to wholly control Huafang Hospital.

  Jianmin Group announced that the company intends to further increase the upstream and downstream industrial chain layout of the big health business, and realize the diversification of services in the big health business field and the effective extension of the business field. The company intends to transfer all the equity of Zhejiang Huafang Medical Co., Ltd. held by related parties with its own funds, and the company’s transfer of equity this time constitutes a related party transaction.

  This time, the company intends to acquire 72.67%, 21.65% and 5.68% of the shares of Zhejiang Huafang Medical Co., Ltd. held by Huali Pharmaceutical Group Co., Ltd., Zhejiang Huali Investment Management Co., Ltd. and Suzhou Yuanyi Zhiyuan Equity Investment Partnership (Limited Partnership) with its own funds, and the transaction price of the shares totals 15.2044 million yuan.

  The main asset of Huafang Medical, the subject of this transaction, is its wholly-owned subsidiary, Hangzhou Huafang Hospital Co., Ltd. (hereinafter referred to as Huafang Hospital). This transaction company will wholly control Huafang Hospital by acquiring 100% equity of Huafang Medical. Huafang Hospital is a comprehensive hospital established according to the second-class standard. The hospital is fully equipped and has more than 10 clinical medical departments, among which anorectal, traditional Chinese medicine and gynecology are well developed.

  Luwei Optoelectronics listed today at a price of 25.08 yuan/share.

  According to the announcement of the exchange, Luwei Optoelectronics was listed in science and technology innovation board of Shanghai Stock Exchange today, with the company’s stock code of 688401, the issue price of 25.08 yuan/share and the issue price-earnings ratio of 70.31 times.

Omnidirectional active safety is the real skill, ask the new M5 omnidirectional anti-collision system to lead the same level

Recently, Yu Chengdong’s remarks at the "16th China Automotive Blue Book Forum" have attracted widespread attention and caused waves in the automotive industry. He claimed that the first omnidirectional anti-collision system not only has all-round protection capabilities for forward, lateral and backward, but also exceeds the existing industry standards in some performance. With the go LIVE column of Yiche’s "Easy Start" column, the active safety capabilities of the new M5 and three popular new energy vehicles are also evaluated horizontally. Let’s take a look at who has the higher active and passive safety factor!

1718787995506

In daily driving, it is inevitable that there will be some unexpected situations. In the face of the "corner and stationary vehicle" scene, the new M5 has excellent performance in recognition, emergency braking and collision avoidance. Even if the speed is 80km/h, it starts to stop in time, while the ideal L6 and Tesla Model Y failed to complete this round of testing.

1718788189011

In the obliquely distributed cone barrel test, the new M5 drove to the 90cm and 60cm piles at 100km/h and 60km/h, respectively, and could automatically stop. Model Y and L6 could recognize the 90cm and 60cm piles at 60km/h, but there was no prompt or braking action.

1718788272858

1718788289946

In the test, the ideal L6 and Tesla Model Y did not recognize the lateral risk when the water horse invaded the lane. However, the new M5 recognized the lateral risk and avoided the danger by interfering with the steering in the opposite direction of the obstacle.

1718788317912

In the test of reversing pedestrians and reversing vehicles, the Wenjiexin M5 can accurately identify and stop vehicles. The Ideal L6 and Tesla Model Y are not equipped with backward AEB and did not participate in this round of testing. It is worth mentioning that looking at the mainstream products of various car companies in the industry, there are few vehicle configurations.

17187883735991718788388537

Because the whole system is equipped with HUAWEI ADS 2.0 high-end intelligent driving system as standard, and adopts the "lidar + visual perception" fusion solution, the new M5 has successfully passed a number of tests. The ideal L6 only has the high-end Max version to provide lidar + visual fusion perception solution, and the Pro version only provides pure visual solution. Tesla Model Y only provides pure visual solution.

1718788471797

In terms of passive safety, the Wenjie new M5 is also worthy of praise. The high-strength steel used in the body accounts for more than 60%, of which hot-formed steel accounts for 19.5%, which has the characteristics of ultra-high tensile strength. Combined with the cage safety body, the torsional stiffness reaches 1.5 times that of Tesla Model Y, which is worthy of "small land".

1718788515790

In terms of performance, the new M5 adopts the same series of M9 front four ball head double fork arm, rear multi-link independent suspension, the only all-aluminum chassis in the same class, combined with HUAWEI DATS 2.0 and star ring scatter, Metropolis red new color scheme and other advantages, not only flexible driving control, but also stable opening.

1718788594356

The series of AEB active safety auxiliary features have been verified in many instances. For example, cyclists who suddenly appear in the field of vision can be quickly identified by the active safety function of the M5 and stopped in time to avoid accidents.

2

(The picture comes from the Internet.)

Are you looking for an SUV that takes into account high-end smart driving, omnidirectional anti-collision ability and strong performance? I think as an all-round powerful player of the rim, the new M5 must be the first choice! And the starting price is 249,800 yuan, and this month you can also enjoy up to 35,000 yuan of car purchase rights, including: ADS high-end function package subsidy rights worth 20,000 yuan, optional rights worth 12,000 yuan and cash rights worth 3,000 yuan.

Announcement of Shenzhen Listed Companies (March 8)

  Cylon Pharmaceuticals: Subsidiary Receives Approval for Pregabalin Listing Application

  () Announcement: Hunan Sailong Pharmaceutical Co., Ltd., a wholly-owned subsidiary, has recently received the approval of Pregabalin’s "Notice of Application for Marketing of Chemical APIs" issued by the State Drug Administration.

  Cylon Pharmaceutical: Subsidiary Receives Approval of Pregabalin Chemical API Listing Application

  On March 7, Cylon Pharmaceutical announced that its subsidiary had received approval for the listing of Pregabalin chemical raw materials.

  Cylon Pharmaceutical: Subsidiary Received Notification of Approval for the Listing Application of Pregabalin, a Chemical API

  Sailon Pharmaceutical announced on the evening of March 7 that Hunan Sailon Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, has recently obtained the approval of pregabalin "Chemical API Marketing Application Approval Notice" issued by the State Food and Drug Administration. The main indications of pregabalin are: for the treatment of post-herpetic neuralgia and fibromyalgia.

  Cylon Pharmaceutical: Subsidiary chemical raw material drug "pregabalin" was approved for listing

  Sailong Pharmaceutical announced that Hunan Sailong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, has recently obtained the "Notice of Approval for the Marketing of Chemical API" approved by the State Drug Administration. It is reported that the main indications of pregabalin are: for the treatment of post-herpetic neuralgia and fibromyalgia.

  Lisheng Pharmaceutical: Ticagrelor API passed the marketing application

  () Announcement: The company has received the "Notice of Approval of Application for Listing of Chemical APIs" issued by the State Drug Administration for ticagrelor APIs, and the variety has passed the application for listing of chemical APIs.

  Garden Bio completed the repurchase of 1.69% of the shares, costing 100 million yuan

  () announcement, as of March 6, 2024, the company through the share repurchase special securities account to the centralized auction transaction to repurchase the company’s shares 9.3072 million shares, accounting for 1.69% of the company’s current total share capital, the minimum transaction price is 10.09 yuan/share, the highest transaction price is 11.83 yuan/share, the total transaction amount is RMB 100 million yuan (including transaction costs). The company’s repurchase has been completed, the actual repurchase time range is September 14, 2023 to March 6, 2024.

  The shareholders’ meeting will be held on March 22 to consider the company’s proposal to apply for a project loan from the bank as collateral for its own assets

  Rifeng shares announced that the third extraordinary general meeting of shareholders will be held on March 22, 2024, and the online voting will be held on the same day. The equity registration date is March 15, and investors who hold Rifeng shares after the market closes on that day can participate in the voting.

  Meeting place: Conference room on the first floor of Guangfeng Industrial Park Company, West District, Zhongshan City.

  The shareholders’ meeting audited a total of one proposal, as follows:

  1. Proposal on the company applying for a project loan from the bank with its own assets as collateral.

  ST plans to sell a 17% stake in CCCC New Energy and optimize its investment structure

  () Announcement, the company plans to transfer the 17% equity of Jiangsu CCCC New Energy Technology Co., Ltd. (referred to as "CCCC New Energy") held by its wholly-owned subsidiary Nanjing Keshu Technology Co., Ltd. (referred to as "Nanjing Keshu") to Lu Yicheng at a price of 40 million yuan. After the transfer is completed, Nanjing Keshu will no longer hold the equity of CCCC New Energy.

  The announcement said that the company’s current main business is cross-border e-commerce export, and its long-term development strategy in the future lies in focusing on strengthening core business capabilities and further strengthening and refining the main business of cross-border e-commerce. In order to further protect the company’s ROI, optimize the company’s investment structure, and improve the asset quality and profitability of listed companies, the company has decided to transfer the equity of CCCC New Energy.

  Jujie Microfiber: The controlling shareholder intends to increase its holdings by 15 million yuan – 30 million yuan

  () Announcement that the controlling shareholder Suzhou Jujie Investment Co., Ltd. intends to increase its holdings by not less than 15 million yuan and not more than 30 million yuan.

  Jujie Microfiber: The controlling shareholder of the company plans to increase its holdings by 15 million yuan – 30 million yuan

  On March 7, Jujie Microfiber announced that the company’s controlling shareholders plan to increase their holdings by 15 million yuan – 30 million yuan.

  Jujie Microfiber’s controlling shareholder plans to spend 15 million yuan to 30 million yuan to increase shares

  Jujie Microfiber announced that the controlling shareholder of the company, Suzhou Jujie Investment Co., Ltd. (referred to as "Jujie Investment", "the main body of the increase") plans to increase its holdings of the company’s shares within the next 6 months from the date of this announcement through the means allowed by the China Securities Regulatory Commission and the Shenzhen Stock Exchange trading system (including but not limited to centralized bidding and block trading, etc.), with a total amount of not less than RMB 15 million yuan and not more than RMB 30 million yuan.

  Dong Chunhong, supervisor of Tuoxin Pharmaceutical, has reduced his holdings by 1,000 shares

  () announcement, the company received the "notice letter on the expiration of the implementation time of the share reduction plan and the result of the reduction" issued by director Qu Guirong and supervisor Dong Chunhong respectively. As of the date of issuance of the notice letter, director Qu Guirong and supervisor Dong Chunhong reduced their holdings by 0 shares and 1000 shares respectively through centralized bidding transactions, and the implementation time of the reduction plan has expired.

  (): It is planned to purchase 100% equity of Hunan Persimmon Bamboo Garden Nonferrous Metals Co., Ltd. by issuing shares and paying cash

  China Tungsten High-tech announced that the company intends to purchase the 100% equity of Hunan Persimmon Bamboo Garden Nonferrous Metals Co., Ltd. jointly held by Minmetals Tungsten Industry Group Co., Ltd. and Hunan Woxi Mining Investment Co., Ltd. by issuing shares and raising supporting funds to no more than 35 specific investors. This reorganization is expected to constitute a major asset reorganization as stipulated in the "Measures for the Administration of Major Asset Restructuring of Listed Companies", and also constitutes a company related transaction. This reorganization does not constitute a reorganization and listing. This transaction will not lead to a change in the actual controller of the company.

  The shareholders’ meeting will be held on March 26 to consider the proposal to acquire all the shares of Zhengzhou Jimei by cash and related party transactions

  Langzi shares announced that the first extraordinary general meeting of shareholders will be held on March 26, 2024, and the online voting will be held on the same day. The equity registration date is March 14, and investors who hold Langzi shares after the market closes on that day can participate in the voting.

  Meeting place: 16th Floor Conference Room, Building 1, Courtyard 3, Dajiaoting South Street, No. 27, Xidawang Road, Chaoyang District, Beijing (Langzi Building).

  The shareholders’ meeting audited a total of one proposal, as follows:

  1. Proposal on the cash acquisition of all the shares and related transactions of Zhengzhou Jimei.

  Henghui Security: the actual 3.76 million shares will be listed on March 11

  () Issue a prompt announcement on the partial lifting of the restrictions on the sale of the issued shares before the initial public offering and listing for circulation. The number of restricted shares listed and circulated this time is 10 million shares, accounting for 6.8693% of the company’s total share capital. The actual number of shares that can be listed and circulated is 3.76 million shares. The listing and circulation date is March 11, 2024 (Monday).

  Liangxin plans to invest 26 million yuan in a holding subsidiary to promote the development of intelligent power distribution business

  () Announcement, the company intends to jointly invest with Shanghai Zhuyong Enterprise Management Partnership (Limited Partnership) (abbreviation: "Zhuyong Enterprise"), Shanghai Zhuyong Enterprise Management Partnership (Limited Partnership) (abbreviation: "Zhuyong Enterprise"), Shanghai Zhuzhi Enterprise Management Partnership (Limited Partnership) (abbreviation: "Zhuzhi Enterprise") to establish Liangyun Zhihui (Guangdong) Co., Ltd. (tentative name, the final name shall be subject to the name approved by the registration authority, abbreviation: "Joint Venture Company"). The registered capital of the joint venture company is tentatively 50 million yuan, of which the company’s capital contribution is 26 million yuan, and the shareholding ratio is 52%. The joint venture company will be included in the scope of the consolidated statement.

  In view of the future market opportunities for the in-depth electrification of various industries and the landing of the dual-carbon target, in order to seize the window period of the intelligent power distribution market and enhance the company’s comprehensive competitiveness, after careful research, the company decided to invest in the establishment of a joint venture company to develop intelligent power distribution related businesses. In the future, the joint venture company will focus on intelligent power distribution business, carry out innovation and optimization around the business model of intelligent power distribution, continue to increase the development of technology and product ecology, improve sales capabilities and delivery capabilities, promote the industrialization of R & D results, promote the rapid development of the company’s intelligent power distribution business, and enhance the company’s comprehensive market competitiveness and brand influence.

  Jinling Sports: Li Jiangang, director and general manager, plans to increase his holdings by 10 million yuan – 20 million yuan

  () announcement, director and general manager Li Jiangang intends to increase holdings 10 million yuan – 20 million yuan.

  Precision Eye launched the "Double Improvement of Quality and Return" action plan

  () At noon on March 7, the announcement on promoting the "double improvement of quality returns" action plan was disclosed, and it is planned to commit to the high-quality development of the company’s operation and the improvement of the level of sustainable development from five measures, and actively maintain market stability.

  The company said that it will continue to focus on its main business, adhere to its medical attributes, and build long-term value. On the basis of the company’s successful investment and operation of 28 ophthalmic hospitals and 3 ophthalmic outpatient departments in 21 major cities in China, in the future, the company will continue to implement the development strategy of "national chain + intra-city integration", adhere to both endogenous growth and extension development, not only practice internal skills, strengthen refined management methods, enhance profitability and core competitiveness, but also use the capital markets platform to carry out mergers and acquisitions, further expand the layout in major cities across the country, and consolidate and increase the market share in advantageous regions, while maximizing the diagnosis and treatment needs of patients for eye health.

  At the same time, the company will pay attention to medical innovation-driven, promote service and product technology upgrades. Improve the company’s internal governance, promote the company’s sustainable development, deeply practice the ESG concept, actively improve the level of ESG governance, and help the company’s high-quality sustainable development.

  In addition, the company will effectively improve the level of information disclosure, establish a matrixed investor relations channel, and convey the intrinsic value of the company. Investor-oriented, focusing on investor returns, and working with investors to achieve a dynamic balance between performance growth and shareholder returns. Build a "long-term, stable and sustainable" shareholder value return mechanism to ensure that shareholders can effectively enjoy the company’s development results. (Tian Limin)

  Li Jiangang, general manager of Jinling Sports, plans to increase the company’s shares from 10 million yuan to 20 million yuan

  Jinling Sports announced that Mr. Li Jiangang, the director and general manager of the company, based on his confidence in the future development of the company and the recognition of long-term investment value, enhances investor confidence, and plans to increase his holdings of the company’s shares within 6 months from the date of disclosure of this announcement. The total amount of the proposed increase is not less than RMB 10 million yuan, not higher than RMB 20 million yuan, and the source of funds required for the increase is equity fund.

  Jinling Sports: Directors plan to increase their shares by 10 million yuan to 20 million yuan

  Jinling Sports announced on the evening of March 7 that Li Jiangang, the director and general manager of the company, based on his confidence in the company’s future development and the recognition of long-term investment value, enhanced investor confidence and planned to increase his holdings of the company’s shares. The total amount of the proposed increase is not less than 10 million yuan, not higher than 20 million yuan. The source of funds required for the increase is equity fund. The increase plan does not set a fixed price or price range.

  Luoping Zinc Power: Fuller Lead-Zinc Mine Suspends Production

  () Announcement, the company received the "Notice of Suspension of Production" issued by the Luoping County Emergency Management Bureau on March 7, 2024, because the company’s Fuller Lead-Zinc Mine Safety Production License (valid period from March 7, 2021 to March 6, 2024) has expired. According to the "Safety Production Law", "Safety Production License Regulations" and other relevant laws and regulations, all production activities will be stopped from now on, and production can only be resumed after going through the extension formalities and reporting for approval. According to the suspension notice, the company’s Fuller Lead-Zinc Mine will stop all production activities from now on.

  Jiuan Medical has repurchased 3.08% of the shares at a cost of about 607 million yuan

  () announced that as of March 7, 2024, the company through the stock repurchase special securities account to the centralized auction transaction accumulated the number of repurchased shares of the company 15.0562 million shares, accounting for 3.08% of the company’s total share capital, the highest transaction price is 41.277 yuan/share, the lowest transaction price is 39.42 yuan/share, the total amount paid is RMB 607 million yuan.

  Luoping Zinc Power: Fuller Lead-Zinc Mine Suspension, Expected to Have Little Impact on Company Operations

  Luoping Zinc and Electricity Announcement, the company received the "Notice of Suspension of Production" issued by the Luoping County Emergency Management Bureau on March 7, 2024. The reason is that the valid period of the safety production license of the company’s Fuller Lead-Zinc Mine is from March 7, 2021 to March 6, 2024, which has now expired. According to the "Safety Production Law", "Safety Production License Regulations" and other relevant laws and regulations, all production activities will be stopped from now on, and production can only be resumed after going through the extension procedures and reporting for approval. According to the suspension notice, the company’s Fuller Lead-Zinc Mine will stop all production activities from now on. According to the preliminary estimate of the mine’s production volume in recent years, this suspension has little impact on the company’s operations.

  () The subsidiary plans to 2113.65 million yuan to participate in the special project of Guangzhou Gongchuangde Storage and invest in Guangzhou Zhiguang Energy Storage

  Desai Battery announced that Huizhou Desai Battery Co., Ltd. (referred to as "Huizhou Battery"), a wholly-owned subsidiary of the company, signed the "Guangzhou Gongchuang Dereserve Equity Investment Fund Partnership (Limited Partnership) Partnership Agreement" with Guangzhou Gongchuang Dereserve Private Offering Fund Management Co., Ltd. (referred to as "Gongchuang Huiji") on March 7, 2024, and jointly invested in the establishment of Guangzhou Gongchuang Dereserve Equity Investment Fund Partnership (Limited Partnership) (tentative name). The total subscribed capital of the partnership is 2135.00 million yuan, of which Huizhou Battery, as a limited partner, subscribed 2113.65 million yuan in equity fund, with a capital contribution ratio of 99.00%; Gongchuang Huiji, as a general partner, subscribed capital contribution of 213,500 yuan, with a capital contribution ratio of 1.00%.

  According to the announcement, the partnership will invest in Guangzhou Zhiguang Energy Storage Technology Co., Ltd. for special projects. Guangzhou Zhiguang Energy Storage Technology Co., Ltd. is mainly engaged in the research and application of industrial technology in the field of energy storage. It provides customers with energy storage technology consulting, energy storage system integration, energy storage equipment sales and other businesses in the technical fields of electrochemical energy storage, mechanical (flywheel) energy storage and super capacitor energy storage. It can also provide core key technologies and equipment such as energy storage battery PACK integration, BMS, PCS and EMS for the majority of energy storage system integrators, and can provide battery and battery PACK testing technology services.

  Desai Battery: The subsidiary plans to invest 2113.65 million yuan to participate in the establishment of an equity investment fund

  Desai Battery announced on the evening of March 7 that Huizhou Desai Battery Co., Ltd. (referred to as "Huizhou Battery"), a wholly-owned subsidiary of the company, and Guangzhou Gongchuanghuiji Private Offering Fund Management Co., Ltd. signed the "Guangzhou Gongchuangde Reserve Equity Investment Fund Partnership (Limited Partnership) Partnership Agreement" to jointly invest in the establishment of Guangzhou Gongchuangde Reserve Equity Investment Fund Partnership (Limited Partnership) (referred to as "Partnership"). The total subscribed capital of the partnership is 21.35 million yuan. Among them, Huizhou Battery, as a limited partner, subscribed 2113.65 million yuan in equity fund subscription, with a capital contribution ratio of 99.00%. The partnership invests special projects in Guangzhou Zhiguang Energy Storage Technology Co., Ltd.

  Tang Renshen: February pig sales 272,000 head

  () Announcement, the company’s February 2024 pig sales 272,000 head (including commercial pigs 247,100 head, piglets 24,900 head), February 2023 pig sales 285,800 head (including commercial pigs 267,800 head, piglets 18,000 head), down 4.83%, down 17.12%; sales revenue totaled 399.82 million yuan, down 9.92%, down 3.44%.

  Keming Foods: Holding subsidiary Xingjiang Pastoral sold 25,900 pigs in February

  () Announcement, the holding subsidiary Xingjiang Pastoral sold 25,900 pigs in February, and the sales volume decreased by 39.31% month-on-month, down 52.39% year-on-year; the sales revenue was 27.2403 million yuan, and the sales revenue decreased by 43.71% month-on-month, down 49.47% year-on-year.

  The controlling shareholder of Jujie Microfiber intends to increase the company’s shares by 15 million to 30 million yuan

  Jujie Microfiber announced that Suzhou Jujie Investment Co., Ltd., the controlling shareholder of the company, plans to increase its holdings of the company’s shares through the means allowed by the China Securities Regulatory Commission and the Shenzhen Stock Exchange trading system (including but not limited to centralized bidding and block trading, etc.) within the next 6 months from the date of the announcement, with a total proposed increase of not less than 15 million yuan and not more than 30 million yuan.

  The general manager of Jinling Sports plans to increase the company’s shares by 10 million to 20 million yuan

  Jinling Sports announced that Li Jiangang, the director and general manager of the company, plans to increase his holdings of the company’s shares within 6 months from the date of disclosure of the announcement, and the total amount of the proposed increase is not less than 10 million yuan and not more than 20 million yuan.

  Keming Foods: Xingjiang Pastoral’s pig sales in February fell by 52.39% year-on-year.

  Keming Food announced that the company’s holding subsidiary Xingjiang Pastoral sold 25,900 live pigs in February 2024, and the sales volume decreased by 39.31% month-on-month, a year-on-year decrease of 52.39%; the sales revenue was 27.2403 million yuan, and the sales revenue decreased by 43.71% month-on-month, a year-on-year decrease of 49.47%.

  From January to February, the company sold 68,500 pigs, down 20.94% from the same period last year; the cumulative sales revenue was 75.6314 million yuan, down 23.86% from the same period last year.

  Zuoli Pharmaceutical: The exclusive variety Lingze tablets are listed as the national second-level protected variety of traditional Chinese medicine

  () Announcement, the company received the "Certificate of Traditional Chinese Medicine Protected Variety" issued by the State Drug Administration, and the company’s exclusive variety Lingze Tablets was listed as the national second-level protected variety of traditional Chinese medicine.

  Tang Renshen: In February 2024, the sales revenue of live pigs was about 400 million yuan, a decrease of 3.44% compared with the previous month.

  Tang Renshen announced on the evening of March 7 that the company’s pig sales in February 2024 were 272,000, down 4.83% year-on-year and 17.12% month-on-month; the total sales revenue was about 400 million yuan, down 9.92% year-on-year and 3.44% month-on-month. The cumulative pig sales in January-February 2024 were 600,200, up 15.85% year-on-year; the sales revenue was about 814 million yuan, up 1.07% year-on-year.

  Jujie Microfiber: The controlling shareholder Jujie Investment plans to increase the company’s shares by 15 million yuan – 30 million yuan

  On the evening of March 7, Jujie Microfiber announced that the board of directors of the company recently received the "notice letter on the plan to increase the company’s shares" issued by the controlling shareholder Suzhou Jujie Investment Co., Ltd. (hereinafter referred to as "Jujie Investment"). The company’s controlling shareholder Jujie Investment plans to increase the company’s shares within the next 6 months from the date of this announcement through the means allowed by the China Securities Regulatory Commission and the Shenzhen Stock Exchange trading system (including but not limited to centralized bidding and block trading, etc.), with a total amount of not less than RMB 5 million yuan and not more than RMB 0 yuan.

  Allianz sharp vision: March 7 to buy back the company’s shares 10,000 shares

  On the evening of March 7, () announced that on March 7, 2024, the company repurchased 10,000 shares of the company for the first time through centralized bidding transactions, accounting for 0.01% of the company’s total share capital.

  Garden Bio: The company’s share repurchase has been completed

  On the evening of March 7, Garden Bio announced that on September 14, 2023, the company repurchased the company’s shares through a centralized auction transaction through a special securities account for share repurchase. As of March 6, 2024, the company had repurchased 9,307,200 shares through a centralized auction transaction through a special securities account for share repurchase, accounting for 1.69% of the company’s current total share capital. The company’s share repurchase has been completed.

  Civil Explosion Optoelectronics: 289,533 shares of the company were repurchased on March 6

  On the evening of March 7, () announced that on March 6, 2024, the company repurchased 289,533 shares of the company for the first time through the stock trading system of the Shenzhen Stock Exchange in a centralized bidding mode, accounting for 0.2766% of the company’s total share capital.

  Rijiu Optoelectronics: Accumulated repurchase of 3,506,800 shares of the company

  On the evening of March 7, () announced that from February 8 to March 6, 2024, the company repurchased a total of 3,506,800 shares of the company through a centralized auction transaction through a repurchase special securities account, accounting for about 1.25% of the company’s current total share capital.

  Rambler: Buyback of company shares 320,000 on March 7

  On the evening of March 7, Rambler announced that on March 7, 2024, the company repurchased 320,000 shares of the company in a centralized bidding mode for the first time through the special securities account for share repurchase, accounting for 0.0360% of the company’s total share capital.

  Huamao shares: repurchased 3 million shares of the company on March 7

  On the evening of March 7, () announced that on March 7, 2024, the company repurchased 3,000,000 shares of the company through a centralized auction transaction through a special securities account for share repurchase, accounting for 0.32% of the company’s current total share capital.

  Tofulong: Professional technology serves biomedicine and helps the development of human health

  On March 7, () released an announcement on the "Double Improvement of Quality Return" action plan. The company said that after 30 years of development, it has grown into a comprehensive pharmaceutical equipment service provider that provides pharmaceutical processes, core equipment, and system engineering overall solutions for global pharmaceutical companies. With its competitive advantages in the industry such as technological innovation, perfect sales network layout, leading brand influence, and comprehensive solution services, the company is in a leading position in the field of domestic pharmaceutical equipment, and continues to narrow the gap with international leaders. While exploring overseas markets, it gradually realizes domestic substitution.

  Yingke Medical: Give full play to the company’s comprehensive competitive advantages and develop into a global industry leader

  On March 7, () issued an announcement on the "Double Improvement of Quality Return" action plan. The company said that it has accumulated more than 10 years of R & D and production experience, and has fully integrated hardware, software, infrastructure and the company’s proprietary technology and expertise. As of June 30, 2023, the company has completed 8 self-developed and self-produced projects, and new products cover 9 product categories and more than 60 product series.

  Xingqi Eye Medicine: Will continue to increase investment in research and development to improve the product layout in various fields of ophthalmology

  On March 7, () issued an announcement on the "Double Improvement of Quality and Return" action plan. The company said that since its establishment, it has always attached importance to the research and development of new products, and will develop new products with independent intellectual property rights as the company’s goal of continuous progress and innovation. R & D investment has increased year by year. In the past three years, the company’s R & D investment has been 84 million yuan, 118 million yuan, and 190 million yuan, accounting for 12.13%, 11.47%, and 15.22% of operating income respectively. After years of development, the company’s R & D center has seven process technology platforms such as conventional ophthalmic preparations, ophthalmic gels, and sustained-release preparations, as well as evaluation technology platforms such as quality research, pharmacological pharmacogenesis research and drug packaging material research.

  Shouhang Hi-Tech: Signed a 429 million yuan solar thermal + photovoltaic integrated project equipment service supply contract

  Recently, the company and China Energy Construction Group Northwest Power Construction Engineering Co., Ltd. signed the "Tangshan Haitai New Energy Technology joint stock company solar thermal + photovoltaic integrated project tower concentrating heat collection system procurement contract", the contract stipulates that the seller is the buyer Tangshan Haitai New Energy Technology joint stock company solar thermal + photovoltaic integrated project to provide contract equipment and services. The total contract amount is RMB 429 million yuan.

  Keming food: holding subsidiary Xingjiang pastoral pig sales revenue in February 2724.03 million yuan, down 43.71%

  Keming Food announced on the evening of March 7 that the holding subsidiary Xingjiang Pastoral sold 25,900 pigs in February 2024, and the sales volume decreased by 39.31% month-on-month and 52.39% year-on-year; the sales revenue was 2724.03 million yuan, and the sales revenue decreased by 43.71% month-on-month and 49.47% year-on-year. From January to February 2024, the company sold 68,500 pigs cumulatively, down 20.94% from the same period last year; the cumulative sales revenue was 75.6314 million yuan, down 23.86% from the same period last year.

  Jilin Aodong issued 2 billion yuan medium-term notes accepted for registration

  () Announcement, the company recently received the "Notice of Acceptance of Registration" issued by the China Interbank Market Dealers Association (China Market Association Note [2024] MTN208), the Dealers Association decided to accept the company’s medium-term note registration, the company’s medium-term note The registration amount is 2 billion yuan, and the registration amount is valid within 2 years from the date of signing the notice.

  Shouhang Hi-Tech: Signed a 430 million yuan solar thermal + photovoltaic integrated project tower concentrating heat collection system procurement contract

  Shouhang Hi-Tech announced that the company and China Energy Construction Group Northwest Power Construction Engineering Co., Ltd. signed the "Tangshan Haitai New Energy Technology joint stock company solar thermal + photovoltaic integrated project tower concentrating system procurement contract", the company for Tangshan Haitai New Energy Technology joint stock company solar thermal + photovoltaic integrated project (tower concentrating system) to provide contract equipment and services, the total contract amount 430 million yuan.

  Shouhang Hi-Tech: Signed a 429 million yuan solar thermal + photovoltaic integrated project tower concentrating heat collection system procurement contract

  Shouhang Hi-Tech announced that recently, the company (hereinafter referred to as the "seller") and China Energy Construction Group Northwest Electric Power Construction Engineering Co., Ltd. (referred to as the "buyer") signed the "Tangshan Haitai New Energy Technology joint stock company solar thermal + photovoltaic integrated project tower concentrating heat collection system procurement contract", the contract stipulates that the seller is the buyer Tangshan Haitai New Energy Technology joint stock company solar thermal + photovoltaic integrated project (tower concentrating heat collection system) to provide contract equipment and services. The total contract amount (tax included) is RMB 429 million yuan.

  Luoxin Pharmaceutical and Shenzhen Unknown Jun have reached a strategic cooperation on the commercialization of intestinal microbiota transplantation (FMT)

  () Announcement: On March 7, 2024, the company and Shenzhen Unknown Jun Biotechnology Co., Ltd. (hereinafter referred to as "Shenzhen Unknown Jun") signed a "Strategic Cooperation Framework Agreement" in Shenzhen, Shenzhen Unknown Jun and/or its affiliates will transplant their intestinal flora into medical technology authorized companies and/or their affiliates to carry out exclusive commercialization cooperation within the scope of cooperation areas and channels agreed upon by both parties, including but not limited to distribution, sales, promotion, etc.

  The specific content of cooperative medical technology is the intestinal flora transplantation project ("FMT"), which involves wrapping fecal bacteria lyophilized powder or fecal bacteria particles in capsules and entering the human intestine by oral administration; or transplanting fecal bacteria isolated from the feces of healthy people into the intestine by nasal feeding, gastric tube insertion, and digestive endoscopic spraying, so as to restore the dynamic balance of intestinal flora, so as to achieve the purpose of treating various intestinal diseases caused by intestinal flora imbalance.

  The announcement said that the company has long focused on the digestive field. This time, the company signed a "Strategic Cooperation Framework Agreement" with Shenzhen Unknown Jun to reach a strategic cooperation on the commercialization of intestinal microbiota transplantation ("FMT"), which will help the company further improve its strategic layout in the digestive field and enhance its comprehensive competitiveness.

  Zuoli Pharmaceutical: Lingze Tablets received the certificate of protected varieties of traditional Chinese medicine

  Zuoli Pharmaceutical announced that the company has received the "Certificate of Traditional Chinese Medicine Protected Variety" issued by the State Drug Administration. The company’s exclusive variety Lingze Tablets is listed as the national second-level protected variety of traditional Chinese medicine, and the protection period is from March 1, 2024 to March 1, 2031.

  Shennong Technology’s application is withdrawn and the application documents are added by summary procedure

  () Announcement, on March 7, 2024, the company issued shares to specific objects by summary procedure in 2023, and the sponsor submitted to the Shenzhen Stock Exchange an application for withdrawing the application documents of Hainan Shennong Technology joint stock company to issue shares to specific objects by summary procedure.

  The company’s current production and operation are normal, and it will also actively promote the purchase and sale of rapeseed and other businesses to promote the large-scale development of the company’s rapeseed seed business. The withdrawal of the application documents for issuing shares to specific objects through the simplified procedure will not have a significant impact on the company’s normal production and operation and sustainable and stable development, and will not harm the interests of the company and shareholders, especially minority shareholders.

  Capital Airlines Hi-Tech signed a major contract related to 429 million yuan

  Shouhang Hi-Tech announced that recently, the company (the "seller") and China Energy Construction Group Northwest Electric Power Construction Engineering Co., Ltd. (the "buyer") signed the "Tangshan Haitai New Energy Technology joint stock company solar thermal + photovoltaic integrated project tower concentrating heat collection system procurement contract", the contract stipulates that the seller is the buyer Tangshan Haitai New Energy Technology joint stock company solar thermal + photovoltaic integrated project (tower concentrating heat collection system) to provide contract equipment and services, the total contract amount (tax included) 429 million yuan, accounting for about 65.73% of the company’s 2022 annual operating income.

  The shareholders’ meeting will be held on March 25 to consider proposals to change the company’s registered capital, amend the company’s articles of association, and handle the registration of industrial and commercial changes

  Canaan Smart announced that the first extraordinary general meeting of shareholders will be held on March 25, 2024, and online voting will be held on the same day. The equity registration date is March 20, and investors who hold Canaan Smart shares after the market closes on that day can participate in the voting.

  Venue: Ningbo Canaan intelligent electric joint stock company conference room, 315 Kaiyuan Road, Cixi City, Zhejiang Province.

  The shareholders’ meeting audited a total of one proposal, as follows:

  1. "Proposal on Changing the Registered Capital of a Company and Amending and Handling the Registration of Industrial and Commercial Changes".

  Guangdong Construction Engineering subsidiary jointly won the bidding for Guangzhou to develop Tianjin Xiqing District 750MW wind power project

  () Announcement, Guangdong Yuantian Engineering Co., Ltd. (referred to as "Yuantian Company"), a wholly-owned subsidiary of the company, received the "Notice of winning the bidding" from Guangzhou Trading Group Co., Ltd.

  The "win the bidding notice" determines that the consortium formed by Yuantian Company (member party) and China Energy Construction Group Guangdong Thermal Power Engineering Co., Ltd. (organizer) is the win the bidding unit of " () Tianjin Xiqing District 750MW Wind Power Project EPC General Contracting [JG2024-0695]". The contract content is the code packet of the released version specified in the invite tenders document. The winning bid price of the project is 4.893 billion yuan, and the total construction period of the project is 18 months. Among them, the construction task undertaken by Yuantian Company is about 1.846 billion yuan.

  According to the invite tenders document, the project plans to install 120 single-unit capacity 6.25MW wind turbines, with an installed capacity of 750MW, and two new 220kV boosting stations. According to the joint tender agreement of the consortium, Yuantian Company is responsible for the civil engineering of 750MW wind turbines (including hoisting platforms, fan foundations), all road engineering construction within the scope of the project, the renovation of Lishuang Highway, all project temporary land use and related compensation for the project, environmental protection engineering, soil and water conservation engineering, labor safety and industrial hygiene engineering, safety monitoring engineering and other related procedures; China Energy Construction Group Guangdong Thermal Power Engineering Co., Ltd. is responsible for the survey and design, all fan units, tower cylinders, box transformers, high and low voltage cables, all equipment and materials procurement of 220KV booster stations, 750MW fan unit hoisting, all 35KV collector lines construction and safety engineering (including tower materials, wires, fittings and other materials procurement), 220KV booster station construction and safety engineering, 220KV outgoing line and opposite side interval renovation engineering materials procurement, construction and safety construction. Special project report preparation, special project acceptance, equipment supervision.

  Guangdong Construction Engineering: Subsidiaries jointly won the bidding of Guangzhou Development Tianjin Xiqing District 750MW wind power project EPC general contracting project

  Guangdong Construction Engineering announced on the evening of March 7 that the consortium formed by Guangdong Yuantian Engineering Co., Ltd. (referred to as "Yuantian Company") (member party) and China Energy Construction Group Guangdong Thermal Power Engineering Co., Ltd. (organizer) is the winning unit of the EPC general contract [JG2024-0695] for the "Guangzhou Development Tianjin Xiqing District 750MW Wind Power Project". The winning bid price is about 4.893 billion yuan, and the total construction period of the project is 18 months. Among them, the construction task undertaken by Yuantian Company is about 1.846 billion yuan. According to the invite tenders document, the project plans to install 120 single-machine capacity 6.25MW wind turbines, with an installed capacity of 750MW, and build 2 new 220kV booster stations.

  ST has a tree: plans to transfer 17% stake in CCCC New Energy to Lu Yicheng

  ST Youkeshu announced that in order to comprehensively focus on the main business of cross-border e-commerce, optimize the investment structure, and further improve the profitability of assets, Youkeshu Technology joint stock company (referred to as "Youkeshu" or "Company") plans to transfer the 17% equity (registered capital contribution 34 million yuan) of Jiangsu CCCC New Energy Technology Co., Ltd. (referred to as "CCCC New Energy") held by its wholly-owned subsidiary Nanjing Keshu Technology Co., Ltd. (referred to as "Nanjing Keshu") to Lu Yicheng at a price of 40 million yuan. After the completion of this transfer, Nanjing Keshu will no longer hold the equity of CCCC New Energy.

  China-UK Technology 48.405 million Restricted Shares Available for Circulation on March 13

  () Announcement, the number of shares issued before the company’s initial public offering is 48.405 million shares, accounting for 64.37% of the company’s total share capital, and the date of listing and circulation is March 13, 2024.

  Fan Zhihong and Chen Haibing, directors of Jinbei Electric, have reduced their holdings by a total of 3.29 million shares

  () announcement, the company’s director and vice president Fan Zhihong, Chen Haibing reduction plan period has expired, a total reduction of the company’s shares 3.29 million shares.

  Huapengfei: The company signed a strategic cooperation framework agreement with the joint stock company of Ririshun Supply Chain Technology

  () Announcement, the company signed a strategic cooperation framework agreement with the Ririshun Supply Chain Technology joint stock company.

  Huakai Yibai granted 16.722 million restricted shares at a grant price of 9.82 yuan/share

  () announcement, the company 2024 restricted stock incentive plan provisions of the restricted stock grant conditions have been achieved, the company deliberated and passed the "on the grant of restricted stock to the incentive object", agreed and determined that the incentive plan restricted stock grant date is March 7, 2024, to meet the conditions of 114 incentive objects granted 16.722 million shares of restricted stock, the grant price is 9.82 yuan/share.

  Huapengfei: Signed a strategic cooperation framework agreement with Ririshun Supply Chain

  Huapengfei announced on the evening of March 7 that the company and Ririshun Supply Chain Technology joint stock company (referred to as "Ririshun Supply Chain") have their own resources and advantages in the field of supply chain, and are committed to commercial cooperation in cross-border integrated logistics. After friendly negotiation between the two sides, it was decided to establish a strategic partnership and sign the "Strategic Cooperation Framework Agreement".

  Fu Xin Ping An Bank Director Qualifications Approved

  Ping An Bank issued an announcement, recently, Ping An Bank joint stock company received the "State Financial Supervision and Administration Administration on Ping An Bank Fu Xin qualification", the State Financial Supervision and Administration approved Fu Xin Ping An Bank joint stock company director qualifications.

  Luoxin Pharmaceutical and micro-ecological R & D enterprise Unknown Jun reached a strategic cooperation

  On March 7, Luoxin Pharmaceutical announced that the joint stock company of Luoxin Pharmaceutical Group (hereinafter referred to as "the company") and Shenzhen Unknown Jun Biotechnology Co., Ltd. (hereinafter referred to as "Shenzhen Unknown Jun") signed the "Strategic Cooperation Framework Agreement" in Shenzhen, Shenzhen Unknown Jun will hold the intestinal flora transplantation (FMT) medical technology authorized company to carry out exclusive commercialization cooperation within the agreed cooperation area and channel scope, and the two sides will establish a win-win strategic partnership on the basis of complementary advantages, mutual benefit and common development.

  The application prospect of microbiota transplantation is huge, and the industry is leading

  The intestinal microbiota is called the "hidden organ" of the human body. More and more studies have found that the intestinal microbiota has an important connection with the occurrence of human health and diseases. When the intestinal microbiota is unbalanced, it will lead to the occurrence of many diseases. There are as many as 85 indications related to the treatment of intestinal microbiota. By regulating the intestinal microbiota, it can affect the health of the human body. The intestinal microbiota can not only become drugs but also serve as new drug targets, so the intestinal microbiota has great application prospects in the treatment of certain diseases. At present, the intestinal microbiota transplantation (FMT) has gradually become one of the most cutting-edge and hot research fields in the industry. Intestinal microbiota transplantation is to transplant the functional flora in the intestines of healthy people into patients to rebuild a healthy intestinal microbiome, in order to restore the diversity of intestinal flora, improve the balance of intestinal flora, and achieve the treatment of intestinal and parenteral diseases.

  Shenzhen Unknown Junzheng, which has reached a cooperation with Luoxin Pharmaceutical this time, is currently the industry-leading AI + BT microbiome research and product development platform, and a leader in the domestic micro-ecology field. According to its official website, Unknown Junzheng has built a leading micro-ecological strain sample and data asset library, and created an international leading bioinformation analysis platform composed of four core platforms of AI drug discovery, algorithms, clinical analysis, and data/computing. It is worth mentioning that Unknown Jun also has an industry-leading micro-ecological pipeline matrix, many of which are First-in-class, and have completed the layout in the fields of cancer, nervous system, digestive system, immune system and other diseases, covering all mainstream drug forms such as formula bacteria, genetically engineered microorganisms, bacterial metabolites, and enterobacteria transplantation. The pipeline layout and promotion capabilities are world-leading. He is the first (only) FMT/enterobacteria transplantation management system in Asia that meets FDA requirements. The production process strictly follows GMP specifications; the production environment is cleaner than the industry standard; the raw and auxiliary materials used are all pharmaceutical grade to ensure the safety of the product.

  The barriers in the digestion field are profound, and the commercialization experience and advantages of established pharmaceutical companies are obvious

  As an established enterprise that has been deeply involved in the pharmaceutical industry for more than 30 years, Luoxin Pharmaceutical has long focused on unmet clinical needs in core disease fields such as digestion, respiration, and anti-tumor. It has listed more than 10 dosage forms, more than 150 varieties, and more than 300 product specifications, forming a rich and competitive product portfolio. The core products are in a leading position in the market for digestive and respiratory diseases. According to IQVIA2023 data, the company’s digestive products, omeprazole enteric-coated capsules, rabeprazole sodium for injection, and lansoprazole for injection, have ranked first in the market share. It is worth noting that the company’s Class 1 innovative drug Tegorasan Tablets is the first self-developed potassium ion competitive acid blocker (P-CAB) in our country. It has been identified as a major special project of national "major new drug creation" science and technology. Currently, two indications have been approved for marketing: reflux esophagitis and duodenal ulcer. The third indication "combined with appropriate antibacterial therapy to eradicate Helicobacter pylori" has been accepted by the State Drug Administration. Recently, the results of the Phase III clinical study of pukanapeptide tablets for the treatment of functional constipation have reached the main efficacy endpoint. In addition, Tegorasan injection is also under development, and there is no similar injection product on the market worldwide. In the field of digestion, whether it is the esophagus of the upper digestive tract, the stomach or the intestines, gallbladder and pancreas of the lower digestive tract, it is the key direction of the company’s future expansion, and is committed to becoming an active leader in the ecosystem of China’s digestive field. Luoxin Pharmaceutical has built a professional commercialization team since the second half of 2021, and has the management experience of localizing the sales system of multinational pharmaceutical companies and the commercialization experience of innovative drugs. It has realized the core product of digestive system, Tegola raw tablets, in the early stage of listing, which has enabled thousands of doctors to quickly gain drug experience accumulation. It was approved to be included in the national medical insurance catalogue at a reasonable price in the same year. The following year of listing,

  Commercialization Blue Ocean Domestic policy support Cooperation Complementary advantages of both parties Deeply empowered

  Since the launch of the Human Microbiome Project in the United States in 2007, the development of micro-ecological medicine and microbial-related technologies has entered an accelerated stage. A large number of microbial pharmaceutical star companies have emerged. According to incomplete statistics, there are more than 50 micro-ecological pharmaceutical companies in the world, and multinational pharmaceutical giants such as Pfizer, Roche, Johnson & Johnson have also laid out micro-ecological pharmaceutical tracks. Intestinal microbiota transplantation research has grown rapidly since 2013 and has received more attention in recent years. There are more than 500 clinical trials related to intestinal microbiota transplantation registered internationally, involving indications including: pseudomembranous enteritis (Clostridium difficile infection), ulcerative colitis, Crohn’s disease, chronic functional diarrhea and constipation, diabetes, insomnia, obesity, autism, liver cirrhosis, allergic diseases, antibiotic resistance, anti-tumor drug resistance, depression, Parkinson’s disease and many other diseases. The patient base is huge. According to public information on the domestic government website, "Microbiota transplantation is becoming a new track in the field of biomedicine, and the global size of the market segment is about 50 billion US dollars." The domestic micro-ecological pharmaceutical industry is in a stage of rapid start, and the future market space is extremely broad. Intestinal microbiota transplantation is expected to become the next explosive point of the pharmaceutical industry. In 2023, the "National Medical Service Technical Specification (2023 Edition) " announced by the National Health Commission officially included "intestinal microbiota transplantation" in the technical specification, supporting the rapid development of the industry.

  Luoxin Pharmaceutical’s digestive field, whether it is the professionalism of the sales team or the department resources at the hospital end, has experienced the polishing and accumulation of time, and the commercialization ability is more advantageous. Unknown Jun is at the leading level in the field of intestinal flora transplantation (FMT) in terms of sample database, R & D capabilities and production process. This cooperation is Luoxin Pharmaceutical’s always-keen insight and forward-looking layout of market demand. The revolutionary significance and clinical value of intestinal flora transplantation as a diagnosis and treatment method will be realized through Luoxin Pharmaceutical’s commercialization capabilities covering hospitals at all levels across the country and Unknown Jun’s self-developed precision enterobacteria transplantation solutions, and jointly explore the domestic blue ocean market opportunities.

  Note: Unknown Jun CMC production workshop

  (): The company and its wholly-owned subsidiaries signed the "Cooperation Framework Agreement" with Gree Supply Chain and Gechuang Supply Chain

  Keheng share announcement, the company and its wholly-owned subsidiaries Yingde Keheng, Zhuhai Keheng, Zhuhai Haoneng, Haoneng Technology and Gree Supply Chain, Gechuang Supply Chain signed the "Cooperation Framework Agreement". Gree Supply Chain and Gechuang Supply Chain gave Jiangmen Keheng, Yingde Keheng, Zhuhai Keheng, Zhuhai Haoneng and Haoneng Technology a total of RMB 650 million for the procurement of raw materials.

  Tang Renshen: February pig sales revenue of about 400 million yuan

  Tang Renshen announced that the company’s pig sales in February 2024 272,000, down 4.83% year-on-year and 17.12% month-on-month; sales revenue totaled 399.82 million yuan, down 9.92% year-on-year and 3.44% month-on-month. From January to February 2024, the cumulative pig sales volume was 60,200, up 15.85% year-on-year; sales revenue was 81.39 million yuan, up 1.07% year-on-year.

  Diou Home Furnishing Shareholder Sichuan Development Fund reduced its holdings by 41,100 shares

  () Announcement that as of the expiration date of the reduction plan, the shareholder Sichuan Development Fund has reduced the company’s shares 41,100 shares through centralized bidding mode, accounting for 0.01% of the company’s total share capital. As of the disclosure date of this announcement, the shareholder Sichuan Development Fund’s reduction plan has been implemented.

  Pulo Pharmaceutical announced the 2023 annual rights distribution plan, proposing to pay 3.16 yuan for 10 grants

  () issued an announcement on March 8, the company’s 2023 annual equity distribution plan is as follows: based on the total share capital 1.1693236 billion shares, cash dividends of 3.16 yuan will be distributed to all shareholders for every 10 shares, and a total of 370 million yuan will be distributed.

  According to the 2023 annual performance report of Prologis Pharmaceutical, the company’s operating income 11.474 billion yuan, an increase of 8.81% year-on-year; net profit attributable to shareholders of listed companies 1.055 billion yuan, an increase of 6.69% year-on-year; basic earnings per share of 0.90 yuan, the same period last year was 0.84 yuan.

  The main business of Pullo Pharmaceutical joint stock company covers the R & D, production and sales of API intermediates, innovative drug R & D and production services (CDMO), preparations, etc., as well as import and export trade business. API intermediate business includes cephalosporin series, penicillin series, psychiatric series, cardiovascular and cerebrovascular series and veterinary drug API intermediate series; innovative drug R & D and production services (CDMO) include R & D services, commercial human drug projects, commercial veterinary drug projects and other commercializations; preparation business includes anti-infective, cardiovascular and cerebrovascular, psychiatric and anti-tumor categories. The company is a large comprehensive pharmaceutical enterprise integrating research, development and production of APIs, preparations and pharmaceutical intermediates. It is a national key high-tech enterprise and a key enterprise in the pharmaceutical industry of Zhejiang Province. It has been awarded the title of "Top Ten Enterprises" in the pharmaceutical industry of Zhejiang Province for nine consecutive years, and the title of AAA credit rating enterprise of Bank of China in Zhejiang Province for ten consecutive years. It has been ranked among the largest taxpayers in Zhejiang Province for five consecutive years. The trademark of "Kangyu" is a famous trademark in Zhejiang Province.

  (Source of data: iFinD)

  Keheng shares will hold a shareholders’ meeting on March 25 to consider the proposal to sign a cooperation framework agreement and related party transactions

  Keheng shares announced that the second extraordinary general meeting of shareholders will be held on March 25, 2024, and the online voting will be held on the same day. The equity registration date is March 18, and investors who hold Keheng shares after the market closes on that day can participate in the voting.

  Venue: Jiangmen City Jianghai District Jiaotou Jiaoxing South Road No. 22 Jiangmen City Keheng Industrial joint stock company 3 floor conference room.

  The shareholders’ meeting audited a total of one proposal, as follows:

  1. Proposal on Signing and Related Transactions.

  Jinling Sports: General Manager Li Jiangang plans to increase his stake in the company from 10 million yuan to 20 million yuan

  On the evening of March 7, Jinling Sports announced that the company received the "Notice Letter of Share Increase Plan" issued by Mr. Li Jiangang, director and general manager of the company on March 7, 2024. Mr. Li Jiangang, director and general manager of the company, plans to increase his holdings of the company’s shares within 6 months from the date of disclosure of this announcement. The total amount of the proposed increase is not less than 10 million yuan and not more than 20 million yuan. The source of funds required for the increase is equity fund.

  Pangang Group: 22 Pangang 01 will pay interest on March 11

  On March 7, Pangang Group Co., Ltd. issued an interest payment announcement that it will pay interest for the period from March 10, 2023 to March 9, 2024 on March 11, 2024.

  According to the interest payment plan, the coupon rate of the current bond variety 1 "22 Pangang 01" is 3.59%. This interest payment is RMB 35.90 (tax included) per lot (face value 1,000 yuan) of "22 Pangang 01". After tax deduction, the actual per-lot interest paid by individuals and securities investment fund bondholders is 28.72 yuan; the actual per-lot interest paid by non-resident enterprises (including QFII and RQFII) is 35.90 yuan.

  Yitong Century: Re-identified as a high-tech enterprise

  On the evening of March 7, () announced that recently, the company received the "High-tech Enterprise Certificate" jointly issued by the Guangdong Provincial Department of Science and Technology, the Guangdong Provincial Department of Finance, and the Guangdong Provincial Taxation Bureau of the State Administration of Taxation. This is a re-identification of the company’s original high-tech enterprise certificate after the valid period expires.

  Longquan Shares: The implementation of this share repurchase plan has been completed

  On the evening of March 7, () announced that the company implemented the share repurchase for the first time on February 28, 2024 through the repurchase special securities account in the form of centralized bidding transactions. As of March 6, 2024, the company has repurchased a total of 3290,000 shares of the company through the share repurchase special account in the form of centralized bidding transactions, accounting for 0.58% of the company’s total share capital. So far, the company’s share repurchase plan has been implemented.

  Jiuan Medical: Accumulated repurchase of 15056236 shares

  On the evening of March 7, Jiuan Medical announced that on February 8, 2024, the company repurchased the company’s shares in a centralized bidding mode for the first time through the special securities account for share repurchase. As of March 7, 2024, the company repurchased a total of 15056,236 shares of the company’s shares in a centralized bidding transaction through the special securities account for share repurchase, accounting for 3.08% of the company’s total share capital.

  Jinling Sports: General Manager plans to increase holdings 10 million yuan – 20 million yuan

  On March 7, Jinling Sports announced that Li Jiangang, the general manager of the company, plans to increase the company’s shares, and the total amount of the proposed increase is not less than 10 million yuan, not higher than 20 million yuan.

  Copyright Daily Economic News

  Luoxin Pharmaceutical: Signed a strategic cooperation framework agreement with Shenzhen Unknown Jun

  On March 7, Luoxin Pharmaceutical announced that the company signed the "Strategic Cooperation Framework Agreement" with Shenzhen Unknown Jun. Shenzhen Unknown Jun and/or its affiliates will transfer their intestinal flora transplantation medical technology authorized companies and/or their affiliates to carry out exclusive commercialization cooperation within the scope of cooperation areas and channels agreed upon by both parties, including but not limited to distribution, sales, promotion, etc.

  Luoxin Pharmaceutical joins hands with Shenzhen Unknown Jun to further enrich the layout of the digestive tract

  On March 7, Luoxin Pharmaceutical announced that the company and Shenzhen Unknown Jun Biotechnology Co., Ltd. (hereinafter referred to as "Shenzhen Unknown Jun") signed a "Strategic Cooperation Framework Agreement" in Shenzhen, Shenzhen Unknown Jun will hold the intestinal flora transplantation (FMT) medical technology authorized company to carry out exclusive commercialization cooperation within the agreed cooperation area and channel scope between the two parties, and the two parties will establish a win-win strategic partnership on the basis of complementary advantages, mutual benefit and common development.

  Broad application prospects of microbiota transplantation

  It is understood that the intestinal microbiota is known as the "hidden organ" of the human body, which is the normal microorganism of the human intestine. By regulating the intestinal microecology, it can affect the health of the human body. The intestinal microbiota can not only become a drug but also serve as a new drug target. Therefore, the intestinal microbiota has great application prospects in the treatment of certain diseases. At present, intestinal microbiota transplantation (FMT) has gradually become one of the most cutting-edge and popular research fields in the industry. Intestinal microbiota transplantation is to transplant the functional microbiota in the intestines of healthy people into patients to rebuild a healthy intestinal microbiota, so as to restore the diversity of intestinal microbiota, improve the balance of intestinal microbiota, and achieve the treatment of intestinal and extraintestinal diseases.

  Shenzhen Unknown Junzheng, which has reached a cooperation with Luoxin Pharmaceutical this time, is currently the industry-leading AI + BT microbiome research and product development platform, and a leader in the domestic micro-ecology field. According to its official website, Shenzhen Unknown Junzheng has built a leading micro-ecological strain sample and data asset library, and created an international leading bioinformation analysis platform composed of four core platforms of AI drug discovery, algorithms, clinical analysis, and data/computing. It is worth mentioning that Shenzhen Unknown also has an industry-leading micro-ecological pipeline matrix, many of which are first-in-class, and have completed the layout in the fields of cancer, nervous system, digestive system, immune system and other diseases, covering all mainstream drug forms such as formula bacteria, genetically engineered microorganisms, bacterial metabolites, and enterobacteria transplantation. The pipeline layout and promotion capabilities are world-leading, and it is the first (only) FMT/enterobacteria transplantation management system in Asia that meets FDA requirements.

  The barriers in the field of digestive system are profound, and the commercialization experience and advantages of established pharmaceutical companies are obvious

  As an established enterprise that has been deeply involved in the pharmaceutical industry for more than 30 years, Luoxin Pharmaceutical has long focused on the unmet clinical needs in the core disease fields such as digestion, respiration, and anti-tumor. It has listed more than 10 dosage forms, more than 150 varieties, and more than 300 product specifications, forming a rich and competitive product portfolio. The core products are in the leading position in the digestive system and respiratory system disease drug market. According to IQVIA2023 data, the company’s digestive system products, such as omeprazole enteric-coated capsules, rabeprazole sodium for injection, and lansoprazole for injection, rank first in the market share.

  Luoxin Pharmaceutical has been building a professional commercialization team since the second half of 2021, and has the management experience of localizing the sales system of multinational pharmaceutical companies and the commercialization experience of innovative drugs. It has realized that the core product of digestive system, Tegola raw tablets, has enabled thousands of doctors to quickly gain drug experience in the early stage of listing, and was included in the national medical insurance catalog at a reasonable price in the year it was approved. The following year, it was listed, and the new commercialization speed of hospital access reached 1,000 and sales doubled.

  Commercialization Blue Ocean Domestic policy support Cooperation Complementary advantages of both parties Deeply empowered

  It is understood that since the launch of the Human Microbiome Project in the United States in 2007, the development of micro-ecological medicine and microbial-related technologies has entered an accelerated stage, and a large number of microbial pharmaceutical star companies have emerged. According to incomplete statistics, there are more than 50 global micro-ecological pharmaceutical companies, and multinational pharmaceutical giants such as Pfizer, Roche, Johnson & Johnson have also laid out micro-ecological pharmaceutical tracks. Intestinal microbiota transplantation research has grown rapidly since 2013, and has received more attention in recent years. There are more than 500 clinical trials related to enterobacteria transplantation registered internationally, involving indications including: pseudomembranous enteritis (Clostridium difficile infection), ulcerative colitis and many other diseases, with a large patient base. The public information on the domestic government website shows that "flora transplantation is becoming a new track in the field of biomedicine, and the global scale of the market segment is about 50 billion US dollars." The domestic micro-ecological pharmaceutical industry is in the stage of rapid start, and the future market space is extremely broad. Intestinal flora transplantation is expected to become the next flash point of the pharmaceutical industry. In 2023, the "National Medical Service Technical Specification (2023 Edition) " announced by the National Health Commission officially included "intestinal flora transplantation" in the technical specification to support the rapid development of the industry.

  At present, Luoxin Pharmaceutical’s digestive system field, whether it is the professionalism of the sales team or the department resources at the hospital end, has experienced the polishing and accumulation of time, and the commercialization ability is more advantageous. Shenzhen Unknown Jun is at the leading level in the field of intestinal flora transplantation (FMT) in terms of sample database, R & D capabilities and production processes. This cooperation is Luoxin Pharmaceutical’s always-keen insight and forward-looking layout to market demand. The revolutionary significance and clinical value of intestinal flora transplantation as a diagnosis and treatment method will be realized through the commercialization ability of Luoxin Pharmaceutical covering hospitals at all levels across the country and the precision enterobacteria transplantation solution independently developed by Shenzhen Unknown Jun, and jointly explore the domestic blue ocean market opportunities. (Qi Hening)

  Picture Note: Shenzhen Unknown Jun CMC Production Workshop

  Dike Co., Ltd.: An advanced packaging and testing equipment has been patented and has not yet been applied to production

  China Fortune Connect, March 7 – () announced that the company recently obtained a patent certificate issued by the State Intellectual Property Office, the patent name is an advanced packaging and testing equipment. The invention patent is the company’s technology research and development and technical reserves. The patent has not been applied to production and will not have a significant impact on the company’s near-term production and operation, but it will help the company to further improve the intellectual property protection system, give full play to the advantages of independent intellectual property rights, and form a continuous innovation mechanism to maintain the company’s technological leadership and enhance the company’s core competitiveness.

  Xintian Pharmaceutical: plans to purchase 85.12% equity of Huilun Pharmaceutical by issuing shares

  () Announcement that the company plans to purchase 85.12% of the shares of Huilun Pharmaceutical held by 88 shareholders of Huilun Pharmaceutical, including Dong Dalun, Dong Zhu and Hainan Qianyao, by issuing shares. After the completion of this transaction, Huilun Pharmaceutical will become a wholly-owned subsidiary of the listed company.

  Luoxin Pharmaceutical joins hands with Shenzhen Unknown Jun to expand the field of intestinal flora transplantation

  On the evening of March 7, Luoxin Pharmaceutical announced that it had signed a "Strategic Cooperation Framework Agreement" with Shenzhen Unknown Jun Biotechnology Co., Ltd. (hereinafter referred to as "Shenzhen Unknown Jun"), and Shenzhen Unknown Jun would hold the intestinal flora transplantation (FMT) medical technology authorized company to carry out exclusive commercialization cooperation within the agreed cooperation areas and channels between the two parties.

  At present, intestinal microbiota transplantation (FMT) has gradually become one of the most cutting-edge and hot research areas in the industry. Intestinal microbiota transplantation is the transplantation of functional microbiota from healthy people’s intestines into patients to rebuild healthy intestinal microbiota, in order to restore intestinal microbiota diversity, improve intestinal microbiota balance, and achieve the treatment of intestinal and extraintestinal diseases.

  Shenzhen Unknown Junzheng, which has reached a cooperation with Luoxin Pharmaceutical this time, is currently the industry-leading AI + BT microbiome research and product development platform, and a leader in the domestic micro-ecology field. According to its official website, Unknown Junzheng has built a leading micro-ecological strain sample and data asset library, and created an international leading bioinformation analysis platform composed of four core platforms of AI drug discovery, algorithms, clinical analysis, and data/computing. It is worth mentioning that Unknown also has an industry-leading micro-ecological pipeline matrix, many of which are first-in-class, and have completed the layout in the fields of cancer, nervous system, digestive system, immune system and other diseases, covering all mainstream drug forms such as formula bacteria, genetically engineered microorganisms, bacterial metabolites, and intestinal bacteria transplantation. The pipeline layout and propulsion capabilities are world-leading.

  As an established enterprise that has been deeply involved in the pharmaceutical industry for more than 30 years, Luoxin Pharmaceutical has long focused on unmet clinical needs in core diseases such as digestion, respiration, and anti-tumor. It has listed more than 10 dosage forms, more than 150 varieties, and more than 300 product specifications, forming a rich and competitive product portfolio. The core products are in a leading position in the market for digestive and respiratory diseases. Since the second half of 2021, Luoxin Pharmaceutical has built a professional commercialization team. It has management experience in localization of sales systems of multinational pharmaceutical companies and commercialization experience in the landing of innovative drugs.

  Intestinal microbiota transplantation research has grown rapidly since 2013, and has received more attention in recent years. More than 500 clinical trials related to intestinal microbiota transplantation have been registered internationally. In 2023, the "National Medical Service Technical Specification (2023 Edition) " announced by the National Health and Health Commission officially included "intestinal microbiota transplantation" in the technical specification, supporting the rapid development of the industry.

  This cooperation is Luoxin Pharmaceutical has always maintained a keen insight into market demand and a forward-looking layout. The revolutionary significance and clinical value of intestinal flora transplantation as a diagnosis and treatment method are expected to be realized through the commercialization capabilities of Luoxin Pharmaceutical covering hospitals at all levels across the country and the precision enterobacteria transplantation solutions independently developed by Unknown Jun. (Nie Pin)

  Wall Nuclear Materials: 2 subsidiaries were re-identified as high-tech enterprises

  On the evening of March 7, () announced that the company’s holding subsidiary, Shanghai Kete New Materials joint stock company and Shanghai Changyuan Electronic Materials Co., Ltd. passed the re-identification of high-tech enterprises and recently received the "High-tech Enterprise Certificate".

  Luoxin Pharmaceutical and Shenzhen Unknown have reached a strategic cooperation

  On the evening of March 7, Luoxin Pharmaceutical announced that the joint stock company of Luoxin Pharmaceutical Group (hereinafter referred to as "the company") and Shenzhen Unknown Jun Biotechnology Co., Ltd. (hereinafter referred to as "Shenzhen Unknown Jun") signed the "Strategic Cooperation Framework Agreement" in Shenzhen, Shenzhen Unknown Jun will hold the intestinal flora transplantation (FMT) medical technology authorized company to carry out exclusive commercial cooperation within the agreed cooperation area and channel scope, and the two sides will establish a win-win strategic partnership on the basis of complementary advantages, mutual benefit and common development.

  Luoxin Pharmaceutical said that the company has been focusing on the digestive field for a long time. This time, the company signed the "Strategic Cooperation Framework Agreement" with Shenzhen Unknown Jun to reach a strategic cooperation on the commercialization of intestinal flora transplantation (FMT), which will help the company to further improve the strategic layout in the digestive field and enhance the company’s comprehensive competitiveness. This agreement is a framework document for the cooperation between the two parties. There are still uncertainties in the follow-up progress, and there are also uncertainties in the impact on the company’s current and future operating results. The signing and performance of this agreement will not affect the independence of the company’s business, and the company’s main business will not become dependent on the partners as a result of

  It is reported that Shenzhen Unknown Jun is currently the industry-leading AI + BT microbiome research and product development platform, and a leader in the domestic micro-ecology field. According to its official website, Shenzhen Unknown Jun has built a leading microecology strain sample and data asset library, and created an international leading bioinformation analysis platform composed of four core platforms of AI drug discovery, algorithms, clinical analysis, and data/computing.

  Chenzhan Optoelectronics: Accumulated repurchase of 2064,210 shares

  On the evening of March 7, () announced that from March 1 to March 7, 2024, the company repurchased 2064,210 shares of the company in a centralized bidding mode through the special securities account for share repurchase, accounting for 1.26% of the company’s total share capital.

  Jiahe Intelligent: The first repurchase of 140,400 shares

  On the evening of March 7, () announced that on March 7, 2024, the company repurchased 140,400 shares of the company through a centralized auction transaction through a repurchase special securities account for the first time, accounting for 0.04% of the company’s current total share capital.

  Luoxin Pharmaceutical and Shenzhen Unknown Jun signed a "Strategic Cooperation Framework Agreement" involving intestinal microbiota transplantation medical technology

  On the evening of March 7, Luoxin Pharmaceutical announced that on March 7, the company and Shenzhen Unknown Jun Biotechnology Co., Ltd. (hereinafter referred to as "Shenzhen Unknown Jun") signed a "Strategic Cooperation Framework Agreement" in Shenzhen. Shenzhen Unknown Jun and/or its affiliates will transplant their intestinal flora into medical technology authorized companies and/or their affiliates to carry out exclusive commercialization cooperation within the agreed cooperation areas and channels, including but not limited to distribution, sales, promotion, etc. Both parties agreed to establish a win-win strategic partnership on the basis of complementary advantages, mutual benefit and common development.

  It is understood that the specific connotation of intestinal flora transplantation medical technology is to wrap fecal bacteria lyophilized powder or fecal bacteria particles in capsules and enter the human intestine by oral administration; or transplant fecal bacteria isolated from the feces of healthy people through nasal feeding, gastric tube insertion, and digestive endoscopic spraying into the intestine to restore the dynamic balance of intestinal flora, so as to achieve the purpose of treating various intestinal diseases caused by intestinal flora imbalance.

  Xintian Pharmaceutical plans to issue an additional 85.12% stake in Huilun Pharmaceutical, forming a dual-category industrial pattern of "traditional Chinese medicine-chemical medicine"

  Xintian Pharmaceutical announced that the company plans to purchase 85.12% of the equity of Huilun Pharmaceutical held by 88 shareholders of Shanghai Huilun Pharmaceutical joint stock company ("Huilun Pharmaceutical"), including Dong Dalun, Dong Zhu and Hainan Qianyao, by issuing shares. After the completion of this transaction, Huilun Pharmaceutical will become a wholly-owned subsidiary of the company. The price of the shares issued this time is 8.12 yuan/share. This transaction is expected to constitute a major asset restructuring.

  It is reported that Huilun Pharmaceutical’s main business is the research and development, production and sales of small molecule chemical drugs, and is committed to innovation and development in the fields of immune inflammation, anti-tumor, cardiovascular and cerebrovascular, gynecology, andrology and other diseases. Through this transaction, the company will further extend its industrial layout to cutting-edge pharmaceutical fields such as small molecule chemical drugs, forming a dual-category industrial pattern of "traditional Chinese medicine-chemical drugs", realizing rich integration of product structure, further expansion of therapeutic fields and upgrading of future innovative drug pipelines, and accelerating the establishment of a leading comprehensive pharmaceutical enterprise.

  Oriental Seiko: No direct partnership with Nvidia

  () Issued an announcement of abnormal stock trading fluctuations. The company has recently noticed that some media have listed the company as a "robot + Nvidia" concept stock. Many relevant media reports mention Guangdong Jiateng Robot Automation Co., Ltd., a shareholding company of Oriental Seiko. Oriental Seiko takes "intelligent equipment manufacturing" as the strategic core, focuses on the direction of high-end intelligent equipment manufacturing, and its main business layout is in the two fields of "intelligent packaging equipment" and "water power equipment". As of now, Oriental Seiko has no direct cooperative relationship with Nvidia. Based on Oriental Seiko’s shareholding ratio of Jiateng Robotics and the accounting treatment of the investment in Oriental Seiko’s consolidated financial statements, the application of robots or AI-related technologies will not have a significant impact on the company’s operating results in the short term.

  Xintian Pharmaceutical plans to acquire 85.12% stake in Huilun Pharmaceutical and resume trading on March 8

  On the evening of March 7, Xintian Pharmaceutical announced that it plans to purchase the 85.12% equity of Huilun Pharmaceutical held by 88 shareholders of Shanghai Huilun Pharmaceutical joint stock company (hereinafter referred to as "Huilun Pharmaceutical"), including Dong Dalun, Dong Zhu and Hainan Qianyao, through the issuance of shares.

  According to the data, Huilun Pharmaceutical’s main business is the research and development, production and sales of small molecule chemical drugs, and is committed to innovation and development in the fields of immune inflammation, anti-tumor, cardiovascular and cerebrovascular, gynecology, andrology and other diseases. Xintian Pharmaceutical said that after the completion of this transaction, the company will further extend its industrial layout to cutting-edge pharmaceutical fields such as small molecule chemical drugs, forming a dual-category industrial pattern of "traditional Chinese medicine-chemical drugs", realizing rich integration of product structure, further expansion of therapeutic fields and upgrading of future innovative drug pipelines, and relying on the integration with underlying assets to enhance the company’s Product Research & Development capabilities, market competitiveness, sustainable development capabilities and anti-risk capabilities, and accelerate the creation of a leading comprehensive pharmaceutical enterprise.

  In addition, Xintian Pharmaceutical said that after the company applied to the Shenzhen Stock Exchange, the company’s shares and convertible corporate bonds resumed trading since the market opened on March 8, and convertible corporate bonds resumed conversion on the same day.

  Huibo Yuntong: Plan to increase funding for big data and AI model research and development projects for enterprise application scenarios

  () announcement, the proposed increase in funding does not exceed 430 million yuan, for enterprise application scenarios for big data and AI model research and development projects, supplementary working capital.

  Huilu Ecology was 575,500 shares by Li Junhao, the son of Li Xiaoming, the actual controller

  () Announcement that Li Junhao, the son of Li Xiaoming, the actual controller of the company, increased his holdings of the company’s shares 575,500 shares on March 6, 2024.

  Huilu Ecology was 575,500 shares by Li Junhao, the son of Li Xiaoming, the actual controller

  Huilu Ecological Announcement, Li Junhao, the son of Li Xiaoming, the actual controller of the company, increased his holdings of the company’s shares 575,500 shares on March 6, 2024.

  Jiansheng Green Energy, a subsidiary of Wenke Holdings, plans to build a photovoltaic power station project

  () Announcement, the company’s holding subsidiary, Guangdong Jiansheng Green Energy Co., Ltd. (abbreviation: "Jiansheng Green Energy") intends to acquire 100% equity of Huizhou Lingdian New Energy Co., Ltd. (abbreviation: "Project Company"), with the project company as the main body to invest in the construction of rooftop distributed photovoltaic projects, with an estimated total installed capacity of about 7.38MW (subject to the actual installed capacity). The total investment of the project is estimated to be 2625.2 million yuan.

  This investment in the construction of a photovoltaic power station project is conducive to enhancing the company’s large-scale business advantages. Together with the company’s other independently developed and operated photovoltaic power stations under construction, the company can expand its coverage in the Pearl River Delta region, enhance the company’s overall competitiveness and product service level, and expand the company’s brand influence.

  Xintian Pharmaceutical’s shares resume trading, convertible bonds resume trading and share conversion

  Xintian Pharmaceutical announced that the company intends to purchase 85.12% of the equity of Huilun Pharmaceutical held by 88 shareholders of Shanghai Huilun Pharmaceutical joint stock company ("Huilun Pharmaceutical"), including Dong Dalun, Dong Zhu and Hainan Qianyao Enterprise Management Partnership (Limited Partnership), by issuing shares ("this transaction"). Upon application, the company’s shares and convertible corporate bonds will be suspended from the opening of the market on February 23, 2024 to March 7, 2024 (Thursday).

  During the suspension period, the company signed the "Trading Framework Agreement" with 88 shareholders of Huilun Pharmaceutical, and has formed a preliminary trading intention. Upon application, the company’s shares and convertible corporate bonds will resume trading from the opening of the market on March 8, 2024 (Friday), and convertible corporate bonds will resume conversion on the same day.

  Huapengfei and Ririshun Supply Chain Signed a Strategic Cooperation Framework Agreement

  Huapengfei announced that in view of the fact that the company and Ririshun Supply Chain Technology joint stock company have their own resources and advantages in the supply chain field, and are committed to commercial cooperation in cross-border integrated logistics and seek common development, the two parties decided to establish a strategic partnership and sign the "Strategic Cooperation Framework Agreement". On the premise of meeting the service experience and cost competitiveness of Ririshun Supply Chain, the company, as the cross-border logistics service team of Ririshun Supply Chain, is entrusted to undertake the cargo transportation tasks of Ririshun Supply Chain, including but not limited to cross-border trucking services, cross-border maritime transportation services, and cross-border railway transportation services. The company provides customized solutions for Ririshun Supply Chain to assist Ririshun Supply Chain in achieving cost reduction and efficiency increase.

  Zuoli Pharmaceutical: The company’s exclusive variety Lingze tablets are listed as the national second-level protected variety of traditional Chinese medicine

  Zuoli Pharmaceutical announced that recently, the company received the "Certificate of Traditional Chinese Medicine Protected Variety" issued by the State Drug Administration. The company’s exclusive variety Lingze Tablet is listed as the national second-level protected variety of traditional Chinese medicine, and the protection period is from March 1, 2024 to March 1, 2031. Lingze Tablet, as one of the important products of the Wuling series, is an exclusive innovative drug for the treatment of benign prostate hyperplasia and the treatment of symptoms such as frequent nocturnal urination. It is a product of the National Basic Drug Catalog and a Class B product of the National Medical Insurance Catalog.

  The 16.7% shares held by Kunlun Investment, the controlling shareholder of Xiangxue Pharmaceutical, were frozen by the judiciary

  On the evening of March 7, () issued an announcement saying that recently, the company checked the system of the Shenzhen branch of China Securities Depository and Clearing Co., Ltd., and learned that part of the company’s shares held by the controlling shareholder Guangzhou Kunlun Investment Co., Ltd. (hereinafter referred to as "Kunlun Investment") had been judicially frozen.

  The announcement shows that the total number of frozen shares held by Kunlun Investment is about 110 million shares, accounting for 73.91% of its shares and 16.7% of the company’s total share capital. As of the announcement date, Kunlun Investment has frozen about 149 million shares, accounting for 100% of its shares and 22.59% of its total share capital.

  Dongfang Seiko: The company does not control Jiateng robots and does not participate in the operation and management of Jiateng robots

  Dongfang Seiko announced that the company has recently noticed that some media have listed the company as a "robot + Nvidia" concept stock. Many relevant media reports mention Guangdong Jiateng Robot Automation Co., Ltd. (hereinafter referred to as "Jiateng Robot"), a shareholding company of Dongfang Seiko. The company explains the relevant matters as follows:

  (1) Explanation of Dongfang Seiko’s investment in Jiateng Robot. In June 2014, Dongfang Seiko disclosed the "Announcement on Cash Subscription for 20% Equity of Guangdong Jiateng Robot Automation Co., Ltd." The company invested in Jiateng Robot in cash subscription to obtain 20% of its capital contribution, and the transaction consideration was 49.12 million yuan. Since June 2014, Dongfang Seiko has never made additional investment in Jiateng Robot. During this period, due to the introduction of new shareholders and the increase in registered capital of Jiateng Robot, as of now, Dongfang Seiko’s investment in Jiateng Robot is 19.8366%.

  (2) Dongfang Seiko’s explanation for not controlling Jiateng Robot and not participating in the operation and management of Jiateng Robot. According to the Company Law and enterprise accounting standards, Dongfang Seiko, as a minority shareholder, does not have the control of Jiateng Robot. Since the initial investment in Jiateng Robot, Dongfang Seiko has never included Jiateng Robot in the scope of consolidated statements, nor has it substantially participated in the operation and management of Jiateng Robot.

  (3) The impact of investing in Jiateng Robotics on the financial performance of Dongfang Seiko. Since the initial investment in Jiateng Robotics in June 2014, in the regular reports disclosed every year, Dongfang Seiko has strictly adhered to the relevant provisions of the enterprise accounting standards, recognized Jiateng Robotics as an "associate" for long-term equity investment, and recognized ROI in each reporting period using the equity method. Jiateng Robotics has not paid dividends from 2020 to 2023.

  (4) Explanation that Dongfang Seiko and Nvidia do not have a direct cooperative relationship. Dongfang Seiko takes "intelligent equipment manufacturing" as the strategic core, focuses on the direction of high-end intelligent equipment manufacturing, and is mainly engaged in the two fields of "intelligent packaging equipment" and "aquatic power equipment". As of now, Dongfang Seiko has no direct cooperative relationship with Nvidia. Based on Dongfang Seiko’s shareholding ratio for Jiateng Robotics and the accounting treatment of the investment in Dongfang Seiko’s consolidated financial statements, the application of robots or AI-related technologies will not have a significant impact on the company’s operating results in the short term.

  Shouhang Hi-Tech signed a procurement contract for the tower concentrating heat collection system of the solar thermal + photovoltaic integrated project

  Shouhang Hi-Tech announced that recently, the company (the "seller") and China Energy Construction Group Northwest Electric Power Construction Engineering Co., Ltd. (the "buyer") signed the "Tangshan Haitai New Energy Technology joint stock company solar thermal + photovoltaic integrated project tower concentrating heat collection system procurement contract", the contract stipulates that the seller is the buyer Tangshan Haitai New Energy Technology joint stock company solar thermal + photovoltaic integrated project (tower concentrating heat collection system) to provide contract equipment and services, the total contract amount (tax included) 428,718,280.00 yuan.

  Liberal Arts Co., Ltd.: Holding subsidiary plans to invest in the construction of photovoltaic power station projects

  Wenke shares announced on the evening of March 7 that the holding subsidiary Guangdong Jiansheng Green Energy Co., Ltd. plans to acquire 100% equity of Huizhou Lingdian New Energy Co., Ltd., and invest in the construction of rooftop distributed photovoltaic projects with the project company as the main body. The total installed capacity is expected to be about 7.38MW. The total investment of the project is estimated to be 2625.2 million yuan.

  Huibo Yuntong: It is planned to raise no more than 432 million yuan for big data and AI model research and development projects for enterprise application scenarios

  Huibo Yuntong announced on the evening of March 7 that it intends to issue shares to specific objects, and the total amount of proceeds raised does not exceed 432 million yuan, which is used for big data and AI large model research and development projects for enterprise application scenarios and supplementary working capital.

  Shengxun shares: 244,400 shares were repurchased for the first time

  On the evening of March 7, () announced that on March 7, 2024, the company repurchased 244,400 shares of the company through a centralized bidding transaction through a special securities account for share repurchase, accounting for 0.30% of the company’s current total share capital.

  Xintian Pharmaceutical plans to acquire 85.12% stake in Huilun Pharmaceutical and resume trading on the 8th

  Xintian Pharmaceutical announced that the company plans to purchase 85.12% of the equity of Huilun Pharmaceutical held by 88 Huilun Pharmaceutical shareholders including Dong Dalun, Dong Zhu and Hainan Qianyao by issuing shares. After the completion of this transaction, Huilun Pharmaceutical will become a wholly-owned subsidiary of the company. As of now, the audit and evaluation of the underlying assets of this transaction have not been completed, and the transaction price of the underlying assets of this transaction has not yet been determined. This transaction is expected to constitute a major asset restructuring. Huilun Pharmaceutical’s main business is the research and development, production and sales of small molecule chemical drugs, and is committed to innovative development in the fields of immuno-inflammation, anti-tumor, cardiovascular and cerebrovascular, gynecological, andrology and other diseases. The company said that after the completion of this transaction, the company will further extend its industrial layout to frontier pharmaceutical fields such as small molecule chemical drugs, forming a dual-category industrial pattern of "traditional Chinese medicine-chemical drugs", and realize the rich integration of product structure, further expansion of the therapeutic field and the upgrade of future innovative drug pipelines. The company’s shares and convertible corporate bonds will resume trading from the opening of the market on March 8, 2024, and convertible corporate bonds will resume conversion on the same day.

  Huarong Chemical appointed Zhang Wei as the general manager of the company

  () Announcement: On March 7, 2024, the board of directors of the company deliberated and approved the "Proposal on the Appointment and Removal of Senior Managers of the Company". Tang Chong was removed as the general manager and continued to serve in the company. Zhang Wei was appointed as the general manager, and at the same time, Zhang Wei’s deputy general manager, CFO, and board secretary were removed. Cai Xiaoqin was appointed as the CFO and Li Si was appointed as the secretary of the board of directors.

  Teyi Pharmaceutical announced the annual rights distribution plan for 2023, and plans to pay 5 yuan for 10 to 4 shares

  () announced on March 8 that the company’s 2023 annual equity distribution plan is as follows: based on the total share capital 364.7389 million shares, a cash dividend of RMB 5.00 will be distributed to all shareholders for every 10 shares, a total of RMB 182 million will be distributed, and a capital provident fund will be transferred to all shareholders for every 10 shares.

  According to Special Pharmaceutical’s annual performance report for 2023, the company’s operating income was 1.067 billion yuan, an increase of 20.38% year-on-year; net profit attributable to shareholders of listed companies was 253 million yuan, an increase of 42.07% year-on-year; basic earnings per share were 0.77 yuan, 0.57 yuan in the same period last year.

  Teyi Pharmaceutical Group joint stock company is mainly engaged in the research and development, production and sales of proprietary Chinese medicines, chemical preparations and chemical raw materials. The company’s main products include cough treasure tablets, Ganmaoling granules, compound Houttuynia cordata tablets, pharyngitis tablets, Xuesaitong dispersible tablets, Ginkgo biloba dispersible tablets, Yixinshu granules, aluminum magnesium carbonate chewable tablets, Maple Polygonum Changweikang tablets, omeprazole enteric-coated capsules, roxithromycin capsules, etorubicin tablets, levofloxacin hydrochloride tablets, skin disease blood poison pills, Yikang Beisong cream, children’s cough syrup, children’s Kechuanling granules, Jinkui kidney gas tablets, etc. In addition, 27 medicines including Cough Treasure Tablets, Jinkui Shenqi Tablets, Erythromycin Enteric-coated Tablets and Erythromycin Tablets have been recognized as "Guangdong Province High-tech Products" by the Guangdong Provincial Department of Science and Technology. The company’s special brand has been recognized as "Guangdong Province Famous Trademark" by the Guangdong Provincial Administration for Industry and Commerce, and the special brand has also been rated as "Guangdong Province Leading Brand in the Industry of Proprietary Chinese Medicine and Traditional Chinese Medicine Decoction Pieces" by the Guangdong Provincial Pharmaceutical Industry Association.

  (Source: Flush iFinD)

  Pengdu agriculture and animal husbandry controlling shareholders acting in concert were judicially frozen 646 million shares

  () Announcement, the company recently received a notice from the company’s controlling shareholder, Shanghai Pengxin (Group) Co., Ltd. (referred to as "Pengxin Group"), the concerted action person of Lhasa Economic and Technological Development Zone Houkang Industrial Co., Ltd. (referred to as "Houkang Industrial"), that its holdings of 646 million shares of the company (10.13% of the company’s total share capital) were frozen by the judiciary.

  Luoxin Pharmaceutical and Shenzhen Unknown signed a strategic cooperation framework agreement

  Luoxin Pharmaceutical announced that the company and Shenzhen Unknown Jun Biotechnology Co., Ltd. signed the "Strategic Cooperation Framework Agreement" on March 7, 2024. Shenzhen Unknown Jun and/or its affiliates will transplant their intestinal flora into medical technology authorized companies and/or their affiliates to exclusively carry out commercialization cooperation within the scope of cooperation areas and channels agreed upon by both parties, including but not limited to distribution, sales, promotion, etc. Both parties agreed to establish a win-win strategic partnership on the basis of complementary advantages, mutual benefit and common development.

  Nenghui Technology terminates the implementation of the 2021 restricted stock incentive plan

  () Announcement, the board of directors and the board of supervisors of the company deliberated and approved the "Proposal on Terminating the Implementation of the 2021 Restricted Stock Incentive Plan and Repurchase, Cancellation and Voiding of Restricted Shares", and intends to decide to terminate the implementation of the incentive plan, and to repurchase and cancel all the first-class restricted stocks that have been granted but not yet lifted and all the second-class restricted stocks that have been granted but not yet vested, and the relevant supporting documents shall be terminated together.

  Lianke Technology announced the 2023 annual rights distribution plan, proposing to pay 5 yuan out of 10

  () announced on March 8 that the company’s 2023 annual equity distribution plan is as follows: Based on the total share capital 202.356 million shares, cash dividends of RMB 5.00 will be distributed to all shareholders for every 10 shares, and a total cash dividend of RMB 101 million will be distributed. No bonus shares will be sent, and no capital reserve will be converted into equity.

  According to the 2023 annual performance report released by Lianke Technology, the company’s operating income was 1.917 billion yuan, an increase of 4.45% year-on-year; net profit attributable to shareholders of listed companies was 169 million yuan, an increase of 51.27% year-on-year; basic earnings per share were 0.88 yuan, 0.61 yuan in the same period last year.

  Shandong Lianke Technology joint stock company is a high-tech enterprise specializing in the research and development, production and sales of silica and carbon black. The silica products mainly include LK, LKHD and LKSIL series rubber industrial silica and non-rubber industrial silica; carbon black products mainly include N100, N200, N300, N400, N500, N600, N700 series and LK series rubber carbon black and special carbon black. The company’s silica and carbon black products have been certified by Pirelli Tire, Yokohama, Zhengxin Rubber, Cooper Tire, () and (), (), Aeolus Tire, Shuangxing Tire, Pulin Chengshan and other well-known tire and footwear companies in the world-renowned tire companies.

  (Source: Flush iFinD)

  Huarong Chemical announced the 2023 annual rights and interests distribution plan, proposing to send 2 yuan to 10

  Huarong Chemical announced on March 8 that the company’s 2023 annual equity distribution plan is as follows: Based on the total share capital 480 million shares, cash dividends of RMB 2.00 will be distributed to all shareholders for every 10 shares, and a total of RMB 96 million will be distributed. No bonus shares will be sent, and no capital reserve will be converted into equity.

  According to Huarong Chemical’s annual performance report for 2023, the company’s operating income was 1.059 billion yuan, down 6.67% year-on-year; net profit attributable to shareholders of listed companies was 139 million yuan, an increase of 13.53% year-on-year; basic earnings per share were 0.29 yuan, 0.27 yuan in the same period last year.

  Huarong Chemical joint stock company is an advanced enterprise dedicated to the green recycling and comprehensive utilization of potassium hydroxide. The main products are high-quality potassium hydroxide. The company focuses on the development of electronic-grade, photovoltaic-grade, reagent-grade, food-grade fine potassium products and chlorine products around modern industries such as new fertilizers, high-end daily chemicals, food and medicine, new energy, and electronic information. The company has won the titles and awards of "National Advanced Collective of Petroleum and Chemical Industry", "Third Class of Science and Technology Progress Award", "Sichuan Province Oil and Gas Chemical Industry" Twelfth Five-Year "Development Advanced Unit", "Sichuan Famous Brand Product Title", "Sichuan Province Famous Trademark" and other titles and awards.

  (Source: Flush iFinD)

  Jujie Microfiber: The controlling shareholder plans to increase the company’s shares by 1,500 to 30 million yuan

  China Fortune Connect, March 7 – Jujie Microfiber announced that based on confidence in the company’s future development and recognition of long-term investment value, the company’s controlling shareholder Suzhou Jujie Investment Co., Ltd. plans to increase its holdings of the company’s shares within the next 6 months from the date of this announcement through the means allowed by the China Securities Supervision Commission and the Shenzhen Stock Exchange trading system (including but not limited to centralized bidding and block trading, etc.), with a total proposed increase of not less than 15 million yuan and not more than 30 million yuan.

  Xintian Pharmaceutical plans to purchase part of the equity of Huilun Pharmaceutical and resume trading on March 8

  Xintian Pharmaceutical announced on the evening of March 7 that it plans to purchase 85.12% of the equity of Huilun Pharmaceutical held by 88 Huilun Pharmaceutical shareholders including Dong Dalun, Dong Zhu and Hainan Qianyao by issuing shares. After the completion of this transaction, Huilun Pharmaceutical will become a wholly-owned subsidiary of the listed company. This transaction does not involve raising supporting funds. At the same time, Xintian Pharmaceutical’s shares and convertible corporate bonds have resumed trading since the opening of the market on March 8, and convertible corporate bonds have resumed conversion on the same day.

  Focus on small molecule chemicals

  Before this transaction, Xintian Pharmaceutical’s main business was the research and development, production and sales of proprietary Chinese medicines. The product indications were mainly for gynecological and urinary diseases, and covered oral, mammary and thyroid, anti-cold, heat-clearing, blood supplementation, cardiovascular diseases, anti-tumor and other disease fields.

  In the field of traditional Chinese medicine, Xintian Pharmaceutical has 32 drug production batches, including 10 national medical insurance catalog varieties, 1 national essential drug catalog variety, 12 over-the-counter (OTC) varieties, and 12 exclusive varieties. The main product pipeline market such as gynecology and urinary system, and many main varieties have achieved a sales scale of over 100 million single products. Among them, Xintian Pharmaceutical has a leading clinical market position and industry position in the gynecological field.

  After years of traditional Chinese medicine industry marketing network construction and market mining, the current product market has covered more than 30 provinces, autonomous regions and municipalities across the country, prescription drug products cover more than 12,000 hospitals above the county (district) level; OTC products cover more than 800 drug chain companies, nearly 100,000 stores, and established long-term and stable business relationships with the headquarters of nearly 500 domestic drug chain companies.

  The main business of the target company, Huilun Pharmaceutical, is the research and development, production and sales of small molecule chemical drugs, and is committed to innovation and development in the fields of immuno-inflammation, anti-tumor, cardiovascular and cerebrovascular, gynecological, andrology and other diseases. After years of technical accumulation and business development, Huilun Pharmaceutical has approved a number of chemical drugs for listing. As of the signing date of the plan, Huilun Pharmaceutical has approved 12 varieties for listing, including 1 new improved drug and 3 first imitation drugs. The drug treatment fields cover immuno-inflammation, anti-tumor, gynecology, andrology, cardiovascular and cerebrovascular systems, etc.

  Huilun Pharmaceutical’s exclusive product, Silvestrat Sodium for Injection, is mainly used to improve acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) accompanied by systemic inflammatory response syndrome. The product has obtained the qualification of accelerated review by the State Food and Drug Administration, and has obtained clinical approval through emergency review. It is also the first drug approved in China for the treatment of ALI and ARDS.

  In terms of performance, from 2022 to 2023, Huilun Pharmaceutical achieved revenue of 414 million yuan and 998 million yuan, and net profit was – 264 million yuan and 30.8325 million yuan.

  Constitutes a material asset reorganization

  According to the transaction plan, Xintian Pharmaceutical plans to purchase 85.12% of the equity of Huilun Pharmaceutical held by 88 Huilun Pharmaceutical shareholders including Dong Dalun, Dong Zhu and Hainan Qianyao by issuing shares. This transaction does not involve raising supporting funds. As of the signing date of the plan, Xintian Pharmaceutical has held 14.88% of the equity of Huilun Pharmaceutical; after the completion of this transaction, Huilun Pharmaceutical will become a wholly-owned subsidiary of the listed company.

  The price of the shares issued this time is 8.12 yuan/share. As of the signing date of the plan, the audit and evaluation of the underlying assets of this transaction have not been completed, and the transaction price has not yet been determined. Judging from the unaudited financial data of the target company in 2023, this transaction is expected to constitute a major asset restructuring, but it will not lead to a change in the actual controller of the company.

  In addition, Dong Dalun, Dong Zhu, Hainan Qianyao, LIUZHENWANG, Huilun Yuyi, Huilun Feihe, Huilun Yunbai, Tianxiang Shengtai, Wang Jinhua, Wang Guangping, Wang Wenyi, Chen Yurong, Ji Weijia, Dong Dahua, Dong Daheng, and Yuan Ye are related parties of Xintian Pharmaceutical, and this transaction constitutes a related party transaction.

  Xintian Pharmaceutical said that after the completion of this transaction, the listed company will further enrich the product pipeline in the company’s specialty field, improve the product matrix, and provide patients with more comprehensive medication options, thereby improving the market coverage and influence of the listed company in the main drug field. At the same time, Xintian Pharmaceutical will integrate the marketing activities of both parties, deeply integrate in the fields of gynecology, andrology and other diseases, improve the efficiency of drug marketing activities in the same department, enrich the choice space of doctors, and simultaneously increase the layout of sales channels such as OTC and e-commerce, as well as sales coverage areas and coordinated development.

  At the same time, Xintian Pharmaceutical will further extend its industrial layout to cutting-edge pharmaceutical fields such as small molecule chemical drugs, forming a dual-category industrial pattern of "traditional Chinese medicine – chemical drugs", realizing rich integration of product structure, further expansion of treatment field and upgrading of future innovative drug pipelines, superimposing the synergy effect of clinical medical research and marketing activities with the products of the target company, further enhancing the clinical marketing capabilities of the company’s core products and the market competitiveness of product pipelines, accelerating the creation of a leading comprehensive pharmaceutical enterprise, and enhancing Xintian Pharmaceutical’s competitiveness in the pharmaceutical industry.

  Zhongbing Hongjian: Completion acceptance of some investment projects with proceeds raised

  () Announcement, the company’s wholly-owned subsidiary Shandong North Binhai Machinery Co., Ltd. (referred to as North Binhai) has completed all the construction content of the approval, and the acceptance team composed of relevant departments and experts has completed the on-site completion acceptance. The environmental protection, fire protection, safety facilities, occupational health, construction and safety engineering quality and project files of the project have passed the special project acceptance organized by the local competent department or construction unit according to the regulations and requirements in the early stage. Recently, the project received the approval of the relevant departments through the completion acceptance.

  Copyright Daily Economic News

  Three special ropeway: the company received a first instance court verdict involving 72.9764 million yuan

  () Announcement, recently, the company received the "Civil court verdict" of the People’s Court of Wuhan East Lake New Technology Development Zone, Hubei Province ([2023] Hubei 0192 Minchu No. 3153). The subject matter of the lawsuit is 72.9764 million yuan. The first-instance judgment result: The defendant, Wuhan Sante Cableway Group Joint Stock Company, within 60 days from the effective date of the judgment, registered the change of the land use right under the WP National Use (2000) No. 150 and WP National Use (2000) No. 151 "State-owned Land Use Certificate" to the name of the third party, Wuhan Hanjintang Investment Co., Ltd.; rejected the other claims of the plaintiff, Hubei Heyuesheng Investment Co., Ltd.

  Zuoli Pharmaceutical: Lingze Tablets Received the "Certificate of Protected Varieties of Traditional Chinese Medicine"

  On March 7, Zuoli Pharmaceutical announced that Lingze tablets received the "Certificate of Protected Varieties of Traditional Chinese Medicine".

  Copyright Daily Economic News

  Continue to increase shareholder returns, Jianfan Bio promotes the implementation of the "Double Improvement of Quality Returns" action plan

  () An announcement on promoting the implementation of the "Double Improvement of Quality and Return" action plan was issued after the market close on March 7. In terms of operation, the company focuses on the main business of blood purification, increases investment in research and development, launches series of blood purification products, and builds a world-class high-tech medical technology enterprise group. In terms of returning shareholders, it actively distributes dividends and shares development results with shareholders, and enhances investor confidence through repurchase, increase holdings, etc.

  Data show that since its listing in 2016, the company has implemented a cash dividend plan for seven consecutive years, with a cumulative cash dividend of 2.642 billion yuan, which is 6.35 times the company’s net IPO raising of 416 million yuan and 1.87 times the company’s net financing (IPO and refinancing) since its listing. The proportion of the company’s cash dividends to net profit has increased from 41% in 2016 to 60% in 2022. The company also shares the company’s development results with investors through various forms of dividends such as "transfer of equity" and "share repurchase". In the future, the company will, in accordance with the relevant provisions of the Articles of Association and the Shareholder Dividend Return Plan for the Next Three Years (2023-2025), take into account the Strategy and Development Plan and Shareholder Return, and continue to increase the return to shareholders under the premise of ensuring the company’s business expansion, so as to create greater value for shareholders.

  In the secondary market, the company carried out share increase and repurchase to actively maintain market stability and enhance investor confidence. Dong Fan, the controlling shareholder and actual controller, chairperson and general manager of the company, increased his holdings by a total of 200 million yuan through centralized bidding transactions from January 20, 2022 to March 11, 2022. The company implemented two phases of the share repurchase plan of the company. The first phase of the share repurchase plan completed on November 12, 2021 had a total transaction amount of 500 million yuan, and the number of shares repurchased 8.8478 million shares, accounting for 1.10% of the company’s total share capital at that time. On July 17, 2023, the company launched the share repurchase plan of the company for the second time, using equity funds to repurchase the company’s shares in a centralized bidding mode of not less than 250 million yuan and not more than 500 million yuan. As of February 28, 2024, the company has repurchased 17.5827 million shares, accounting for 2.18% of the company’s total share capital, and the repurchase amount is 342 million yuan, which will continue to be implemented. So far, the company’s two-phase share repurchase plan has repurchased the company’s shares for a total of 842 million yuan, and the cumulative number of repurchased shares 2643.05 million, accounting for 3.27% of the company’s total share capital. The company has actively launched the share repurchase plan to effectively maintain market stability and boost investor confidence.

  Feneng Oriental: It plans to apply for a comprehensive exposure credit line of not more than 2.43 billion yuan to the Financial Institution Group within the next year

  China Fortune Connect, March 7 – () announcement said that according to the needs of production and operation, in order to reduce financing costs and improve the efficiency of capital use, the company (including wholly-owned and holding subsidiaries) plans to apply to banks, financial leasing companies and other Financial Institution Groups within the next year for a total amount of not more than RMB2.43 million in comprehensive exposure credit lines and handle corresponding loans, financial leasing, factoring and other businesses.

  Rifeng shares: In order to ensure the smooth construction and implementation of related projects, it plans to apply for a project loan from the bank with its own assets as collateral

  China Fortune Connect, March 7 – Rifeng announced that in order to ensure the smooth construction and implementation of the company’s "new energy and special equipment cable assembly project", the company plans to mortgage the state-owned construction land and its under-construction projects in Longchang Community, West District, Zhongshan City, Guangdong Province to the Zhongshan Branch of the Bank of Communications joint stock company, and add no more than 150 million yuan (exposure 150 million yuan) of bank credit and apply for project loans. The specific loan amount and term are subject to the final agreement signed with the bank. The company’s application for project loans from the bank with its own assets as collateral is to meet the capital needs of the company’s under-construction projects, which is conducive to the long-term sustainable development of the company.

  Funeng Oriental: plans to cancel its subsidiary Zhongshan Daewoo, which will help the company improve the efficiency of asset operation

  China Fortune Connect, March 7 – Funeng Oriental announced that the company intends to cancel its wholly-owned subsidiary Zhongshan Daewoo Intelligent Equipment Co., Ltd. This cancellation is conducive to the company’s further integration of resources, improvement of asset operation efficiency, and reduction of management costs. After the cancellation is completed, Zhongshan Daewoo will no longer be included in the company’s consolidated financial statements, which will not have a material impact on the company’s consolidated financial statements, nor will it have an adverse impact on the company’s overall business development and profitability.

  Double in 10 days! Big bull stocks urgently clarify

  On the evening of March 7, Dongfang Seiko, a bull stock with 8 daily trading limits in 10 days, issued an announcement of abnormal fluctuations in stock trading for the third time.

  This time, the company disclosed in detail the investment in Jiateng Robotics, whose current shareholding ratio is close to 20%. The company said that the application of robots or AI-related technologies will not have a significant impact on the company’s operating results in the short term, while continuing to emphasize that "there is no direct partnership with Nvidia".

  From the perspective of the transaction returns after the daily limit on March 7, the game of hot money in Dongfang Seiko is in full swing. There are many well-known hot money seats in the top five of buying and selling, and the net transaction is relatively close.

  Holding Jiateng Robot 19.84%

  On March 7, Dongfang Seiko rose by the daily limit again. In this way, the company’s closing price rose by a cumulative 20% for 3 consecutive trading days. According to the relevant regulations of the Shenzhen Stock Exchange, this situation belongs to the abnormal fluctuation of stock trading. Since February 23, the company has harvested 8 daily limit in 10 days, and the cumulative increase in stock price has reached 100%.

  On the evening of March 7, the company released its third announcement of abnormal stock price fluctuations since the current round of gains.

  The announcement said that the company has recently noticed that some media have listed the company as a "robot + NVIDIA" concept stock, and many relevant media reports have mentioned Guangdong Jiateng Robot Automation Co., Ltd. (referred to as "Jiateng Robot").

  The announcement shows that in June 2014, Dongfang Seiko invested in Jiateng Robot in cash subscription to obtain 20% of its investment ratio, and the transaction consideration was 49.12 million yuan. Since June 2014, Dongfang Seiko has never made additional investment in Jiateng Robot. During this period, due to the introduction of new shareholders and the increase in registered capital of Jiateng Robot, as of now, Dongfang Seiko’s investment ratio in Jiateng Robot is 19.8366%.

  The company said that since the initial investment in Jiateng Robot, Dongfang Seiko has never included Jiateng Robot in the scope of consolidated statements, nor has it substantially participated in the operation and management of Jiateng Robot. The company adopts the equity method to confirm the ROI of the investment in each reporting period, and the confirmed ROI in the past three years is 3.06 million yuan, 3.88 million yuan, 3.14 million yuan and – 1.78 million yuan respectively.

  The announcement said that as of now, Dongfang Seiko has no direct cooperation relationship with Nvidia. Based on Dongfang Seiko’s shareholding ratio for Jiateng Robot and the accounting treatment of the investment in Dongfang Seiko’s consolidated financial statements, the application of robots or AI-related technologies will not have a significant impact on the company’s operating results in the short term.

  Jiateng robot repeatedly sends "good"

  Although Dongfang Seiko has tried its best to downplay the influence of Jiateng Robotics and Nvidia, it has repeatedly released "good news" on official Weibo and other channels, and has been noticed by the market.

  According to its official website, Jiateng Robotics is a global enterprise headquartered in Shunde, China. It was established in 2002 and focuses on the research and development and manufacturing of mobile robot (AGV) bodies. It is the world’s leading provider of AGV robots and intelligent logistics warehousing systems. "Committed to promoting the transformation and upgrading of the manufacturing industry and the development of new quality productivity, to be the best AGV to help people around the world carry and run errands."

  On January 9, Jiateng Robot released a message on the official Weibo, based on years of long-term cooperation and deep consensus in the intelligent application field, NVIDIA, the global artificial intelligence leader, highly recognized Jiateng’s leading generative AI, and presented the application in a multi-scene and multi-modal display at the CES exhibition in the United States where intelligent innovation projects are gathered. In particular, the successful application of Jiateng’s generative AI on laser forklifts has depicted a vivid and magnificent vision for the promotion and popularization of thinking mobile robots in the industry, and has become a typical example of NVIDIA’s global artificial intelligence players at CES.

  On February 28, Jiateng Robot’s official Weibo account was again favorable, claiming that its Jiateng 8.5 cm ultra-thin fork arm omnidirectional unmanned stacking forklift conference was held in the studio of Guangdong Jiateng Robot Headquarters.

  From the dragon and tiger list on March 7, the short-term game of capital in Oriental Seiko does not seem to have ended. There are still many well-known hot money seats in the top five of buying and selling, including CITIC Securities Xi’an Suzaku Street Sales Department, East Asia Qianhai Securities Shenzhen Branch, etc. In addition, Shenzhen Stock Connect seats also participated.

  BYD applies for a patent for a hydraulic control system to prevent the load from shaking

  According to the announcement of the State Intellectual Property Office, the joint stock company applied for a project entitled "Hydraulic control system and its control method, and vehicle", public number CN117658019A, and the application date is August 2022.

  The patent abstract shows that the present invention provides a hydraulic control system and a control method thereof, as well as a vehicle. The hydraulic control system includes an oil pump, a first oil cylinder connected to the oil pump, and a motor for driving the oil pump to supply oil to the first oil cylinder. The telescopic rod of the first oil cylinder is connected to the first load member. The hydraulic control system also includes a controller connected to the motor and a buffer switch connected to the controller. The controller is used to control the motor. The buffer switch is used to drive the first load member in the telescopic rod of the first oil cylinder. When moving in the extended direction to a preset stroke, a buffer signal is generated and sent to the controller; the controller controls the motor to reduce from the first speed to the second speed based on the buffer signal, so that the speed at which the telescopic rod of the first oil cylinder drives the first load member to move is reduced from the In the present invention, the controller controls the motor speed to decrease or even stop slowly based on the buffer signal, which can eliminate the impact caused by inertia when the first cylinder mechanically travels to the end, and prevent the first load member from shaking.

  BYD applies for patents related to sodium-ion batteries to provide over-discharge protection

  According to the announcement of the State Intellectual Property Office, BYD’s joint stock company applied for a project entitled "A sodium-ion battery positive electrode piece, sodium-ion battery and application", public number CN117673243A, and the application date is August 2022.

  The patent abstract shows that this application provides a sodium-ion battery positive electrode sheet, a sodium-ion battery, and applications. The sodium-ion battery positive electrode sheet includes an active material and an over-discharge protector, including an over-discharge protector of the chemical formula M.

  BYD applies for patents for anti-skid devices and rail vehicles to reduce wear on running wheels

  According to the announcement of the State Intellectual Property Office, the BYD joint stock company applied for a project called "anti-skid device and rail vehicle", public number CN117657223A, and the application date is August 2022.

  The patent abstract shows that the present application discloses an anti-skid device and a rail vehicle. The rail vehicle is used to travel on a metal rail beam, and the anti-skid device includes a skid monitoring unit and an electromagnetic coil; the skid monitoring unit is used to monitor the skid of the rail vehicle; the electromagnetic coil is arranged facing the metal rail beam and is electrically connected to the skid monitoring unit. When the skid monitoring unit detects the skid of the rail vehicle, the voltage or current of the electromagnetic coil is increased, so that the magnetic force of the electromagnetic coil on the metal rail beam is increased. Therefore, during the running of the rail vehicle, the skid monitoring unit can monitor in real time whether the running wheels of the rail vehicle are slipping. When the skid monitoring unit detects the skid of the rail vehicle, the voltage or current of the electromagnetic coil is controlled to increase. In this way, the friction between the running wheels and the metal track beam can be increased to reduce the degree of skidding of the running wheels on the metal track beam, thereby reducing the wear of the running wheels.

  BYD applies for optical structure, end point shell and end point patent, patented technology can make pattern formation have three-dimensional effect

  According to the announcement of the State Intellectual Property Office, the BYD joint stock company applied for a project called "optical structure, end point shell and end point", public number CN117677087A, and the application date is August 2022.

  The patent abstract shows that this application provides an optical structure, an end point housing, and an end point. The optical structure includes a substrate layer, a pattern layer, and a microlens layer. The substrate layer includes opposing first and second surfaces. The pattern layer is arranged on the first surface of the substrate layer. The pattern layer includes a plurality of pattern units arranged in an array, and each pattern unit is part of a preset pattern. The microlens layer is arranged on the second surface of the substrate layer. The microlens layer includes a plurality of microlenses arranged in an array. Each microlens corresponds to a pattern unit, and each pattern unit is located within the projection of the corresponding microlens on the pattern layer. Wherein, the plurality of microlenses are used to cause the plurality of pattern units to form a preset pattern with a stereoscopic effect. The present application provides an optical structure, the end point of the housing and the end point, by each pattern unit in the pattern layer is provided as part of a predetermined pattern, so that a predetermined pattern having a stereoscopic effect can be formed by a plurality of microlenses.

  BYD applies for a battery preparation system patent to improve battery preparation efficiency

  According to the announcement of the State Intellectual Property Office, BYD’s joint stock company applied for a project entitled "Cell Preparation System, Cell Preparation Method, Laminated Cell and Battery", public number CN117673427A, and the application date is August 2022.

  The patent abstract shows that the present invention provides a battery cell preparation system, a battery cell preparation method, a laminated battery cell and a battery. The battery cell preparation system includes a handling mechanism, a positioning member, a roller set for transporting the diaphragm, and a laminating stage disposed below the roller set. The diaphragm is partially laid on the laminating stage, and the diaphragm can be folded when the laminating stage is switched between the first laminating position and the second laminating position. The handling mechanism is used for transporting the first pole piece to the diaphragm above the laminating stage laminated in the first laminating position, and for transporting the second pole piece to the diaphragm above the laminating stage laminated in the second laminating position. The positioning member can be moved between the first auxiliary position and the second auxiliary position, and the positioning members located in either auxiliary position are bonded to the surface of the diaphragm facing away from the lamination stage from one side of the diaphragm in the width direction to the other side. It is used to fix the lamination stage relative to the lamination stage to support the diaphragm during the lamination position switching process of the lamination stage, and move to the corresponding auxiliary position when the lamination stage completes the lamination position switching and the diaphragm is laminated with a first pole piece or a second pole piece.

  BYD applied for a patent for the control method, system, storage medium and target controller of the logic section, which increased the flexibility of manual path selection and greatly improved the dispatching efficiency

  According to the announcement of the State Intellectual Property Office, BYD joint stock company applied for a "control method, system, storage medium and target controller of logical section", public number CN117657259A, and the application date is August 2022.

  The patent abstract shows that the present disclosure relates to a control method, system, storage medium and target controller of a logical section. By acquiring a section control instruction triggered by a dispatcher through the automatic vehicle monitoring system ATS, the section control instruction includes the dispatcher. The ATS selects a target logical section from a plurality of preset logical sections, and the section control instruction is used to instruct the corresponding section path of the target logical section as an artificial path, or to instruct to cancel the section path as the artificial path. According to the section control instruction, section control is performed on the target logical section; the method can use the selected logical section as an artificial path, and no longer rely on the position of the signal to determine the manual path. In this way, the flexibility of manual path selection is increased, and the scheduling efficiency is greatly improved.

  BYD applies for a patent for bogies and rail vehicles, which can enhance the riding experience for those located inside the vehicle

  According to the announcement of the State Intellectual Property Office, BYD’s joint stock company applied for a project called "Bogies and Rail Vehicles", public number CN117657234A, and the application date is August 2022.

  The patent abstract shows that this application discloses a bogie and a rail vehicle. The bogie includes a shaft bridge, a first elastic member, a second elastic member, a first support frame and a second support frame; the lower ends of the two elastic members are connected to the shaft bridge; the first support frame is used to fix the vehicle body connected to the rail vehicle; the second support frame is connected to the upper ends of the two elastic members, and the second support frame is rotatably connected to the first support frame. Thereby, the first support frame is used for connecting to the vehicle body, the second support frame is connected to the upper ends of the two elastic members, the lower ends of the two elastic members are connected to the shaft bridge, and the first support frame is rotatably connected to the second support frame. In this way, when the rail vehicle provided with the bogie travels in the extending direction of the track beam, if there is a difference in the height position of the two running surfaces of the track beam, the vehicle body swings about the rotation axis of the first support frame and the second support frame, and the vehicle body swings with less freedom, which can improve the riding experience of the person located in the vehicle body.

  BYD applies for an information processing patent to achieve the effect of non-sensory parking for vehicles

  According to the announcement of the State Intellectual Property Office, the BYD joint stock company applied for an application entitled "Information Processing Method, Server, Parking Method, Parking System and Vehicle", public number CN117671989A, and the application date is August 2022.

  The patent abstract shows that the present application relates to an information processing method, which is applied to a server, comprising: acquiring parking information of a plurality of vehicles, wherein the parking information of each vehicle includes the vehicle position and the vehicle attitude of the vehicle parking; determining the parking position and the direction of the parking space based on the parking information; determining the usable parking space based on the parking position and the direction of the parking space; obtaining a parking space map including the usable parking space according to the available parking space. Through the information processing method applied to the server by the present application, it is possible to expand the search range of the parking space, and recommend a parking space with a high confidence level for the vehicle, thereby realizing the non-sensory parking effect of the vehicle. The present application also provides a vehicle, an information processing method applied to the vehicle, a parking system and a parking method applied to the parking system.

  BYD patented identification method for display devices to improve system start-up efficiency

  According to the announcement of the State Intellectual Property Office, the BYD joint stock company applied for a "identification method, device, medium, display system and vehicle of display equipment", public number CN117676157A, and the application date is August 2022.

  The patent abstract shows that the present disclosure relates to an identification method, device, medium, display system and vehicle of a display device to improve system start-up efficiency. Applied to a controller, the controller is connected to at least one display device, and each said display device is provided with a memory for storing a device code of the display device; the method comprises: establishing a communication connection with a target display device to be identified, and the target display device is one of the at least one display device; after the communication connection is successfully established, access the memory of the target display device through the target memory address to read the device code stored in the memory; determine the model of the target display device based on the read device code.

  BYD applies for a patent for rotary components to improve the safety and service life of rotary components

  According to the announcement of the State Intellectual Property Office, BYD’s joint stock company applied for a project entitled "Rotary components and motor components, electric assemblies and vehicles with them", public number CN117672662A, and the application date is August 2022.

  The patent summary shows that the present invention discloses a swirl assembly and a motor assembly, an electric motor assembly and a vehicle having the same, the swirl assembly comprising: a primary housing, the primary housing is provided with a primary winding; a secondary housing, one end surface of the secondary housing in the axial direction is directly opposite the primary housing, a secondary winding is provided in the secondary housing, and the secondary housing is facing away from the primary housing. A first annular wall is formed on the other end surface, and a balance hole is formed inside or on the surface of the first annular wall. The swirling component of the present invention fully considers the dynamic balance problem during the high-speed rotation of the secondary winding during the design process, and the balance hole on the secondary side casing can reduce the weight of the secondary side casing, so as to maintain the quality distribution of the secondary side casing. Uniformity, reduce the failure rate of the swirling component, and improve the safety and service life of the swirling component.

  () Apply for a patent for monodisperse magnetic nanoparticles and their preparation method, and prepare magnetic nanoparticles with basically the same morphology and controllable particle size

  According to the announcement of the State Intellectual Property Office, Guangzhou Da’an Gene joint stock company applied for a project called "a monodisperse magnetic nanoparticle and its preparation method", public number CN117658224A, and the application date is August 2022.

  The patent abstract shows that the embodiment of the present application belongs to the technical field of magnetic nanomaterials, and relates to a monodisperse magnetic nanoparticle and a preparation method thereof, including adding a weakly basic salt and polyethylene glycol to ethylene glycol, mixing uniformly to obtain A liquid; dissolving a soluble iron salt in ethylene glycol to obtain B liquid; mixing A liquid and B liquid and performing ultrasonic operation to obtain a precursor liquid; heating the precursor liquid, cooling the reaction product to room temperature, pouring out the supernatant to obtain the reaction product; washing and drying the reaction product to obtain the magnetic nanoparticle. The present application can achieve the purpose of regulating the particle size of the product, and preparing the magnetic nanoparticle with a substantially uniform morphology and controllable particle size. At the same time, the preparation method is simple and reliable, and mass production can be achieved.

  () Apply for a patent for a four-way valve and air conditioning equipment to solve the problem of refrigerant backflow in the refrigerant system, thereby improving the lifespan of the refrigerant circulation system

  According to the announcement of the State Intellectual Property Office, Zhejiang Dunan artificial environment joint stock company applied for a project called "four-way valve and air conditioning equipment", public number CN117662804A, and the application date is August 2022.

  The patent abstract shows that the present application relates to the technical field of heat exchange, in particular to a four-way valve and air conditioning equipment. In particular, the four-way valve provided by the present application includes a first nozzle and a main valve body. The first nozzle is used to connect the exhaust port of the compressor. The main valve body is provided with a valve cavity, and the first nozzle is connected to the main valve body and connected to the valve cavity. The valve cavity is provided with a flow blocking structure. When the refrigerant flows from the first nozzle to the valve cavity, the refrigerant can push the flow blocking structure to move in a direction away from the first nozzle so that the first nozzle communicates with the valve cavity. When the refrigerant has a tendency to flow from the valve cavity to the first nozzle, the refrigerant can push the flow blocking structure to move in a direction close to the first nozzle to cut off the first nozzle and the valve The four-way valve provided herein solves the problem of refrigerant backflow in a refrigerant system, thereby increasing the life of the refrigerant circulation system.

  TCL Technology applies for a patent for the preparation method of side electrodes, which is conducive to the development of narrow-bezel or even bezel-less panels

  According to the announcement of the State Intellectual Property Office, the () group joint stock company applied for a project entitled "Side electrode preparation method, substrate with side electrode, electrode and display panel", public number CN117672963A, and the application date is August 2022.

  The patent abstract shows that the present application discloses a method for preparing side electrodes, a substrate with side electrodes, electrodes, and a display panel. The side surface of the first substrate of the present application includes a transition surface, and the side surface is connected to the first surface through the transition surface. The transition surface includes at least one of a plane and a curved surface. In this way, the side electrode can be effectively prevented from falling off, and an adhesive layer is provided between the first substrate and the side electrode, which can improve the adhesion of the side electrode process, improve the yield, and facilitate the development of narrow-bezel or even bezel-free panels.

  BYD Semiconductor applies for an overcurrent protection circuit patent, which can avoid frequent circuit disconnection affecting the use of power devices

  According to the announcement of the State Intellectual Property Office, BYD Semiconductor joint stock company applied for an application entitled "An overcurrent protection circuit and a control method based on overcurrent protection circuit", public number CN117674788A, and the application date is August 2022.

  The patent abstract shows that the present invention provides an overcurrent protection circuit and a control method based on the overcurrent protection circuit. The overcurrent protection circuit includes a comparator and a signal modifier, and the output end of the comparator is connected to the input end of the signal modifier; the input end of the comparator is connected to the current output end of the switching component in the power device; and the output end of the signal modifier is connected to the switching control end of the switching component. Through the embodiment of the present invention, the overcurrent protection of the power device is realized by modifying the control signal of the switching component, without completely disconnecting the circuit and then manually resetting, avoiding frequent disconnection of the circuit affecting the use of the power device, and enabling All cases where the current is too large are treated with overcurrent protection, which avoids damage to the power device due to the absence of overcurrent protection treatment due to the presence of some cases where the current is too large.

Yang Mi’s successful transformation? This is an immature realist film

1905 movie network feature If you give birth to a child with a serious birth defect,Will you choose to save or not to save?


The movie puts us in such a dilemma and moral confusion, and Mr. Xu, played by Guo Jingfei, and Jiang Meng, played by Yang Mi, are decisively on the opposite side.

Mr. Xu’s daughter was suffering from anorectal disease, and he chose not to save her in the pain. When he confronted Jiang Meng head-on, he repeatedly questioned, "What about the future?"


In his opinion, even if the child survives, he will continue to grow up in this unjust world and suffer from the pain of not being understood.

Jiang Meng, a 19-year-old girl with congenital defects, was abandoned by her biological parents after birth, and finally survived healthily with the help of a welfare home and a foster family.


She was also an abandoned child with a defective disease. Her strong empathy and compassion drove Jiang Meng to rescue the child. She became stubborn and even broke into the hospital to steal the child.


In her eyes, she was this abandoned child, the common unity of fate. Since she survived, this child must also strive to survive.


So who really has the right to decide whether a child lives or dies? 


At the film’s premiere at the Pingyao Film Festival, Yang Mi said, "No one can define the happiness of others, and no one can control their lives."


Similarly, the film only shows this phenomenon without polish. In the gap where Guo Jingfei and Yang Mi cannot understand each other, they do not judge the choices of the two sides, and throw contradictions and difficulties to the audience without providing any answers.



Liu Jie’s films are often based on social news events, and the creative process of the script is also a process of social investigation.


"Baby" was inspired by Liu Jie’s friend, who gave birth to a child with cerebral palsy.The couple needs to decide within three days whether to let him liveAfter struggling and thinking day and night, he finally decided to save the child and give up the superior city life, taking the child to live in the suburbs.


Another source of creation is the director’s several visits to the orphanage, where he finally discovered that there were more than 1,200 disabled abandoned babies in foster care in two villages outside Beijing.


In 2012, our country officially said that the total incidence of birth defects in China was about 5.6%. Liu Jie, the director, said, "When I learned that the birth defect rate is 5.6 percent, which means that nearly 1 million children with birth defects are born every year, and 30 percent of them will die, 40 percent will be disabled for life, and 30 percent will survive, it also motivated me to make this film. I don’t know who to blame, I can only make it as it is."


Although Liu Jie has directed such commercial films, realistic literary films are the main axis of his work sequence.From "Baby", the entanglement of law and reason is also his consistent theme of expression.


In addition to the plot line of Jiang Meng’s rescue of the disabled baby, "Baby" also shows the relationship and fate between Jiang Meng and the foster caregiver.


Foster care is not adoption, and there is no relationship between guardianship and guardianship. The law stipulates that abandoned babies in foster care need to leave the foster family when they reach adulthood at the age of 18. But Jiang Meng did not want to leave her elderly adoptive mother who was alone, nor did she want her to live in a nursing home, so she fell into another paradox and dilemma of law and love.

The realism of "Baby" has both neutral humanitarian spirit and realistic aesthetic style.


The film narrates the story from a calm and alienated objective perspective. The camera always surrounds and follows Jiang Meng, and reality is gradually constructed and perceived from what she sees and hears.


The use of long-lens hand-held shaking in the natural scene and the use of emotional soundtracks are reduced. This documentary audio-visual style can be seen in the films of the Dane brothers, in the films of Farhati, and in a series of Romanian New Wave works.

This shooting style is also an actor-centered aesthetic, and its greatest advantage is that it frees up the actor’s performance space, allowing the camera to improvise in a real environment and capture more realistic performances.


From the very first shot, we saw a completely different Yang Mi, her hair is messy, her face is full of freckles, her face is gray and weak, not only subverting the image, but also challenging her to speak Nanjing dialect in the play.

Yang Mi’s all-out experiential performance method, just like Gong Li, Zhao Wei and Ma Yili,This really allows her to fit into the context of the story well, and as much as possible to fade away the audience’s established impression of her.


But throughout the film, she always frowned, showing a hesitant and confused expression, with relatively simple emotional changes.

Compared with Li Hongqi, who played the mute army, his rich body language and facial expressions stole a lot of the limelight, but there were also some problems of using too much force.

On the contrary, Guo Jingfei did it properly.The director asked him to try to find the feeling of "three days and three nights without sleep", and he also deduced a measured sense of decadence from this character state.


The film lost more points due to the thinness of the script and the imperfection of the character design.


The dramatic conflict of the film is inseparable from the confrontation between the protagonist and the three forces of personal inner, external opponents and social environment.


We can see Jiang Meng’s persistence and stubbornness, but we cannot see the undercurrent in her heart; we can see her and her adoptive mother’s estrangement, unable to penetrate into their more intimate and complex emotional relationship; we can see Xiaojun’s confession and love for Jiang Meng, but fail to know Jiang Meng’s true attitude towards him.

Yang Mi revealed at the premiere that Jiang Meng’s character is not only physically disabled, but also mentally ill. But the movie did not clearly explain and write, which caused the audience to have some damage to the actor’s performance and the overall cognition of the role.


Although maintaining an objective distance and starting the whole narrative from Jiang Meng’s perspective, the film will inevitably be criticized for being biased towards Jiang Meng’s position choice.


Even if there is a scene of social children’s groups splashing paint on Guo Jingfei’s house, the handling is only a brief taste, and the controversial discussion of abandoned babies is not comprehensive.

Obviously, "Baby" is still a long way from a more mature and in-depth realist film, but the film’s attention to the living conditions of social abandonment groups and the disabled is sure to attract some public attention.


Isn’t that the greatest significance of this film’s existence?


Finally, just as the director Liu Jie wished, "I hope this group of people can live happily in the sun in the future."

How "fickle" is the Great Wall Gun? N kinds of modifications, as needed!

How many transformations can a pickup truck have? The answer of the Great Wall Gun is, N kinds! At the fiery Guangzhou International Auto Show, the trailer version of the off-road pickup truck, the rescue gun and the travel gun of the Great Wall Gun showed the audience how "fickle" the Great Wall Gun was. In fact, this is not the first time that the Great Wall Gun has "transformed". The rich modification scheme makes the ever-changing Great Wall Gun more attractive.

How "fickle" is the Great Wall Gun? N kinds of modifications, as needed!

Modification is to have fun.

The so-called modification is to make the car more suitable for its unique use environment. In this respect, people who are obsessed with fishing have a deep understanding. The fish and fishing tackle with nowhere to put, the scorching heat of the scorching sun, and the regret of not being able to travel far were all troubled before the appearance of the Great Wall Gun Off-road Pickup Fishing Edition, but after it, the problem was solved.

The wild fishing version converts the container into a pulley drawer-type partition storage bin, which can classify fishing gear and fish and bid farewell to the dilemma of fishing line entanglement and sewage cross-flow; Full-coverage gantry, set up a large number of expansion fixed points, and place fishing rods, shovels and other items in different categories; In addition, the framework of the gantry extends all the way to the roof, and larger outdoor equipment such as kayaking can be placed above the gantry through fixed components, and you can fish or play in the water.

How "fickle" is the Great Wall Gun? N kinds of modifications, as needed!

How "fickle" is the Great Wall Gun? N kinds of modifications, as needed!

How "fickle" is the Great Wall Gun? N kinds of modifications, as needed!

It’s not just fishing enthusiasts who like to leave, but their concern for the quality of life makes more people yearn for nature. The Great Wall Gun Off-road Pickup Off-road Travel Edition and Travel Gun that were previously unveiled make the whole scene pickup life available to everyone.

The Great Wall Gun Off-road Pickup Leisure Travel Edition is mainly based on the surrounding situation of the city, with side curtains installed to create a cool place at any time; With car refrigerator and outdoor mobile kitchen, you can enjoy the scenery and cook delicious food at the same time. A combined drawer is installed in the back bucket (canopy with flat cover), which is convenient for placing all kinds of tools/appliances necessary for life and meets the needs of multiple scenes.

How "fickle" is the Great Wall Gun? N kinds of modifications, as needed!

The traveling gun considers the advantages and disadvantages of various large and medium-sized RVs, and makes full use of the body space while retaining most of the functions of RVs, so as to ensure the simplicity of the vehicle shape, portability and good passability, so that you can stay in the camp at any time during the journey and enjoy the natural scenery.

How "fickle" is the Great Wall Gun? N kinds of modifications, as needed!

Travel outside, in addition to married with children, it is also possible to tow a tugboat. At this time, the trailer version of the Great Wall Gun off-road pickup truck will come in handy. It has the announcement of towing, which can be legally towed on the road, 11 unique off-road equipment with fever level, 7 all-terrain driving modes, three locks, tank turning, Bailuchi tires, crawling mode, winch, wading throat, nitrogen shock absorption, off-road expert mode, multi-link, off-road information display, etc., making it easy to be competent for towing yachts, motorcycles, RV and other tasks.

How "fickle" is the Great Wall Gun? N kinds of modifications, as needed!

In addition, the Great Wall Cannon also has a multi-functional camper, which integrates cross-country, living, exploring and storing things, and is specially tailored for outdoor adventure, cross-country and extreme enthusiasts, making "self-sufficient" outdoor life a reality.

How "fickle" is the Great Wall Gun? N kinds of modifications, as needed!

Modification is a fearless journey.

Some people yearn for leisure, while others pursue wild conquest. In the modification culture of the Great Wall Gun, cross-country modification is quite worth seeing.

The cross-country pickup truck version of Great Wall Gun, which was unveiled at Chengdu Auto Show, mainly focuses on long-distance cross-country, redesigned the wading throat with low wind noise, added a quick-release anti-roll frame in the car to improve the safety level and meet the extreme challenges, designed a multi-purpose custom side plate rack and a sliding reset tray in the rear bucket, and installed various types of roof tents on the gantry. The wheels used the world-famous Avandia wheels with the prestigious KM3 tires of Bailuchi to adapt to more difficult and dangerous outdoor road conditions. On the whole, the cross-country pickup truck crossing version of the Great Wall Gun takes the details of field driving into account, and it is worthy of being an experienced cross-country old gun.

How "fickle" is the Great Wall Gun? N kinds of modifications, as needed!

How "fickle" is the Great Wall Gun? N kinds of modifications, as needed!

On the basis of the off-road pickup truck of the Great Wall Gun, the wild guns for outdoor enthusiasts have specially strengthened the long-distance crossing ability, equipped with a portable auxiliary fuel tank, a container rack capable of carrying three full-size spare tires, and added roof racks and spotlights, which can meet the long-distance crossing of various road conditions such as plateau, Gobi and grassland. It can be said that the wild gun represents the ultimate concept of the Great Wall gun off-road pickup truck, that is, a product tailored for all-terrain, full-load and long-life outdoor crossing, which explains the highest level of off-road spirit.

How "fickle" is the Great Wall Gun? N kinds of modifications, as needed!

How "fickle" is the Great Wall Gun? N kinds of modifications, as needed!

Not long ago, at the Beijing Auto Show, the black bullet with black and orange color matching attracted people’s attention with its domineering shape. This powerful performance pickup truck for heavy cross-country enthusiasts has various cross-country kits such as side treads for rock climbing, front and rear double winches, spotlights, etc. It uses professional adjustable damping shock absorbers, and the chassis is raised by 80mm as a whole. The full-size cross-country tires of Toyo Dragon Claws and the fever-grade off-road equipment make cross-country more calm and pure.

How "fickle" is the Great Wall Gun? N kinds of modifications, as needed!

How "fickle" is the Great Wall Gun? N kinds of modifications, as needed!

Modification is the responsibility.

As a national brand that cares about the country, Great Wall Gun not only pays attention to the fun modification, but also makes full use of its own product advantages to carry out tool modification, just like howard the duck in key occasions. The rescue cannon displayed at Guangzhou International Auto Show is a good partner for retrograde people.

The rescue gun was modified based on the commercial pickup truck of Great Wall Gun, and the cargo box was changed into a rescue mobile warehouse, equipped with professional rescue equipment such as generators, lifebuoys, demolition machines, medical boxes, stretchers and oxygen tanks. The whole vehicle is equipped with rescue equipment such as car radio, long-distance telescopic antenna (relay antenna) and climbing ladder. The chassis suspension is raised and the passability is enhanced, which can cope with various complicated road conditions and can be put into rescue scenes such as medical treatment, fire fighting, communication and outdoor.

How "fickle" is the Great Wall Gun? N kinds of modifications, as needed!

Long before the rescue cannon appeared, the Great Wall cannon played a pioneering role in major events in many countries. During the war, the Great Wall Gun took advantage of the big container and was converted into a sterilization gun for environmental sterilization. In flood fighting, Great Wall Gun reached a strategic cooperation with Blue Sky Rescue Team to transport personnel and equipment in Huangshan disaster relief, becoming a car version of Noah’s Ark. In the future, Great Wall Gun will launch a customized model for Blue Sky Rescue to provide professional rescue vehicles with better off-road capability, loading capacity and comfort for registered members of Blue Sky Rescue. Climbing Mount Everest, as the official working vehicle of the media to measure the action of Mount Everest, the Great Wall Gun off-road pickup truck provides a strong guarantee for Everest elevation measurement and media communication and other related work with its strong off-road performance, loading and comfort, and helps the national cause; To do public welfare, the Great Wall cannon cross-country pickup truck set foot on the Hoh Xil Nature Reserve, accompanied volunteers to pick up garbage, and returned to Hoh Xil as a pure land.

How "fickle" is the Great Wall Gun? N kinds of modifications, as needed!

Modification is infinite possibilities.

As a leading brand in the pickup truck industry, Great Wall Gun insists on in-depth development and category splitting. On the basis of successfully developing the three sub-categories of passenger, commercial and off-road markets, it expands N-type modified cars, which are divided by appearance, interior and configuration. Unlimited possibilities of pickup trucks are used to build family universal cars to meet the diversified needs of users in all directions, and through modification, the barriers between different circles are broken, so that users who like to play and know how to play become attached to each other because of Great Wall Gun and modification.

On the other hand, Great Wall Gun practices corporate responsibility, and relies on the powerful off-road function of products and the unlimited modification space of open containers to expand unlimited application scenarios, protect people’s livelihood, add a sense of weight to the Great Wall Gun brand and make the users of Great Wall Gun feel more proud.

On the basis of a series of modified models, the Great Wall Gun will also launch a brand-new modified model that is bigger, cleaner, smarter and more fashionable. You want it all!

Xiaomi Automobile, which invested 10 billion yuan, has earned back 4 million yuan.

Headline reported today.
The photo of Xiaomi car was exposed again. Different from the declaration map published on the website of the Ministry of Industry and Information Technology and the spy photos circulated on the Internet, this time it is a millet SU7 with a light green appearance. Fresh colors, many young people said that they were moved and "must rush."On the hot search together with the photos of Xiaomi car, it is the topic that "Xiaomi car will lose 3 million fines if the media leaks". Therefore, some netizens ridiculed, and a supplier was fined 1 million yuan for leaking Xiaomi’s design draft at the beginning of this year. At present, Xiaomi Automobile has earned 4 million yuan. In addition to the photos of Xiaomi Automobile, Lei Jun, the founder, chairman and CEO of Xiaomi Group, also talked about Xiaomi Automobile in the CCTV face-to-face column yesterday. Lei Jun said that he built the car with the assurance that he was determined to win. There are two principles for Xiaomi to build a car. The first one is "keeping the integrity surprisingly". Keeping the integrity is to fully respect the laws of the automobile industry and use the mature technology of the automobile industry to ensure that the first car can be built well; The second is "ten times the investment". Generally, a car company invests about 300 to 400 people in building a car, and about 1 billion or 2 billion R&D funds, while Xiaomi invested 3,400 engineers in the first car, and the entire R&D investment exceeded 10 billion.More and more details show that "the first car for young people" is about to be pushed into the spotlight and be judged by the market.Xiaomi car "hit the face"?On November 15th, the first model of Xiaomi Automobile appeared in the 377th batch of Announcement of Road Motor Vehicle Manufacturers and Products issued by the Ministry of Industry and Information Technology. The declaration map shows that the first model of Xiaomi Automobile is a pure electric car, and there are two models, namely SU7 and SU7 Max.As soon as the picture came out, many fans thought that Xiaomi’s car hit Porsche. The media electric gorilla made a series of pictures, comparing the front face, taillights and waistline of Xiaomi car and Porsche TayCan. "It’s not that Porsche can’t afford it, but that Xiaomi is more cost-effective." Some car fans even ridiculed Xiaomi’s car "Bao Shi Mi".In terms of specific parameters, the length, width and height of Xiaomi SU7 are 4997mm/1963mm/1455mm, the wheelbase is 3000mm, and the height of Xiaomi SU7 Max is 1440mm, and the other parameters are the same. Xiaomi SU7 will have two battery capacity versions, the battery pack capacity is 101kWh and 73.6kWh respectively, of which the battery life of 101kWh is 800km and 750km; respectively; The battery life of 73.6kWh battery pack is 668km and 628km respectively. Xiaomi Automobile adopts ternary lithium-ion battery made in Contemporary Amperex Technology Co., Limited, and its driving motor has a peak power of 220kW/275kW. It is also equipped with an automobile event data recording system (EDR). In addition, when the spy photos of Xiaomi’s car frame were exposed, some fans thought that the handle area of Xiaomi’s car interior door panel was similar to Tesla Model 3.At present, there are various spy photos, "ID photos" and unpainted driving photos of Xiaomi Automobile on the Internet, and most rice noodles are satisfied with the appearance of Xiaomi Automobile exposed at present.Does Xiaomi Automobile insist on cost performance?At present, the news on the market is that Xiaomi car is divided into standard version, Pro version, Max version, and track version that will not be mass-produced, and the price is concentrated at 190,000-300,000 yuan. Guo Ming, an analyst at Tianfeng International Securities, said that the key selling points of Xiaomi Automobile are autonomous driving, software ecology and 800V fast charging and power configuration, and the estimated price is less than 300,000 yuan. Han Lu, a senior car blogger, previously broke the news that Xiaomi Automobile is positioned as a C-class luxury car with a minimum price of around 300,000 and a high allocation of around 500,000. At present, this Weibo has been deleted. Earlier, the article said that Xiaomi Automobile was priced at 260,000 yuan and divided into two versions. The price of low-profile models ranges from 260,000 to 300,000 yuan, and the price of high-profile models exceeds 350,000 yuan. However, the price of Xiaomi car will be as low as 200,000, or 200,000-300,000, or more than 300,000. The price of the three stages directly determines whether Xiaomi car still focuses on the familiar "cost-effective" formula. After the announcement of building a car, Lei Jun initiated a vote on the pricing of Xiaomi car, with nearly 20,000 people participating, with the largest number of netizens choosing less than 100,000 yuan, followed by 100,000-150,000 yuan. However, from the current exposure of Xiaomi car configuration, the pricing below 150,000 is indeed somewhat difficult. Xiaomi automobile, which has not yet been released, has already faced an increasingly new energy market. This year, new energy vehicles started a price war. Near the end of the year, in order to rush sales, the promotion methods of car companies are becoming more and more crazy. According to a document issued by Cui Dongshu, the current secretary-general of the National Passenger Car Market Information Association, the promotion of new energy vehicles increased especially in November this year, and it has reached the historical high promotion level since last November.According to the data of Easy Car, in the last month of 2023, Jiyue, BYD, Tucki, Zhiji, etc. adjusted the prices of various series of vehicles one after another, and other new energy vehicles also introduced various preferential policies to buy before the end of the year. Can the fans be satisfied with the final pricing of Xiaomi Automobile at the moment of rushing sales volume and volume price at the end of the year? Is Xiaomi Auto released this year?Yesterday was also Lei Jun’s 54th birthday. Last night, Lei Jun sent a message thanking his friends for their birthday wishes, with a picture that "everything will work out in the end". Because of this point in time and the word "car", netizens, while wishing Lei Jun a happy birthday, also wondered whether the Xiaomi auto conference was coming. The blogger "Game Technology" of Xiaohongshu previously published a document saying that Xiaomi has "finalized" the launch conference of Xiaomi Automobile in Beijing on the 28th. The internal staff of Xiaomi Automobile denied that "the time has not been fixed yet, and we are really considering this time point". There have been more and more official actions of Xiaomi Automobile, such as Xiaomi Automobile Weibo, which has just been opened and the speed of light is off the assembly line, Xiaomi Automobile official website, which has only a few photos, and some Xiaomi Houses in Beijing and Shanghai, which have started to confirm the display of automobiles. According to national business daily, the four major manufacturing workshops (stamping, welding, painting and assembly) in the first-phase factory of Xiaomi Automobile have been built, and small-batch trial production has started, and all the produced cars are parked in the assembly workshop. At the Xiaomi 14 conference, Lei Jun said when answering questions from netizens that Xiaomi Automobile is progressing very smoothly and will be officially listed in the first half of next year. When the time is right, report to everyone. Will this "appropriate time" be the end of this year? In the "Face-to-Face" column, Lei Jun said that he was a little anxious: "I am particularly worried that everyone will not buy it if it doesn’t catch fire; I am even more worried that everyone will buy it. If you wait for 1-2 years, you will definitely be scolded. Can the upcoming Xiaomi car satisfy the majority of rice noodles? And what changes will Xiaomi cars and rice noodles bring to the automobile industry? We will wait and see.

Picturesque novel

Wisteria (Chinese painting) Wu Guanzhong is selected from the Chinese Art Palace (Shanghai Art Museum) "Chinese Scenery-Lin Fengmian and Wu Guanzhong Art Exhibition"

I read Wang Zengqi’s novel "The Apprentice", in which I wrote that the great grandfather of the fourth season was jealous of the people, and I thought of Mr. Wang himself.

Mr. Wang is famous for painting, and he also wants to be a painter. His father is a painter. He went to The National SouthWest Associated University at the age of 19. Mr. Wang once said that if he failed, he would go to the National College of Fine Arts. However, Mr. Wang has been admitted. If he fails, he will go to the Art College. Perhaps there will be another master in the history of modern painting in China.

The plot of The Appreciator is very simple, telling the story of a great painter and a fruit delivery vendor. It is also a story about a bosom friend. We all know that Yu Boya and Zhong Ziqi, one playing the piano and the other listening to the piano, performed a deep feeling of "high mountains and flowing water". Although Ye San is a fruit vendor, he knows Ji Xianmin and his paintings. Ji Xianmin’s paintings are never seen by people, but he can see them in Yuzryha. Ye San’s appreciation of his paintings is what Ji Xianmin is proud of. Ji Jian-min painted the wrong lotus, and Ye San pointed it out, so Ji Jian-min repainted it and gave it to Ye San. Sometimes Ji Jian-min gave Ye San a painting without the title, and Yuzryha San could sell it. Ye San said, I won’t sell any of your paintings. Sure enough, after Ye San’s death, according to his will, his son buried all the paintings given by Ji Yumin.

Mr. Wang Zengqi knows Chinese painting. He wrote this novel to pay tribute to the literati paintings in China after the Song and Yuan Dynasties (he knew many painters in ancient China), and also devoted his understanding of China ink painting (including techniques) to the text. For example, Mr. Wang painted the ink lotus and wisteria, such as "there is wind in wisteria, and the flowers are messy". Mr. Wang himself painted many wisteria with this kind of messy flowers.

During his visit to Iowa, Mr. Wang gave a speech entitled "My Creative Career". When talking about the relationship between China’s literature and painting, he said that some people say that his novels are poetic novels, but he hopes that some people will say that his novels are picturesque novels.

This is really what Mr. Wang hopes, and it is also the case. Mr. Wang’s works are indeed full of painting meaning-China’s ink spirit, the art of blank space in Chinese painting.

He also visited some art galleries and museums in America. In the Boston Museum, he saw a Song Huizong’s copy of Zhang Xuan’s "Dao Lian Tu" and admired it immensely. He mentioned this painting in a conversation and said, "That thread is so long that I can’t wait to kowtow to it when I write it." In the novel, Mr. Wang used Zhang Daqian to write about the painting of Mohe lotus by Ji Yumin, saying that "the lotus leaves he painted are not hooked, and the lotus stalks are not pricked, and he likes to make them long, and the lotus stalks are very long, and they are all in one stroke." This is all Mr. Wang’s own experience.

Author: Subei

Text: Northern Jiangsu Picture: Wu Guanzhong Editor: Wu Dongkun Editor: Shu Ming

Please indicate the source when reprinting this article.